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inTRoDuCTion
The developmental plasticity hypothesis proposes that environmental exposures, acting at 
different stages of fetal and early postnatal development, lead to permanent adaptations in 
the structure, physiology and function of various organ systems.1 This early programming 
contributes to short-term survival, but increases the susceptibility of cardiovascular disease 
in adulthood.1 This hypothesis is supported by observational studies demonstrating that low 
birth weight, as a measure of reduced growth in utero, is associated with an increased risk of 
the development of cardiovascular disease in later life.2 Low birth weight has also been related 
to cardiovascular risk factors such as hypertension and cholesterol levels, although systematic 
reviews suggest small effects.3-4 Birth weight is merely a marker of fetal growth and environ-
ment, and does not account for the influence of postnatal growth. Retrospective follow up 
studies have shown that individuals with a low birth weight and high rates of childhood weight 
gain have increased risks of cardiovascular disease5-6, suggesting that fetal and childhood 
growth are both related to cardiovascular health and disease in later life. The exact growth pat-
terns and underlying biological mechanisms linking fetal and childhood growth with disease in 
later life are not fully understood. 
The increased risk of cardiovascular disease among children with a low birth weight may 
result from growth induced early developmental adaptations in cardiovascular structures and 
function. Detailed studies in animals and humans have demonstrated that fetal and childhood 
growth variation leads to cardiovascular structural and hemodynamic adaptations in early life.7-
14 Decreased fetal growth has been associated with adaptive fetal haemodynamic changes, 
consistent with an increase in cardiac afterload and compromised arterial compliance.7 Also, it 
has been suggested that fetal growth restriction induces primary cardiac and vascular changes 
in childhood.14 In addition, there is growing evidence for changes in cardiovascular proper-
ties due to factors that influence fetal growth. Maternal smoking during pregnancy has been 
associated with impaired endothelial function15, thicker carotid artery intima media thickness 
and lower arterial distensibility in childhood.16
These cardiovascular adaptations due to early growth and its determinants, might partly 
explain the association between early growth and cardiovascular disease in adulthood. Studies 
focused on the effect of prospectively measured fetal and childhood growth patterns on car-
diovascular development in childhood might therefore extend our knowledge on the origins 
of cardiovascular disease in the earliest phase of life.
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obJECTivES
The specific aims of this thesis were to study (Figure 1):
1. Fetal, infant and childhood growth patterns and determinants related to the development 
of the cardiovascular system in childhood.
2. Early environmental determinants associated with cardiovascular and metabolic develop-
ment.
3. The associations of inflammation in early pregnancy, as measured by first trimester 
C-reactive protein levels, with fetal growth and pregnancy complications.
GEnERAl DESiGn
Most studies presented in this thesis were embedded in the Generation R Study, a population-
based prospective cohort study from fetal life until young adulthood in Rotterdam, The 
Netherlands.17-18 The Generation R Study is designed to identify early environmental and 
genetic determinants of growth, development and health in fetal life and childhood. All 
pregnant women living in the study area with a delivery date between April 2002 and January 
2006 were eligible for enrolment in this study. Enrolment was aimed at early pregnancy, but 
figure 1. Proposed pathways through which early environment exposures and growth lead to 
cardiovascular and metabolic adaptations
Growth in early life 
Fetal growth, size at birth, 
childhood growth 
 
Cardiac adaptations 
Left cardiac structures and 
function 
 
Vascular adaptations 
Arterial stiffness, blood 
pressure 
 
Metabolic adaptations 
 Type 2 diabetes 
 
Cardiovascular and metabolic adaptations 
 
Fetal and infant environmental factors 
Parental smoking, anthropometrics, maternal C-reactive 
protein levels, infant diet 
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was possible until the birth of the child. In total, 9,778 mothers were enrolled in the study, 
of whom 8,880 (91%) were included during pregnancy (Figure 2). Assessments were planned 
in early pregnancy (<18 weeks of gestation), mid-pregnancy (18 - 25 weeks of gestation) and 
late pregnancy (≥25 weeks of gestation), and included physical examinations, blood and urine 
collection, fetal ultrasound examinations, and self-administered questionnaires. In a subgroup 
of 1,232 Dutch women and their children, more detailed assessments of fetal and postnatal 
figure 2. Design and data collection in The Generation R Study
         
Fetal period 
Physical examinations: Parental anthropometrics, ultrasound 
assessments of fetal growth 
Questionnaires: Parental health, life style and diet 
Biological samples: Maternal blood 
 
Birth 
Birth characteristics obtained from midwives and hospital 
records 
Biological samples: Cord blood 
 
Pre-school age (0 - 4 years) 
Visits to child health care centers: Anthropometrics 
Questionnaires: Parental and child health, diet and life style 
 
 School age (6 years) 
Physical examinations: Anthropometrics, body composition, 
ultrasound assessments of cardiovascular development 
Biological samples: Maternal and child blood 
 
Total cohort enrollment 
Enrolment during pregnancy (N = 8,880 mothers) and at 
birth (N = 898 mothers) 
 
Random Dutch subgroup  
Enrolment during pregnancy (N = 1,232 mothers) 
 
Random Dutch subgroup fetal period 
Physical examinations: Additional ultrasound assessments of 
cardiovascular development 
 
Random Dutch subgroup pre-school age (0 - 4 years) 
Physical examinations: Additional assessments of child 
anthropometrics, body composition, ultrasound assessments 
of cardiovascular development 
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growth and development were conducted until the child age of 48 months. This subgroup is 
ethnically homogeneous, excluding confounding or effect modification by ethnicity. In the 
preschool period from birth to 48 months of age, data collection was performed in all children 
by questionnaires and visits to the routine child health care centers. At the age of 6 years, all 
participating children were invited to a dedicated research center in the Erasmus MC -Sophia 
Children’s Hospital. Measurements during this visit included anthropometrics, body composi-
tion, cardiovascular development, and body fluid specimen collection.
In addition, two studies were performed in the Nurses’ Health Study II.19 The Nurses’ Health 
Study II is an ongoing prospective cohort study of 116,430 female registered nurses from 15 
US states, aged 25 to 42 years, that started in 1989. Participants are followed up via biennial 
self-administered questionnaires that inquire about health-related lifestyle, anthropometric 
variables and medical events. The average follow-up for the cohort exceeds 90% for each 2-year 
period. In 2001, the mothers of approximately 35,794 Nurses’ Health Study II participants who 
were alive, still participating in the study, and had no history of cancer in 2001 were enrolled 
in the Nurses’ Mothers’ Cohort.20 This cohort aimed to collect information on the prenatal, peri-
natal and early life exposures of the nurse daughters through questionnaires. The information 
provided by the participating nurses and their mothers has led to many new insights on health 
and disease.
ouTlinE of ThESiS
The objectives are addressed in several studies presented in this thesis. In Chapter 2, the rela-
tion between fetal, infant and childhood growth patterns and determinants and cardiovascular 
development is studied. In Chapter 2.1, cardiac reference growth charts until the age of 2 years 
are presented. Chapters 2.2 and 2.3 describe the influence of fetal and infant growth, body 
composition and measures of obesity on cardiovascular development in childhood. Chapter 
2.4 presents the associations of third trimester placental and fetal haemodynamics and cardio-
vascular structures and function at the child age of 6 years.
In Chapter 3, specific early environmental determinants of cardiovascular development 
are discussed. Chapter 3.1 addresses the association of parental smoking in pregnancy with 
cardiovascular development in childhood. Chapters 3.2 and 3.3 focus on parental smoking in 
pregnancy and the risk of adult-onset hypertension and type 2 diabetes, respectively. In Chap-
ter 3.4 the associations of breastfeeding patterns in infancy with cardiovascular structures and 
function until the age of 24 months are evaluated. The associations of breastfeeding in infancy 
and the introduction of solid foods with cardiovascular development at the age of 6 years are 
assessed in Chapter 3.5.
Chapter 4 addresses the associations of inflammation in early pregnancy as measured 
by first trimester C-reactive protein levels, with maternal and neonatal complications. In 
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Chapter 4.1 the associations of C-reactive protein levels, maternal blood pressure and the risks 
of gestational hypertensive disorders are presented. Chapter 4.2 describes the associations of 
C-reactive protein levels, fetal growth and the risks of neonatal complications. 
Finally, Chapter 5 provides a general discussion of our study and previous studies per-
formed to identify the early determinants of cardiovascular development, health and disease. 
This discussion concludes with implications and directions for future research.
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AbSTRACT
Cardiac structural adaptations in response to physical growth and obesity in older children 
have been identified and might have long term consequences. We examined the associations 
of growth and obesity with cardiac structures during the first two years of life. In a population-
based prospective cohort study among 974 children, left atrial diameter, left ventricular 
diastolic diameter, left ventricular mass, aortic root diameter and fractional shortening were 
repeatedly measured by ultrasound at the ages of 1.5, 6 and 24 months. Height, weight and 
subcutaneous fat mass were measured at the same visits, and blood pressure was measured at 
the age of 24 months. Height, weight, body mass index and body surface area were positively 
associated with all cardiac structures during the first two years of life. At the age of 24 months, 
as compared to normal weight children, obese children had a greater left ventricular mass (1.04 
SDS; 95% CI, 0.20 to 1.89), and a higher fractional shortening (0.91 SDS; 95% CI, 0.02 to 1.80). 
Nonsignificant tendencies were found for left atrial diameter, left ventricular diastolic diameter 
and aortic root diameter. Our results suggest that normal variation in growth affects cardiac 
structures in early life. Overweight and obese children show cardiac adaptations already at the 
age of two years. Further studies are needed to assess whether these structural adaptations 
influence the risk of cardiovascular disease in later life.
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inTRoDuCTion
In childhood and adolescence, cardiac dimensions are closely related to physical growth.1-2 
Previous studies have shown associations of height, weight, body mass index (BMI) and body 
surface area (BSA) with cardiac size in children and adolescents.3-6 Body composition, especially 
lean body mass, has also been recognized as an important determinant of cardiac parameters 
in children.4, 7-8 Because of the increasing prevalence of obesity in children, much attention 
has been focused on the influence of obesity on cardiovascular structure and function.6, 9-11 
In school age children and adolescents, both overweight and obesity are associated with 
structural cardiac changes, such as an increase in left atrial diameter, left ventricular dimen-
sions and mass and an elevated blood pressure, as compared to normal weight individuals.5-6, 
12 Recent studies have also shown preclinical alterations in the aortic elastic properties in obese 
children.13 Since cardiac structures track from childhood to adulthood, early cardiac structural 
adaptations in response to physical growth might have consequences in later life.
Therefore, we assessed in a population-based cohort study among 974 children the associa-
tions between growth characteristics, obesity and left cardiac structures during the first two 
years of life.
mATERiAlS AnD mEThoDS
Design and study population
The study was embedded in the Generation R Study, a population-based, prospective cohort 
study from fetal life onwards.14 This cohort includes mothers, fathers and their children of dif-
ferent ethnicities living in Rotterdam, The Netherlands, and has been described in detail previ-
ously.14 Mothers were enrolled between 2001 and 2005, and all children were born between 
April 2002 and January 2006. Enrolment was aimed at early pregnancy (gestational age <18 
weeks) at the routine fetal ultrasound examination in pregnancy but was allowed until birth 
of the child. More detailed assessments of fetal and postnatal growth and development were 
conducted in a random subgroup of 1,098 Dutch children (Supplementary material, Figure 
S1). The study has been approved by the Medical Ethics Committee of the Erasmus Medical 
Center, Rotterdam. Written informed consent was obtained from all parents of participants. The 
present analysis was limited to singleton live births (N = 1,071). None of these children had 
congenital heart disease. Detailed information on anthropometrics and body composition was 
available in 994 children. In 974 children, one or more echocardiographic measurements were 
performed during the first two years of life.
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Child anthropometrics, body composition and blood pressure
Information about child anthropometrics was obtained by measurements at the research cen-
ter at the ages of 1.5, 6 and 24 months. Length was measured in supine position to the nearest 
0.1 cm by a neonatometer (Holtain Limited®) at the age of 1.5 and 6 months, and height was 
measured in upright position at the age of 24 months. Weight was measured in naked infants 
to the nearest grams by using an electronic scale (SECA®). BMI (kg/m2) and BSA (m2) were 
calculated.15 For child BMI, we obtained age adjusted standard deviation scores (SDS) using 
Dutch reference growth curves (Growth Analyzer 3.0, Dutch Growth Research Foundation, 
Rotterdam, The Netherlands). Children were categorized as normal weight (SDS BMI <1.10), 
overweight (SDS BMI 1.10 – 2.29), or obese (SDS BMI ≥2.30) at the age of 24 months as defined 
by Cole et al.16 Subcutaneous fat mass was measured as biceps, triceps, suprailiacal and sub-
scapular skinfold thickness (SFT) using a standard skinfold caliper (SlimGuide, Creative Health 
Products®) as previously described.17 Total subcutaneous fat mass was measured as the sum 
of biceps and triceps SFT (peripheral subcutaneous fat mass) and suprailiacal and subscapular 
SFT (central subcutaneous fat mass). At 24 months of age, systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) were measured to the nearest mmHg at the left upper arm by using 
an automatic sphygmomanometer (Vital Signs Monitor CAS 740; CAS Medical Systems, Inc., 
Branford, Connecticut, USA).18 The mean of two consecutive measurements was used in the 
analyses. Blood pressure measurements were successfully performed in 70% of the children. In 
215 children, blood pressure was measured only once due to crying and oppositional behavior.
Cardiac outcomes
Two-dimensional M-mode and Doppler echocardiographic measurements were performed 
using ATL-Philips Model HDI 5000 (Seattle, WA) equipment at the ages of 1.5, 6 and 24 months. 
In total, 86% of the measurements were performed by a single echocardiographer. The other 
measurements were performed by two other echocardiographers. The echocardiographers 
were supervised by a pediatric cardiologist. Echocardiographic measurements were success-
fully performed in 90%, 92% and 85% of the children examined at 1.5, 6 and 24 months. Missing 
echocardiograms were mainly due to crying or unavailability of equipment or echocardiogra-
pher. Left atrial diameter, aortic root diameter, interventricular end-diastolic septal thickness, 
left ventricular end-diastolic diameter as a measure of left ventricular end-diastolic volume, left 
ventricular end-diastolic posterior wall thickness, and shortening fraction were measured and 
left ventricular mass was calculated as described previously.19
Covariates
Gestational age was established by fetal ultrasounds.20 Date of birth, infant sex and birth 
weight were obtained from midwife and hospital registries. Information on maternal age, 
pre-pregnancy weight, parity and smoking habits during pregnancy was obtained by question-
naires. Maternal height was measured without shoes and heavy clothing in the first trimester of 
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pregnancy. Socio-economic status was defined as highest completed education according to 
the classification of Statistics Netherlands.21 Information about breastfeeding was collected by 
postnatal questionnaires and medical records.
Statistical methods
Associations of child anthropometrics with repeatedly measured cardiac structures and frac-
tional shortening at 1.5, 6 and 24 months of age were first assessed using regression analysis 
for repeated measures using the Proc Mixed module of SAS. To compare effect estimates for the 
associations of child anthropometrics and body composition with cardiac structures at differ-
ent ages, all measurements were converted to SDS. The best fitting models were constructed 
and the models can be written as:
Cardiac Outcome = β0 + β1 x Anthropometric Measurement + β2 x Child Age + β3 x Anthropo-
metric Measurement x Child Age + Terms for additional variables
In these models, “β0 + β1 x Anthropometric Measurement” reflects the intercept, “β2 x Child Age” 
reflects the slope of change in SDS of cardiac structures and fractional shortening per week. 
The term “β3 x Anthropometric Measurement x Child Age” reflects the difference in change in 
SDS of cardiac structures and fractional shortening per week with increasing anthropometrics.
Subsequently, we performed multiple linear regression models to study the associations 
of blood pressure with cardiac structures at the age of 24 months, and the change in anthro-
pometrics and body composition in the time period of 1.5 months to 24 months with cardiac 
structures at the age of 24 months, and with the change in cardiac structures in the time period 
of 1.5 to 24 months. We used the same models to assess the differences in cardiac structures 
and fractional shortening between normal weight, overweight and obese children. The cat-
egory of normal weight children was taken as the referent. All analyses were adjusted for child 
gender, gestational age, birth weight, breastfeeding status, and maternal height, weight, parity, 
educational level and smoking habits during pregnancy. Multiple linear regression models 
were additionally adjusted for child age at measurement and analyses with growth rates as 
determinant were additionally adjusted for time between measurements. For all analyses, miss-
ing values were imputed with the mean for continuous variables or with an additional category 
for categorical variables. 
Statistical analyses were performed using the SAS version 9.2 (SAS for Windows Version 
9.2; SAS Institute, Cary, NC), including the Proc Mixed module for unbalanced repeated mea-
surements and the Statistical Package of Social Sciences version 17.0 for Windows (SPSS Inc, 
Chicago, IL, USA).
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RESulTS
Subject characteristics
Maternal and child characteristics are shown in Table 1. The overall median gestational age was 
40.3 weeks (95% range 35.8 – 42.4 weeks), with a mean birth weight of 3,510 grams (g) (SD 543 
g). Descriptives of all cardiac measurements are given in the Supplementary material (Table S1). 
Overall, boys had a larger aortic root diameter and left ventricular mass at all ages. Of the 701 
children who underwent successful echocardiographic examinations at the age of 24 months, 
53 were overweight (8.0%) and 5 were obese (0.7%). 
Table 1. Subject characteristics
maternal characteristics measure (n = 974)
Height (cm) 170.0 (6.3)
Weight (kg) 71.3 (13.1)
Parity (%)
  0 602 (61.8)
  ≥1 370 (38.0)
Missing 2 (0.2)
Educational level (%)
  Primary school 19 (2.0)
  Secondary school 320 (32.9)
  Higher education 622 (63.9)
  Missing 13 (1.3)
Smoking during pregnancy (%)
  Never 675 (69.3)
  First trimester only 79 (8.1)
  Continued 116 (11.9)
  Missing 104 (10.7)
Child characteristics
birth (n = 974)
Gestational age (weeks) 40.3 (35.8 – 42.4)
Boys (%) 499 (51%)
Weight (g) 3,510 (543)
Preterm birth (%) 42 (4.3)
Low birth weight (%) 37 (3.8)
Age 1.5 months (n = 861)
Age (months) 1.5 (1.0 – 2.9)
Length (cm) 57.0 (2.6)
Weight (g) 4942 (710)
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normal growth variation and cardiac structures
Table 2 presents regression coefficients of the associations of child anthropometrics and body 
composition with the repeatedly measured left cardiac structures and fractional shortening 
until the age of 24 months. Height, weight, BMI and BSA were positively associated with left 
ventricular diastolic diameter and left ventricular mass, (all P values <0.05) at all ages, and with 
aortic root diameter at the age of 6 and 24 months. For left atrial diameter, child anthropomet-
rics also showed a positive tendency. At the age of 1.5 months, total subcutaneous fat mass 
was associated with left atrial diameter and both total and central fat mass were associated 
Table 1. Subject characteristics (continued)
Child characteristics
Body mass index (kg/m2) 15.2 (1.4)
Body surface area (m2) 0.3 (0.0)
Subcutaneous fat mass (mm)
  Total 24.1 (6.7)
  Central 12.1 (3.4)
  Peripheral 12.1 (3.8)
Age 6 months (n = 867)
Age (months) 6.3 (5.5 – 8.3)
Height (cm) 68.7 (2.6)
Weight (g) 7930 (883)
Body mass index (kg/m2) 16.8 (1.3)
Body surface area (m2) 0.4 (0.0)
Subcutaneous fat mass (mm)
  Total 27.2 (5.8)
  Central 12.8 (3.2)
  Peripheral 14.4 (3.5)
Age 24 months (n = 821)
Age (months) 25.1 (23.7 – 28.2)
Height (cm) 89.0 (3.2)
Weight (g) 12,649 (1,377)
Body mass index (kg/m2) 15.9 (1.3)
Body surface area (m2) 0.5 (0.0)
Subcutaneous fat mass (mm)
  Total 27.3 (6.6)
  Central 11.7 (3.1)
  Peripheral 15.6 (4.4)
Systolic Blood Pressure (mmHg) 101.2 (10.6)
Diastolic Blood Pressure (mmHg) 62.3 (10.8)
Values represent means (SD), medians (95% range) or numbers (%).
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with fractional shortening. At older ages, no consistent associations were observed between 
subcutaneous fat mass and cardiac structures. No association with SBP or DBP measured at 24 
months with any of the cardiac structures or fractional shortening was found.
Table 3 shows that gain in height, weight and BSA between the ages of 1.5 and 24 months 
were positively associated with left atrial diameter, aortic root diameter, left ventricular mass 
and left ventricular diastolic diameter at the age of 24 months. The increase in BSA was the 
strongest determinant, with 0.17 SDS (95% CI, 0.07 to 0.27), 0.33 SDS (95% CI, 0.24 to 0.42), 0.35 
SDS (95% CI, 0.25 to 0.44) and 0.26 SDS (95% CI, 0.16 to 0.35) change in left atrial diameter, left 
ventricular diastolic diameter, left ventricular mass and aortic root diameter respectively per 
SDS change in BSA. A higher weight gain and increase in BSA tended to be associated with 
cardiac growth, particularly with left ventricular mass, whereas height gain between 1.5 and 
24 months showed a strong association with aortic root diameter growth rate (Supplementary 
material, Table S2). The effect estimates for the associations between growth characteristics 
and cardiac structures at 24 months were not materially affected by adjustment for blood pres-
sure (data not shown).
overweight, obesity and cardiac structures
Figure 1 shows the differences of left cardiac structures and fractional shortening between 
normal weight, overweight and obese children. As compared to normal weight children, left 
ventricular mass was significantly greater in both overweight (0.44 SDS, 95% CI, 0.17 to 0.71)
figure 1. Left cardiac structures and fractional shortening in normal, overweight and obese children at 24 
months of age
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Differences in cardiac structures and fractional shortening SDS between overweight and obese children, 
as compared to the reference group (normal weight). Adjustments were made for child gender, 
gestational age, birth weight, breastfeeding status, age at visit, and maternal height and weight at intake, 
parity, educational level and smoking habits during pregnancy.
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and obese (1.04 SDS; 95% CI, 0.20 to 1.89) children. Nonsignificant tendencies were found for 
left atrial diameter, left ventricular diastolic diameter and aortic root diameter. The cardiac 
contractility indicated by fractional shortening was similar in normal and overweight children, 
and was higher in obese children (0.91 SDS; 95% CI, 0.02 to 1.80). SBP and DBP did not differ 
between the normal weight, overweight and obese children.
DiSCuSSion
In this population-based prospective cohort study, we observed positive associations of weight, 
height, BMI and BSA with left atrial diameter, aortic root diameter, left ventricular diastolic 
diameter and left ventricular mass during the first two years of life. Furthermore, this study 
provides evidence that overweight and obesity already in early childhood exert an influence 
on the cardiac size.
Strengths and limitations
A major strength of this study was its prospective design in a large cohort of children. Because 
of the repeated measurements, we were able to investigate the effect of early growth rates 
on the left cardiac structures. A limitation might be that information on left cardiac structures 
was missing in 10%, 8% and 15% of the children measured at the ages of 1.5, 6 and 24 months, 
respectively. Blood pressure measurements were successfully obtained in only 70% of the chil-
dren. Missing echocardiographic or blood pressure measurements could lead to both selection 
bias and loss of power. Our results would be biased if the associations between anthropomet-
rics, blood pressure and cardiac structures and function differ between those included and not 
included in the study. This seems unlikely, but cannot be excluded. Although we adjusted the 
regression models for several potential confounders, residual confounding might be an issue, 
as in any observational study. No information was available about dietary patterns, except for 
breastfeeding status. However, other components of child diet may influence the relationship 
of anthropometric measures and cardiac structures. More detailed information about child 
nutrition, including macronutrients and micronutrients intake, during the first two years would 
provide additional information.
Growth and Cardiac Structures
In children and adolescents, cardiac growth is influenced by physical growth, including body 
size and body composition. Results from the Bogalusa Heart study showed in 160 healthy 
children and young adults aged 9 to 22 years a strong association between height and left 
ventricular mass.3 The same study demonstrated that there is a positive association between 
left ventricular mass in childhood and adolescence across BMI quartiles.22 Various studies 
observed that body composition measured by SFT, bioelectric impedance or dual energy X-ray 
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absorptiometry, was also closely related to cardiac size in childhood and adolescence.2-3, 7-8 
Results from the Muscatine Study indicated fat free mass as a determinant of cardiac size and 
growth during adolescence8, and another study among children supported the findings that 
lean tissue mass was a strong predictor in the youth.7 In our study, we observed no consistent 
associations of subcutaneous fat mass measures with cardiac structures during the first two 
years of life. These results seem to be in contrast to the associations of BMI with left cardiac 
structures. BMI represents both fat free mass and fat mass though, and lean body mass might 
also be elevated in obese individuals. Our results are in line with the hypothesis that the 
demands of lean body mass are the primary determinants of left ventricular mass in children.7
In normal and hypertensive children, SBP and left ventricular mass are shown to be posi-
tively associated across a wide range of blood pressure values.7, 11-12, 23 Sorof and colleagues 
observed left ventricular hypertrophy in 27% of adolescents with systolic hypertension, and 
that patients with left ventricular hypertrophy had a greater BMI than those without hypertro-
phy. These observations suggest that left ventricular hypertrophy can occur early in the course 
of hypertension in young individuals and that the combination of obesity and hypertension 
enhances the risk for adverse cardiovascular outcomes.23 However, in our study, there was no 
difference in SBP or DBP between the normal weight, overweight and obese children, and the 
effect estimates for the associations between growth characteristics and cardiac structures 
were not materially affected by adjustment for blood pressure.
obesity and Cardiac Structures
The recognition of obesity as an important determinant of cardiac remodeling, has led to 
increased interest in the influence of overweight and obesity on early cardiovascular develop-
ment.6, 9-12 In the Strong Heart Study among adolescents aged 14 to 20 years, both overweight 
and obese participants had a greater left ventricular diameter and mass than normal weight 
adolescents.6 Di Salvo demonstrated that obesity, in absence of hypertension, was associated 
with significant reduction in systolic myocardial deformation properties in childhood, involving 
both the right and left ventricle.10 In our cohort, we showed that overweight and obesity exert a 
significant influence on left cardiac structures already in early childhood. Severe obesity is also 
associated with arterial wall stiffness and endothelial dysfunction in children.24 Obese children 
have a larger abdominal aortic diameter and increased aortic stiffness compared to normal 
weight children, suggesting that preclinical changes in the aortic elastic properties are already 
early detectable.13 The present study showed a nonsignificant tendency towards a larger aortic 
root diameter in overweight and obese children.
mechanisms
The associations of obesity with cardiac structures in childhood may be explained by various 
interrelated hemodynamic, metabolic, neurohormonal, and genetic mechanisms. In adulthood, 
obesity related hypertension creates a continuous pressure overload25, inducing concentric 
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left ventricular hypertropy.26 Elevated blood pressure and an increase in left ventricular mass 
have been previously described in obese children.11-12 In our study, the associations between 
growth and cardiac structures were not explained by blood pressure. In normotensive patients, 
obesity is related to an elevated cardiac output and chronic volume overload27-29, leading to 
an eccentric left ventricular hypertrophy. These changes are most likely due to the increased 
metabolic demand of the higher lean and fat mass in obesity29, what might establish an effect 
already in early childhood. Another possible pathway that links obesity with cardiovascular 
remodeling, is through its association with insulin resistance and hyperinsulinemia. Studies in 
children found significant partial correlations of insulin with left ventricular mass and percent-
age of fat, suggesting that insulin may mediate the relation of fatness to cardiac structures.30 
In addition, obesity is related to a stimulated sympathetic outflow and inappropriately 
activated renin-angiotensin system.29, 31-32 These neurohormonal mechanisms may induce 
hemodynamic changes such as peripheral vasoconstriction and volume retention. Finally, the 
influence of body size and obesity on left cardiac structures might be explained by a common 
genetic mechanism that modulates both somatic and cardiac growth.33 The mechanisms that 
are associated with cardiac remodeling in childhood and adulthood remain subject to further 
investigation.
Perspectives
Cardiac structural adaptations in response to physical growth and obesity might have conse-
quences in later life. This study demonstrated that physical growth is an important determinant 
of cardiac development in infancy and early childhood. Furthermore, the results of this study 
indicate that obesity is not only a risk factor for cardiovascular disease in later life, but also 
affects cardiac development as early as from the age of two years. Our results suggest that left 
cardiac size and function in adulthood have at least part of their origin in infancy and early 
childhood. Further studies are needed to investigate the possible influence of early cardiac 
growth and adaptations on the risk of cardiovascular disease in later life.
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SuPPlEmEnTARy mATERiAl
Table S1. Cardiac structures and fractional shortening at the ages of 1.5, 6 and 24 months
Echocardiographic measurements boys Girls P value
1.5 months (n = 402) (n = 376)
Left atrial diameter (mm) 17.0 (1.9) 16.6 (1.9) <0.01
Left ventricular diastolic diameter (mm) 22.5 (1.8) 21.5 (1.9) <0.01
Left ventricular mass (g) 15.2 (3.1) 13.8 (2.8) <0.01
Aortic root (mm) 12.0 (1.2) 11.5 (1.1) <0.01
Fractional shortening (%) 35.4 (4.8) 35.4 (5.1) 0.92
6 months (n = 420) (n = 381)
Left atrial diameter (mm) 18.0 (1.9) 17.9 (1.8) 0.59
Left ventricular diastolic diameter (mm) 25.6 (1.8) 24.7 (1.9) <0.01
Left ventricular mass (g) 20.3 (4.1) 18.4 (3.7) <0.01
Aortic root (mm) 13.9 (1.2) 13.4 (1.2) <0.01
Fractional shortening (%) 37.2 (4.6) 37.1 (4.8) 0.72
24 months (n = 358) (n = 343)
Left atrial diameter (mm) 20.7 (2.5) 20.5 (2.4) 0.23
Left ventricular diastolic diameter (mm) 31.9 (2.4) 30.9 (2.3) <0.01
Left ventricular mass (g) 32.5 (5.7) 30.0 (5.1) <0.01
Aortic root (mm) 16.7 (1.4) 16.0 (1.4) <0.01
Fractional shortening (%) 35.4 (4.6) 35.4 (4.6) 0.99
Values represent means (SD). Differences between boys and girls were compared using independent 
samples t-test.
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figure S1. Flow chart of the participants included in the analyses 
 
 
 
 
Focus Cohort postnatal participation 
N = 1,098 
 N = 27 Excluded, due to twin pregnancies 
 
Singleton live births 
N = 1,071 
 
Data on child anthropometrics or body composition 
available N = 994 
   
 
Data on cardiovascular structures available 
N = 974 
 
Participation in 6 weeks visit: N = 861 
Cardiac ultrasounds: N = 778 (90%) 
 
Participation in 6 months visit: N = 867 
Cardiac ultrasounds: N = 801 (92%) 
 
Participation in 24 months visit: N = 821 
Cardiac ultrasounds: N = 701 (85%) 
 
N = 77 Excluded, due to missing child 
anthropometric or body composition 
 
 
N = 20 Excluded, due to missing 
cardiovascular measurements 
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AbSTRACT
Fetal exposure to parental smoking may lead to developmental adaptations and promote 
various diseases in later life. This study evaluated the associations of parental smoking during 
pregnancy with the risk of hypertension in the daughter in adulthood, and assessed whether 
these associations are explained by birth weight or body weight throughout life. We used 
data on 33,086 participants of the Nurses’ Health Study II and the Nurses’ Mothers’ Cohort. Cox 
proportional hazards models were used to examine the associations of maternal and paternal 
smoking during pregnancy with the nurse daughter, with self-reported physician-diagnosed 
hypertension from 1989 until 2007. Overall, 8,575 (25.9%) mothers and 18,874 (57.0%) fathers 
smoked during pregnancy. During follow-up, 7,825 incident cases of adult-onset hypertension 
were reported. Both maternal and paternal smoking of ≥15 cigarettes/day during pregnancy 
were associated with increased risks of hypertension (RR 1.19, 95% CI 1.09 to 1.29, and RR 1.18, 
95% CI 1.12 to 1.25, respectively) in the age-adjusted models. Further adjustment for birth 
weight did not affect the effect estimates appreciably, while additional adjustment for body 
shape and weight until age 18, or current body mass index, attenuated the associations with 
both maternal and paternal smoking (RR 1.07, 95% CI 0.98 to 1.16, and RR 1.06, 95% CI 1.01 
to 1.12, respectively). The associations of parental smoking during pregnancy with the risk of 
hypertension in the offspring were largely explained by body weight throughout life, suggest-
ing that these associations may not reflect direct intrauterine mechanisms.
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inTRoDuCTion
Fetal developmental adaptations to a suboptimal intrauterine environment may affect the 
structure, physiology and function of various organ systems. These adaptations lead to a better 
short-term survival through fetal growth retardation, but may increase the susceptibility of 
cardiovascular disease in adulthood.1 This hypothesis is supported by various studies reporting 
consistent associations between lower birth weight and an elevated blood pressure in later 
life.2-4 Indeed, birth weight is a product of genetic and environmental factors affecting fetal 
growth and gestation length, but the specific intrauterine exposures and mechanisms linking 
low birth weight to an elevated risk of hypertension are not well understood.
Parental smoking during pregnancy is an established risk factor of a compromised intra-
uterine environment and might lead to developmental adaptations influencing postnatal 
blood pressure levels. Epidemiologic studies of parental smoking during pregnancy and blood 
pressure levels in offspring have demonstrated inconsistent results5-14, and the mechanisms 
through which prenatal smoke exposure might program blood pressure in later life are 
unclear. Prenatal smoke exposure is associated with reduced birth weight and increased risk of 
overweight in both childhood and adulthood. (Holly R. Harris, ScD, Walter C. Willett, MD, DrPH, 
Karin B. Michels, ScD, PhD, unpublished data, 2012)14-16 Birth weight is inversely associated 
with blood pressure in later life2-4, and overweight in adulthood is positively associated with 
the risk of hypertension, as demonstrated in Framingham Heart Study participants.17 There-
fore, birth weight and body weight throughout life might mediate the association between 
maternal smoking and blood pressure development. Thus far, the majority of studies has been 
conducted in child populations, and has mainly focused on the effect of maternal smoking only 
on blood pressure development. The impact of parental smoking during pregnancy on the risk 
of adult hypertension is unclear.
Therefore, the aims of this study were to assess the associations of maternal and paternal 
smoking during pregnancy with hypertension in adulthood, and to examine whether birth 
weight or body weight throughout life explain these associations, in a large cohort of US 
women.
mEThoDS
Study population
The Nurses’ Health Study II (NHS II) is an ongoing prospective cohort study of 116,430 female 
registered nurses that started in 1989.18 Participants are followed up via biennial self-adminis-
tered questionnaires that inquire about health-related lifestyle, anthropometric variables and 
medical events. In 2001, the mothers of approximately 35,794 NHS II participants were enrolled 
in the Nurses’ Mothers’ Cohort.19 The participating mothers completed a questionnaire on the 
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prenatal, perinatal and early-life exposures of the nurse daughters. The 113 Nurses who were 
adopted were excluded from the study, as were 1,013 nurses without information about mater-
nal and paternal smoking during pregnancy with the nurse daughter. The study protocol was 
approved by the institutional review boards of the Brigham and Women’s Hospital and Harvard 
School of Public Health, Boston, USA, and the National cancer Institute, Bethesda, Maryland, 
USA.
Assessment of parental smoking
Information on smoke exposure in utero was collected on the 2001 Nurses’ Mothers’ Cohort 
questionnaire.20 Mothers were asked to report if they ever smoked cigarettes during preg-
nancy with the nurse daughter, the number of cigarettes they smoked daily during pregnancy, 
whether they stopped smoking during pregnancy, and if so, during which trimester. Maternal 
smoking was categorized as never smoked; stopped smoking in first trimester of pregnancy, 
continued smoking <15 cigarettes/day during pregnancy; and continued smoking ≥15 ciga-
rettes/day during pregnancy. The questionnaire also inquired if the nurse’s father ever smoked 
during pregnancy and the number of cigarettes he smoked. Paternal smoking was categorized 
as never smoked; smoked <15 cigarettes/day during pregnancy; and smoked ≥15 cigarettes/
day during pregnancy. To investigate the association of both parents smoking independent 
and combined with the risk of hypertension, maternal and paternal smoking during pregnancy 
data were categorized into no parental smoking during pregnancy; only paternal smoking 
during pregnancy; and maternal smoking only and both parents smoking during pregnancy.
Ascertainment of hypertension
The baseline and biennial follow-up questionnaires of the NHS II asked participants about 
physician-diagnosed hypertension and the year of diagnosis. Self-reported hypertension was 
previously validated in the NHS II.21 Review of the medical records of a randomly selected 
subset of participants, suggested a sensitivity of self-reported hypertension of 94% and a 
specificity of a nurse reporting no diagnosis of hypertension of 85%. For the current analysis, 
1,582 women who reported physician-diagnosed hypertension at baseline (1989) were consid-
ered to have early onset, prevalent hypertension. Incident cases included participants who first 
reported hypertension on any of the subsequent questionnaires and whose date of diagnosis 
was after the return of the 1989 baseline NHS II questionnaire. For the analyses on incident 
cases, prevalent cases were excluded from the analysis, as the exact onset of their hypertension 
could not be dated.
Covariates
Information about covariates was obtained from the Nurses’ Mothers’ Cohort as well as the NHS 
II questionnaires. The 2001 Nurses’ Mothers’ Cohort questionnaire collected data on the nurse 
daughter’s gestational age, birth weight and breastfeeding status, maternal and paternal age at 
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birth of the nurse daughter, educational level, occupation and home ownership at the time of 
the daughter’s birth, maternal pre-pregnancy weight, paternal weight, parental height and the 
occurrence of pregnancy complications (preeclampsia and eclampsia) during the pregnancy 
of the nurse daughter. The 1989 NHS II questionnaire assessed age, height, weight at age 
18, self-classified race of the nurse, and family history of hypertension at baseline. To assess 
body fatness in childhood, a nine-level figure drawing originally developed by Stunkard22 was 
used to ascertain body shape at ages 5 and 10. Few participants reported their body fatness 
as greater than level 5 at ages 5 and 10, and therefore figures 5 - 9 were combined into a 
single category. Nurses’ weight, smoking status and oral contraceptive use were additionally 
ascertained from the 1989 NHS II questionnaire and were updated with data from each bien-
nial questionnaire cycle. Body mass index (BMI) at age 18 and current BMI were calculated by 
dividing the participants’ reported weight in kilograms by height in meters squared as assessed 
in 1989. A Dietary Approaches to Stop Hypertension (DASH) score was calculated from the 1991 
semi-quantitative food frequency questionnaire and updated every 4 years.23 The DASH score 
was constructed based on foods and nutrients emphasized or minimized in the DASH diet24, 
focusing on 8 components: high intake of fruits, vegetables, nuts and legumes, low-fat dairy 
products and whole grains, and low intake of sodium, sweetened beverages, and red and pro-
cessed meats. Information on alcohol intake was also retrieved from the 1991 semi-quantitative 
food frequency questionnaire and updated every 4 years. Physical activity was expressed in 
metabolic equivalent task scores, and was ascertained in 1989, 1993, 1997, 2001 and 2005.
Statistical methods
Cox proportional hazards regression models were used to estimate the rate ratios (RR’s) and 
95% confidence intervals (CI’s) of the risk of incident hypertension by maternal and paternal 
smoking. Participants contributed follow-up time from the return of the 1989 questionnaire to 
the report of physician diagnosed hypertension, death, or end of follow-up on June 1, 2007. To 
investigate the association of parental smoking on early onset hypertension, logistic regression 
models were used to estimate the odds ratio’s (OR’s) and 95% CI’s of prevalent hypertension in 
1989 by maternal and paternal smoking. We considered birth weight, childhood somatotype 
and BMI in adolescence and adulthood as potential explanatory variables for the associations 
of maternal and paternal smoking during pregnancy with the risk of hypertension.
Regression models were adjusted for age (Model 1), and in addition for perinatal variables 
(maternal and paternal age at delivery, maternal pre-pregnancy BMI, paternal BMI, maternal 
and paternal educational level, occupation, house ownership at the time of the daughter’s 
birth, and the occurrence of pregnancy complications (preeclampsia and eclampsia) during the 
mothers’ pregnancy, nurses’ ethnicity, gestational age, breastfeeding status and family history 
of hypertension) (Model 2), for birth weight (Model 3), and for adult life variables (nurses’ hus-
bands’ educational level, pretax household income, smoking, oral contraceptive use, height, 
DASH score, alcohol intake and physical activity) (Model 4). To examine whether body weight 
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throughout life explained the associations, we additionally adjusted Model 4for body shape of 
the nurses at age 5, body shape at age 10 and BMI at age 18 (Model 5) or current BMI (Model 
6). The proportion of the associations potentially explained by current BMI was estimated 
using a SAS macro that calculates the point and interval estimates of the percent of exposure 
effect explained by the intermediate variable (Mediate SAS; Harvard School of Public Health; 
available at http://www.hsph.harvard.edu/faculty/donna-spiegelman/software/mediate/).25To 
investigate the association of both parents smoking independent and combined with the risk 
of hypertension, we compared the effect estimates of smoking by father only (N = 12,165), and 
mother only and both parents combined (N = 8,575), with no parental smoking during preg-
nancy (N = 12,346). Trend tests were performed across the level of the number of cigarettes 
smoked. Effect modification by current BMI was assessed with a likelihood ratio test comparing 
the model with the cross-product term between the exposure variable and the potential effect 
modifier, to the model with main effects only. Because time of observation was between the 
return of the NHS II questionnaire in 1989 and the NHS II questionnaire in 2007 and exposure 
was assessed in 2001, both prospective and retrospective analyses were combined in the 
analyses on incident hypertension. Therefore, sensitivity analyses were performed restricting 
Table 1. Age-standardized characteristics of the study population of the mothers, fathers and nurse 
participants of the Nurses’ Health Study II Cohort by maternal smoking during pregnancy
Subject characteristics maternal smoking during pregnancy
Nonsmoker
(N = 24,511)
Quit smoking in 
first trimester 
(N = 1,092)
Continued 
smoking <15 
cig/d (N = 4,232)
Continued 
smoking ≥15 
cig/d (N = 2,626)
maternal
  Age at daughter’s birth (years) 26.5 (5.1) 25.4 (4.4) 26.2 (4.7) 25.8 (4.6)
  BMI before pregnancy (kg/m²) 21.4 (2.6)  20.9 (2.3) 20.9 (2.4) 21.0 (2.6)
  Attended college (%) 36 42 41 38
  Professional occupation (%) 3 4 3 3
Paternal
  Age at daughter’s birth (years) 29.2 (5.7) 28.1 (5.3) 29.1 (5.4) 28.9 (5.3)
  BMI (kg/m²) 23.6 (2.8) 23.5 (2.8) 23.6 (2.7) 23.5 (2.8)
  Attended college (%) 41 50 49 47
  Professional occupation (%) 30 34 33 35
  Smoked during pregnancy (%) 50 74 79 80
  Family owned house at 
daughter’s birth (%)
49 38 44 43
Pregnancy and childhood
  Preeclampsia or eclampsia 
during pregnancy (%)
4 4 3 3
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Table 1. Age-standardized characteristics of the study population of the mothers, fathers and nurse 
participants of the Nurses’ Health Study II Cohort by maternal smoking during pregnancy (continued)
Subject characteristics maternal smoking during pregnancy
Nonsmoker
(N = 24,511)
Quit smoking in 
first trimester 
(N = 1,092)
Continued 
smoking <15 
cig/d (N = 4,232)
Continued 
smoking ≥15 
cig/d (N = 2,626)
  Gestational age at birth 
(weeks)
39.4 (2.3) 39.5 (2.4) 39.3 (2.4) 39.2 (2.5)
  Birth weight (g) 3,336 (502) 3,258 (510) 3,162 (512) 3,113 (512)
  Ethnicity white (%) 96 96 97 98
  Family history of hypertension 
(%)
50 54 49 50
  Breastfed in infancy (%) 56 46 43 44
  Body shape at age 5 <level 
5 (%)
94 93 93 93
  Body shape at age 10 <level 
5 (%)
89 89 87 88
  BMI at age 18 (kg/m²) 20.9 (3.0) 21.1 (3.0) 21.3 (3.1) 21.5 (3.4)
Adulthood (baseline, 1989)
  Age in 1989 (years)* 34.3 (4.7) 33.8 (4.5) 34.0 (4.5) 33.2 (4.4)
  Smoking
    Never (%) 71 62 61 62
    Past (%) 20 25 25 23
    Current (%) 9 13 14 15
  Oral contraceptive use
    Never (%) 17 13 15 15
    Past (%) 68 72 70 70
    Current (%) 15 15 14 14
  Pretax household income 
>75,000 dollar (%)
57 61 59 60
  Husband attended college (%) 82 83 84 83
  Height (cm) 165 (7.0) 165 (7) 165 (7) 164 (7)
  BMI (kg/m²) 23.3 (4.4) 23.5 (4.5) 23.6 (4.5) 24.0 (4.7)
  Physical activity (METs/wk)† 24.1 (34.1) 24.4 (31.9) 25.0 (34.6) 26.1 (39.1)
  Alcohol intake (g/day) 2.9 (5.7) 3.6 (5.4) 3.8 (6.5) 3.7 (6.9)
  DASH score 24.0 (5.1) 24.2 (5.1) 24.1 (5.1) 23.8 (5.2)
Abbreviations: BMI, body mass index; METs, metabolic equivalents; and DASH, Dietary Approaches to 
Stop Hypertension
Values are means (SD) unless otherwise indicated
*Value is not age adjusted
†Metabolic equivalents from recreational and leisure-time activities
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follow-up to the prospective component, between the return of the NHSII Questionnaire 2001 
(exposure assessment) and the NHSII Questionnaire 2007 (outcome assessment). 
All statistical analyses were performed using the Statistical Analysis System (SAS) statistical 
software version 9.2 (SAS Institute Inc, Cary, North Carolina).
RESulTS
1,582 Women reported physician-diagnosed hypertension at baseline (1989). During 533,902 
person-years of follow up, 7,825 incident cases of physician-diagnosed hypertension were 
reported. Participant characteristics by maternal smoking during pregnancy are presented in 
Table 1. As compared to mothers who never smoked during pregnancy, mothers who contin-
ued smoking 15 cigarettes/day or more, were more likely to have attended college, and did 
less often own a house at the time of the nurses’ birth. Daughters of mothers who continued 
smoking ≥15 cigarettes/day during pregnancy, were born with lower birth weight, were less 
frequently breastfed, were more often smokers in adulthood, and had a higher alcohol intake 
than daughters of mothers who did not smoke during pregnancy. In total 12,346 (37.3%) moth-
ers of the study participants reported that neither parent smoked during pregnancy, 1,866 
(5.6%) reported maternal smoking only, 12,165 (36.8%) reported paternal smoking only, and 
6,709 (20.3%) reported that both parents smoked during pregnancy.
In the age-adjusted Cox proportional hazards model, maternal smoking of ≥15 cigarettes/
day during pregnancy was associated with an increased incidence of hypertension in the 
offspring as compared to no maternal smoking during pregnancy (RR 1.19, 95% CI 1.09, 1.29) 
(Table 2). Adjustment for perinatal variables, birth weight and adult life variables did not 
appreciably change the observed associations. The RR’s were decreased by additional adjust-
ment for body shape at age 5, body shape at age 10 and BMI at age 18 (RR 1.13, 95% CI 1.03, 
1.23), and inclusion of current BMI completely eliminated the associations (RR 1.07, 95% CI 0.98, 
1.16). In the age-adjusted models we did not observe an increased risk when mothers reported 
first trimester smoking only, or continued smoking of <15 cigarettes/day during pregnancy, 
although our results suggested a dose-response trend (P for trend <0.01). The trend test was 
no longer significant after additional adjustment for current BMI of the nurse. Body mass 
index was estimated to mediate 60% (95% CI 10%, 111%) of the association between maternal 
smoking of 15 cigarettes/day or more and the risks of adult-onset hypertension accounting 
for possible confounding variables. Using similar models focused on the associations of the 
number of cigarettes smoked during pregnancy by the father with the risk of hypertension 
in the offspring, we observed in the age-adjusted models that as compared to no paternal 
smoking during pregnancy, paternal smoking of 15 cigarettes/day or more was associated with 
an increased risk of hypertension in the adult offspring (RR 1.18, 95% CI 1.12, 1.25) (Table 2). 
The RR’s only slightly changed after adjustment for perinatal variables, birth weight and adult 
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life variables. Similarly, the effect of the quantity of paternal smoking attenuated after adjust-
ment for body weight throughout life, although the associations of paternal smoking of 15 
cigarettes/day or more remained significant. The estimated mediation proportion indicated 
that current BMI accounted for 49% (95% CI 22%, 76%) of the association between paternal 
smoking of 15 cigarettes/day or more and the risks of adult-onset hypertension adjusting for 
possible confounders.
In the age-adjusted models, paternal smoking only, as well as maternal smoking only and 
both parents smoking during pregnancy combined, were associated with an increased risk of 
adulthood hypertension (Table 3); the strongest association was found for both parents smok-
ing during pregnancy (RR 1.13, 95% CI 1.07, 1.20). However, the associations were reduced after 
adjusting for childhood body shape and BMI at age 18, and were eliminated when current BMI 
was added to the models (RR 1.01, 95% CI 0.95, 1.08).
No significant interactions were observed for the risk of hypertension, by current BMI. When 
restricting follow-up to incident events counted after exposure assessed in 2001, the RR’s of 
the fully adjusted models were slightly higher for both maternal smoking in first trimester only 
and continued smoking of <15 cigarettes/day, and marginally lower for maternal smoking ≥15 
cigarettes/day. The RR’s of the fully adjusted models of paternal smoking remained stable, with 
larger confidence intervals.
Comparably, in the logistic regression models on prevalent hypertension cases in 1989, 
the associations of the quantity of both maternal and paternal smoking during pregnancy 
decreased after adding body weight throughout life to the models, and were completely 
eliminated after adjustment for current BMI (OR 0.99, 95% CI 0.81, 1.21, and OR 1.05, 95% CI 
0.92, 1.18, respectively) (Supplementary material). Adding body weight throughout life to the 
logistic regression models similarly decreased the association of both parents smoking inde-
pendent and combined, compared to no parental smoking during pregnancy with the risk of 
early onset hypertension (Supplementary material).
DiSCuSSion
In this prospective cohort study of 33,086 nurses, we observed weak positive associations 
between both maternal and paternal smoking during pregnancy with the risk of hypertension 
in their adult daughters. However, observed associations were largely eliminated after adjust-
ment for body weight throughout life, with BMI closest to the diagnosis of hypertension having 
the greatest impact. Most of the effect of parental smoking during pregnancy on the daughter’s 
hypertension risk was mediated through current BMI, but some independent effect remained.
Blood pressure shows moderate tracking between childhood and adulthood26, and factors 
that influence blood pressure in early life might have consequences for the risk of hypertension 
in later life. Studies of parental smoking during pregnancy in relation to the development of 
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blood pressure in the offspring have mainly focused on childhood blood pressure and had 
inconsistent results. Several studies suggested a positive association of fetal smoke exposure 
with blood pressure during childhood5-8, while other studies found no evidence of an effect 
of maternal smoking on blood pressure.9-10 A systematic review of nine observational studies 
suggested that maternal smoking during pregnancy was associated with a slightly elevated 
blood pressure in children.12The inconsistent results between studies might be explained by 
a diminishing influence of parental smoking behavior during pregnancy on offspring blood 
pressure with increasing age, when influences from behavior and environmental factors such 
as BMI become increasingly important. In adult participants of the 1958 British Birth Cohort, 
adult offspring of mothers who smoked during pregnancy had a higher blood pressure on 
average than offspring of non-smokers, but the associations were attenuated after adjustment 
for postnatal influences across life.14 Second, previous studies varied in the level of adjustment 
for possible confounders, most notably postnatal weight or BMI.
In the present analysis, adjustment for body weight throughout life attenuated considerably 
the association of parental smoking during pregnancy and adult hypertension. Previous stud-
ies suggested that intrauterine smoke exposure leads to adaptations in weight and predispose 
to an increased risk of overweight and obesity in the offspring in childhood, adolescence and 
adulthood.(Holly R. Harris, Walter C. Willett, Karin B. Michels, unpublished data, 2012)14-16 Obe-
sity and weight gain are major risk factors for developing hypertension.17, 27 Thus the associa-
tion of parental smoking during pregnancy with the risk of hypertension in adulthood might 
be mediated through the programming of body weight throughout life. These findings are 
supported by a study in children, which suggested that childhood BMI and weight trajectory 
largely mediated the associations of maternal smoking during pregnancy with the offspring’s 
systolic blood pressure at the age of seven.11However, parental smoking in pregnancy may also 
be a proxy of behavioral lifestyle factors clustering in smoking families that not only affect the 
risk of adult-onset hypertension, but also fosters the development of overweight and obesity 
throughout life.
Because of the inverse relation between birth weight and blood pressure in later life, and the 
widely acknowledged association of maternal smoking during pregnancy with birth weight, 
we also investigated the influence of birth weight on the association of parental smoking dur-
ing pregnancy and adult hypertension. The influence of birth weight in the pathway appeared 
to be limited. In line with our findings, in a recent meta-analysis, the associations of fetal smoke 
exposure with child overweight were independent of birth weight.15
In the present study cohort, we observed similar effect estimates for the associations of 
paternal smoking during pregnancy with the risk of hypertension in the offspring, compared to 
maternal smoking. Although passive smoke exposure is known to cause cardiovascular disease 
in adults28, and maternal exposure to second hand smoke in pregnancy is associated with a 
reduction in birth weight29, the effect of maternal active smoking is expected to be larger than 
the effect of maternal second hand smoke exposure in pregnancy. If the associations between 
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maternal smoking during pregnancy with blood pressure in the offspring would be due to direct 
intrauterine mechanisms, we would expect stronger effects for maternal than paternal smok-
ing on health outcomes in the offspring. Moreover, the associations of numbers of cigarettes 
smoked by the parents and the specific period during pregnancy of fetal smoke exposure with 
risk of hypertension also attenuated after adjustment for life course body weight. Brion and 
colleagues reported in children aged seven years similar associations for maternal and paternal 
smoking during pregnancy with offspring systolic blood pressure.13 The authors subsequently 
concluded that differences in child blood pressure found in minimally adjusted models are not 
because of a biological influence of maternal smoking on the intrauterine environment, but 
rather are a marker for other environmental factors. In addition, the effects of postnatal passive 
smoke exposure might be more important than the effects of intrauterine smoke exposure, 
especially in childhood when children live in close proximity to their parents. In healthy pre-
school children, parental smoking during childhood was an independent risk factor for higher 
blood pressure in the offspring.30
A limitation of the study was that data on parental smoking and associated covariates were 
collected retrospectively after several decades. We expect that any resulting misclassification 
is likely to be non-differential with respect to adult disease status and would therefore bias 
the associations towards the null. However, in a subgroup of our study population a high 
agreement of the daughters’ reports of maternal smoking during pregnancy as compared to 
the mothers’ reports was reported (sensitivity ranged from 74% to 85% and specificity ranged 
from 90% to 95%, kappa = 0.72 - 0.81).20 Second, both prospective and retrospective analyses 
were combined. However, actual exposure took place a considerable time before the outcome 
of interest, and it is assumed that reporting of exposure is independent of the outcome of 
interest. In addition, in the sensitivity analysis performed with time of observation between 
2001 and 2007, the results were not appreciably changed. Third, the diagnosis of hypertension 
was obtained through self-reports. Although hypertension reporting has been validated previ-
ously in the NHS II21, and self-reported hypertension appeared strongly predictive of coronary 
heart disease in the Nurses’ Health Study I31, it cannot be excluded that misclassification has 
occurred. Finally, although comprehensive information about covariates was available, the 
possibility of residual confounding due to insufficient measured or unmeasured factors should 
be considered. The major strengths of the study are the large sample size and the availability 
of information on paternal smoking during pregnancy. The study relied primarily on maternal 
reports of parental smoking during pregnancy, which are likely to be superior to the reports of 
the daughters.
Perspectives
Parental smoking is a modifiable risk factor of compromised intrauterine environment and 
there is broad evidence of its deleterious effects on fetal health. Understanding the influence 
of adverse fetal environment on cardiovascular disease and its risk factors may have important 
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implications on the knowledge of the pathogenesis and prevention of cardiovascular disease. 
This study provides limited evidence of a direct intrauterine effect of prenatal smoke exposure 
on vascular function. The weak associations of maternal and paternal smoking during preg-
nancy with the risk of hypertension in adulthood were largely attenuated after adjustment for 
body weight throughout life. Our observations may be explained by a mediating role of BMI 
of the effect of parental smoking on hypertension through the programming of body weight 
throughout life, or a marker of unhealthy lifestyle behaviors clustering in smoking families, 
that influence the development of BMI. The exact mechanisms linking parental smoking, body 
weight and the risks of incident hypertension in adulthood remain subject for further investiga-
tion.
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AbSTRACT
background Shorter duration of breastfeeding in infancy has been suggested to be associated 
with an increased risk of cardiovascular disease in adulthood. Early cardiovascular adaptations 
due to breastfeeding may explain these associations.
Aim To investigate whether breastfeeding affects left cardiac structures and blood pressure 
development in early childhood. 
Study Design Prospective cohort study from fetal life until the age of two years. 
Subjects Information about the duration and exclusivity of breastfeeding was collected by 
questionnaires at the ages of 2, 6 and 12 months in 933 children.
outcome measures Left cardiac structures (left atrial diameter, aortic root diameter and left 
ventricular mass), fractional shortening and blood pressure at the ages of 1.5, 6 and 24 months. 
Results No differences in cardiac structures, fractional shortening and blood pressure were 
observed between breastfed and non-breastfed children. Duration and exclusivity of breast-
feeding were not consistently associated with any cardiac structure, fractional shortening, or 
blood pressure until the age of 24 months. Also, there was no association of breastfeeding 
with cardiac growth between 6 months and 24 months. All analyses were adjusted for child 
age and sex. Additional adjustment for child anthropometrics, maternal age, anthropometrics, 
family history, maternal cardiovascular risk factors, pregnancy or delivery complications, parity, 
socio-economic status, smoking status and alcohol consumption during pregnancy did not 
materially change the effect estimates.
Conclusions Our results do not support the hypothesis that early postnatal cardiovascular 
adaptations underlie the previously shown associations between breastfeeding and cardiovas-
cular disease in adulthood. Further studies are needed to investigate whether and at what age 
the associations appear.
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inTRoDuCTion
Prolonged breastfeeding in infancy may have a favorable effect on cardiovascular disease and 
its risk factors in later life.1 Prior research demonstrated inverse associations of breastfeeding 
with body mass index2, total cholesterol and low density lipoprotein (LDL) cholesterol levels3 
and a positive association with high density lipoprotein (HDL) cholesterol levels4 in adulthood. 
Two meta-analyses suggested that adults who had been breastfed had a slightly lower systolic 
blood pressure than those who were not breastfed.5-6 Human breast milk differs from infant 
formula in several ways that affect the growth of human infants.7 Human breast milk has a dis-
tinct lipid profile and contains hormones and growth factors that may influence the develop-
ment of the cardiovascular system.8-9Associations of breastfeeding with cardiovascular disease 
might be explained by developmental plasticity, which refers to the ability of an organism to 
develop in various ways, depending on the particular environment or setting.10 The increased 
risks of cardiovascular disease among subjects who were not breastfed may reflect the long 
term consequences of adaptive responses in cardiovascular structure and function to nutrition 
in infancy. However, results from studies relating breastfeeding with cardiovascular morbidity 
and mortality seem to be inconsistent. A recent meta-analysis of four studies suggested no 
association between breastfeeding and the risk of death from cardiovascular disease.11 Data 
from previous studies are confined by the retrospective gathered information on breastfeed-
ing, providing suboptimal data and potential for biased results. 
Left ventricular mass, left atrial size, aortic root size and blood pressure are related to cardio-
vascular morbidity and mortality. Studies in children demonstrated that left ventricular mass 
and blood pressure track from childhood to adulthood.12-14 We have recently shown tracking of 
left cardiac structures from birth until the age of 2 years15, suggesting that left cardiac structures 
and function are at least partly established in early life. Early exposures, such as breastfeeding, 
may affect cardiovascular and blood pressure development, and this association might already 
be present in early life. Prospectively collected data on breastfeeding and early cardiovascular 
development enables identification of potential developmental adaptations and critical time 
periods, which might have consequences for later life. 
Therefore the aim of this study was to investigate whether breastfeeding duration affects 
left cardiac structures and blood pressure development in early childhood.
mATERiAlS AnD mEThoDS
Design and study population
This study was embedded in the Generation R Study, a population-based, prospective cohort 
study from fetal life until young adulthood.16-17 The study is designed to identify early envi-
ronmental and genetic causes of normal and abnormal growth, development and health. The 
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total cohort consists of 9,778 mothers and their children living in Rotterdam, The Netherlands. 
Mothers were aimed to enroll during early pregnancy, but enrollment was allowed until birth. 
Additional and more detailed assessments of growth and development are conducted in a 
random subgroup of Dutch children.17 In total 1,106 children participated in this subgroup 
during the postnatal phase and 1,098 children participated in the postnatal assessments at 
the research center (Figure 1). Multiple births (N = 27) were excluded from the analysis. The 
present analysis was limited to singleton live births (N = 1,071). None of the remaining children 
had congenital heart disease. Detailed information on infant feeding was available in 1,035 
children. In 933 children, one or more echocardiographic measurements or blood pressure 
measurements were performed during the first two years of life. A total of 823 (74%) singleton 
live births participated in the assessments at the age of 1.5 months, 845 (76%) at 6 months, and 
807 (73%) at 24 months of age (Figure 1).
figure 1. Flowchart of the participants included in the analyses 
 
 
 
 
Focus Cohort postnatal participation 
N = 1,098 
 N = 27 Excluded, due to twin pregnancies 
Singleton live births 
N = 1,071 
 
Data on infant feeding available 
N = 1,035 
 
Data on cardiovascular structures or blood pressure 
available N = 933 
   
 
Participation in 6 weeks visit: N = 823 
Cardiac ultrasounds: N = 715 (87%) 
 
Participation in 6 months visit: N = 845 
Cardiac ultrasounds: N = 751 (89%) 
 
Participation in 24 months visit: N = 807 
Cardiac ultrasounds: N = 703 (87%) 
Blood pressure measurements: N = 555 (79%) 
 
N = 36 Excluded, due to missing data on 
infant feeding 
 
N = 102 Excluded, due to missing 
cardiovascular or blood pressure 
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breastfeeding 
Information about breastfeeding was collected by postnatal questionnaires at the infant ages 
of 2, 6 and 12 months. Medical records were used to establish breastfeeding initiation in case 
of missing information on the starting of breastfeeding in the questionnaires. Breastfeeding 
was coded as ever breastfed or never breastfed. Breastfeeding duration was categorized as <2 
months, 2 - 4 months, 4 - 6 months and ≥6 months. The duration of exclusive breastfeeding was 
derived from information about duration of breastfeeding and at what age formula feeding, 
other types of milk and solid food were introduced in the first 6 months of life. This resulted in 
three categories: never breastfed, partially breastfed (indicating breastfeeding, other milk and/
or solid food) and exclusively breastfed for at least 4 months (only breastfeeding, no other milk, 
solid food, or fluids other than water).
Cardiovascular outcomes 
Two-dimensional M-mode and Doppler echocardiographic measurements were performed 
using ATL-Philips Model HDI 5000 (Seattle, WA) equipment at the child age of 1.5, 6 and 24 
months. In total, 86% of the measurements were performed by a single echocardiographer. The 
other measurements were performed by 2 other echocardiographers. The echocardiographers 
were supervised by a pediatric cardiologist. Echocardiographic measurements were success-
fully performed in 87%, 89% and 87% of the children examined at 1.5, 6 and 24 months. Missing 
echocardiograms were mainly due to crying or unavailability of equipment or echocardiogra-
pher. Left atrial diameter, aortic root diameter, interventricular end-diastolic septal thickness 
(IVSTD), left ventricular end-diastolic diameter (LVEDD), left ventricular end-diastolic posterior 
wall thickness (LVPWTD), and shortening fraction as a quantification of cardiac function, were 
measured using methods recommended by the American Society of Echocardiography.18 Left 
ventricular mass was computed using the formula derived by Devereux et al.19: 
Left ventricular mass = 0.80 × 1.04((IVSTD + LVEDD + LVPWTD)3 − (LVEDD)3)+ 0.6
Previously, a good intra and inter observer reproducibility of the ultrasound measurements 
was shown in this study. The intraclass correlation coefficient between and among observers 
was calculated in 30 subjects and varied between 0.85 and 0.99.15 The procedure of the blood 
pressure measurements has been described in detail elsewhere.20 Briefly, systolic blood pres-
sure and diastolic blood pressure were measured to the nearest mmHg at the left upper arm by 
using an automatic sphygmomanometer (Vital Signs Monitor CAS 740; CAS Medical Systems, 
Inc., Branford, Connecticut, USA21). The child was seated quietly during the measurements, and 
a cuff was selected with a cuff width approximately 40% of the arm circumference and long 
enough to cover 90% of the arm circumference.22 Diastolic blood pressure was taken at the fifth 
Korotkoff phase. The mean of the two readings was used for the data analysis. Blood pressure 
measurements were successfully performed in 69% of the children examined at 24 months. In 
218 children, it was not possible to measure blood pressure twice due to crying and opposi-
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tional behavior. Thus, their blood pressure was based on one measurement. No differences in 
blood pressure values between those with two or one measurement were observed.
Covariates
Date of birth, infant sex, Apgar score at 5 minutes, and birth weight were obtained from 
midwife and hospital registries. Gestational age adjusted SD scores were constructed for birth 
weight. Weight and height were measured at the visits at the age of 1.5, 6 and 24 months. Body 
mass index (kg/m2) was calculated. Information on maternal age, pre-pregnancy weight, parity, 
maternal hypertension, high cholesterol and heart abnormalities, family history of hyperten-
sion, stroke and myocardial infarction at an age <65 years, highest education finished, family 
household income, smoking status and alcohol consumption during pregnancy was obtained 
by the questionnaires. Socio-economic status was indicated by maternal education and family 
household income in this population. Maternal education was defined as highest followed 
education according to the classification of Statistics Netherlands and categorized in primary, 
secondary and higher.23 Family income, defined by the total net month income of the house-
hold, was categorized as ‘<1200 €’ (below social security level), ‘1200 - 2000 €’ and ‘>2000 €’ 
(more than modal income). Information about doctor-diagnosed pregnancy complications, i.e. 
pregnancy induced hypertension, preeclampsia and gestational diabetes, was retrieved from 
medical records and verified according to current guidelines.24-25 Maternal height and weight 
were measured without shoes and heavy clothing and body mass index was calculated (kg/m2) 
at the research center in the first trimester of pregnancy.
Statistical methods
Differences in characteristics between children who were ever breastfed versus never breastfed 
were tested using independent samples t-tests and Chi-square tests. Differences in baseline 
characteristics among the different categories of breastfeeding duration were assessed using 
the ANOVA tests and Chi-square tests. Associations of duration and exclusivity of breastfeeding 
with left cardiac structures and blood pressure were assessed with linear regression models. 
At all ages, the category with highest breastfeeding duration was taken as the referent for the 
analyses. For the analyses on cardiac structures at the age of 1.5 months, this was the combined 
group of breastfeeding categories with a duration of >1.5 months. For the analyses on cardiac 
structures at the age of 6 months, this was the combined group of breastfeeding categories 
with a duration of >4 months and for the analysis at 24 months, this was the category with 
a duration of breastfeeding ≥6 months. Tests for trends were performed using breastfeeding 
duration as a continuous variable in the linear regression analyses. First, these models were 
adjusted for infant sex and age. Subsequently, to take account for maternal and child anthro-
pometrics analyses were adjusted for gestational age adjusted SD scores for birth weight, 
Apgar score at 5 minutes, height and weight at measurement, child weight gain from birth to 
moment of measurement, maternal age, height, weight, parity, maternal hypertension or heart 
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abnormalities, family history of hypertension, stroke and myocardial infarction at an age <65 
years, pregnancy complications, educational level, family household income, smoking status 
and alcohol consumption during pregnancy. The selection of covariates was based on results 
from previous studies and correlations with breastfeeding status and left cardiac structures. All 
statistical analyses were performed using the Statistical Package for the Social Sciences version 
15.0 for Windows (SPSS Inc, Chicago, IL, USA).
RESulTS
Table 1 presents the characteristics of the mothers and infants by breastfeeding status. The total 
percentage of boys was 51.0%. The overall median ages (95% range) of the children at the visits 
were 1.5 months (1.0 - 2.8), 6.3 months (5.5 - 8.3), and 25.1 months (23.7 - 28.2). The majority of 
children (N = 842, 90%) were breastfed during infancy, of which in 83.8% (N = 706) the exact 
duration of breastfeeding was known. The median (95% range) duration of breastfeeding was 5 
(0.5 - 12.0) months. In total, 24.6% (N = 207) of all children were exclusively breastfed during at 
least 4 months. The prevalence of breastfeeding initiation did not differ by sex and birth weight. 
Higher educated mothers tended to initiate breastfeeding more frequently.
Table 1. Subject characteristics (N = 933)
breastfeeding
 (n = 842)
no breastfeeding
 (n = 91)
P value
maternal characteristics 
Age (years) 32.2 (22.8, 39.5) 32.3 (19.5, 38.4) 0.18
Height (cm) 171.1 (6.3) 169.9 (6.2) 0.09
Weight (kg) 71.3 (12.6) 73.5 (17.0) 0.24
Body mass index (kg/m2) 24.4 (4.1) 25.4 (5.4) 0.08
Parity ≥1 (%) 311 (37.5) 39 (42.9) 0.31
Highest completed educational level mother <0.01
  Primary (%) 14 (1.7) 4 (4.4)
  Secondary (%) 250 (29.7) 52 (57.1)
  Higher (%) 569 (67.6) 34 (37.4)
  Missing (%) 9 (1.1) 1 (1.1)
Family household income, no. (%) 0.12
<1,200 6 (0.7) 2 (2.2)
  1,200 – 2,000 12 (1.4) 3 (3.3)
>2,000 774 (91.9) 78 (85.7)
  Missing 50 (5.9) 8 (8.8)
Smoking during pregnancy, no. (%) 0.17
  Not 596 (70.8) 61 (67.0)
  First trimester only 69 (8.2) 5 (5.5)
  Continued 85 (10.1) 16 (17.6)
  Missing 91 (10.8) 9 (9.9)
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Table 2 presents the associations of breastfeeding status, duration and exclusivity with the 
repeatedly measured left cardiac structures and fractional shortening, adjusted for child sex and 
age at visit. No significant associations of breastfeeding with any of the cardiac outcomes were 
observed. Additionally adjusting for gestational age adjusted SD scores for birth weight, Apgar 
score at 5 minutes, height and weight at measurement, child weight gain from birth to moment 
of measurement, and for maternal age, height, weight, parity, maternal hypertension, high cho-
lesterol or heart abnormalities, family history of hypertension, stroke or myocardial infarction at 
an age <65 years, pregnancy complications, socio-economic status, smoking status and alcohol 
consumption during pregnancy did not materially change these associations. Supplementary 
Table S1 shows the effect of adjusting for child anthropometrics and maternal factors. Similar 
results were observed for the association of breastfeeding with systolic and diastolic blood 
Table 1. Subject characteristics (N = 933) (continued)
maternal characteristics
breastfeeding
 (n = 842)
no breastfeeding
 (n = 91)
P value
Alcohol consumption during pregnancy, no. (%) <0.01
  Not 205 (24.3) 41 (45.1)
  First trimester only 125 (14.8) 9 (9.9)
  Continued 425 (50.5) 32 (35.2)
  Missing 87 (10.3) 9 (9.9)
Family history of cardiovascular diseases, no. (%)a 340 (40.4) 40 (44.0) 0.64
Risk factors for cardiovascular diseases, no. (%)b 21 (2.5) 5 (5.5) 0.25
Pregnancy or delivery complications, no. (%)c 69 (8.2) 11 (12.1) 0.24
Childhood characteristics
Gestational age (weeks) 40.3 (36.0, 42.4) 40.1 (34.1, 42.5) 0.02
Male, no. (%) 425 (50.5) 51 (56.0) 0.31
Apgar score at 5 minutes <7, no. (%) 8 (1.0) 1 (1.1) 0.61
Birth weight (g) 3,518.9 (534.2) 3,477.5 (586.6) 0.49
Low birth weight (<2,500 grams), no. (%) 29 (3.4) 5 (5.5) 0.32
Preterm birth (<37 weeks), no. (%) 32 (3.8) 6 (6.6) 0.20
Duration of breastfeeding, no. (%)
<2 months 190 (22.6)
  2 - 4 months 158 (18.8)
  4 - 6 months 93 (11.0)
  ≥6 months 264 (31.4)
  Missing 137 (16.3)
Visit 1.5 months, no. (%) 740 (87.9) 83 (91.2) 0.35
Visit 6 months, no. (%) 759 (90.1) 86 (94.5) 0.18
Visit 24 months, no. (%) 733 (87.1) 74 (81.3) 0.13
Values are means (SD), medians (95% range), or no.’s (%). Differences between ever and never breastfed 
were compared using independent samples t-tests or Chi-square tests.
aIncludes family history of hypertension, stroke and myocardial infarction <65 
bIncludes maternal cardiovascular risk factors, consisting of maternal hypertension, high cholesterol and 
heart abnormalities
cIncludes pregnancy or delivery complications, consisting of maternal preeclampsia, pregnancy induced 
hypertension and diabetes gravidarum
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pressure, as presented in Table 3 and Supplementary Table S2. Table 4 shows the associations 
of breastfeeding status, duration and exclusivity with the growth of left cardiac structures in 
the time period 6 months to 24 months. Breastfeeding was not significantly associated with the 
growth of any of the cardiac structures. The effect estimates were not substantially affected by 
adjustment of the models for gestational age adjusted SD scores for birth weight, Apgar score 
at 5 minutes, height and weight at measurement, child weight gain from birth to moment of 
measurement, and maternal age, height, weight, parity, maternal cardiovascular risk factors, 
family history for cardiovascular diseases, pregnancy complications, socio-economic status, 
smoking status and alcohol consumption during pregnancy as shown in Supplementary Table 
S3.
Table 3. Association of duration and exclusivity of breastfeeding with systolic and diastolic blood pressure 
at the age of 24 months
Systolic blood pressure (mmhg) Diastolic blood pressure (mmhg)
breastfeeding 24 months (N = 555) 24 months (N = 555)
Ever 
Never (N = 91) 0.45 (-2.34, 3.23) 0.85 (-2.04, 3.74)
Ever (N = 842) Reference Reference
Duration
Never (N = 91) 0.58 (-2.42, 3.57) 0.49 (-2.63, 3.60)
0 - 2 months (N = 190) 1.28 (-0.97, 3.54) 0.72 (-1.62, 3.06)
2 - 4 months (N = 158) -2.30 (-4.68, 0.07) -2.44 (-4.91, 0.03)
4 - 6 months (N = 93) -0.34 (-3.09, 2.42) -2.25 (-5.11, 0.61)
≥6 months (N = 264) Reference Reference
P for trend 0.84 0.56
Exclusivity
Never (N = 61) 1.22 (-1.91, 4.34) 1.78 (-1.47, 5.02)
Partial ≥4 months (N = 340) 0.97 (-1.02, 2.96) 1.13 (-0.93, 3.19)
Exclusive ≥4 months (N = 169) Reference Reference
Values are regression coefficients (95% confidence interval) based on multiple linear regression models. 
Models are adjusted for child’s sex and age at visit.
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DiSCuSSion
In this prospective cohort study among children, we found no evidence of an association of 
type of infant feeding with left cardiac morphology, fractional shortening and blood pressure at 
the age of 1.5, 6 and 24 months. Also no associations of duration or exclusivity of breastfeeding 
with any of the cardiovascular outcomes were observed. Adjusting for infant sex, gestational 
age adjusted SD scores for birth weight, Apgar score at 5 minutes, age and anthropometrics 
and for maternal age, anthropometrics, parity, maternal cardiovascular risk factors, family 
history for cardiovascular diseases, pregnancy complications, socio-economic status, smoking 
status and alcohol consumption during pregnancy did only slightly affect the effect estimates.
A major strength of this study is its prospective design from fetal life onwards, in a large 
cohort of children. Most of the studies conducted so far, were based on recall of infant feed-
ing after several decades, making recall bias an important concern. Another strength is the 
availability of detailed information about the duration and exclusivity of breastfeeding. This 
enabled us to investigate the influence of duration of breastfeeding and whether results differ 
among children who were exclusively or partially breastfed. Furthermore, during the first 2 
years of life, the effect of other postnatal exposures related to cardiovascular disease in adult-
hood, such as obesity and smoking, are confined. A potential limitation of the study is that 
the associations between breastfeeding and left cardiac structures and blood pressure may 
Table 4. Association of breastfeeding with growth of left cardiac structures between 6 and 24 months
Change in left atrial 
diameter (mm)
Change in aortic root 
diameter (mm)
Change in left 
ventricular mass (g)
breastfeeding (N = 532) (N = 531) (N = 487)
Ever 
Never (N = 91) -0.20 (-0.99, 0.58) 0.19 (-0.23, 0.61) 1.34 (-0.44, 3.12)
Ever (N = 842) Reference Reference Reference
Duration
Never (N = 91) -0.20 (-1.07, 0.66) 0.06 (-0.40, 0.52) 0.86 (-1.07, 2.80)
0 - 2 months (N = 190) 0.11 (-0.55, 0.76) -0.16 (-0.51, 0.19) -0.39 (-1.88, 1.11)
2 - 4 months (N = 158) 0.10 (-0.60, 0.81) -0.27 (-0.64, 0.11) -0.48 (-2.05, 1.09)
4 - 6 months (N = 93) -0.25 (-1.09, 0.59) -0.26 (-0.70, 0.19) -0.55 (-2.44, 1.35)
≥6 months (N = 264) Reference Reference Reference
P for trend 0.41 0.22 0.93
Exclusivity
Never (N = 61) 0.07 (-0.83, 0.96) 0.10 (-0.38, 0.58) 0.74 (-1.28, 2.77)
Partial ≥4 months (N = 340) 0.34 (-0.24, 0.93) -0.13 (-0.44, 0.18) -0.68 (-2.00, 0.65)
Exclusive ≥4 months (N = 169) Reference Reference Reference
Values are regression coefficients (95% confidence interval) based on multiple linear regression models. 
Models are adjusted for child’s sex and age at visit.
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depend on additional dietary patterns. In the analysis, we did not adjust for other components 
of infant diet. More detailed information about infant nutrition, including macronutrients and 
micronutrients intake, during the first two years would provide additional information. Another 
limitation was that because of the young age at examination and the limited time available at 
the three visits, we were not able to get a higher percentage of successful cardiovascular and 
blood pressure measurements. Missing outcome measurements could have led to selection 
bias. In our study, mothers of children who did not have any measurements were younger at 
enrolment than the mothers of children who had at least one cardiovascular or blood pressure 
measurement. Our results would be biased if the associations between breastfeeding and 
the cardiovascular or blood pressure measurements differ between those included and not 
included in the study. This seems unlikely, but cannot be excluded. Also, the Generation R Focus 
cohort comprises a relatively healthy and high educated group of Dutch women and children. 
Although the starting rates of breastfeeding in our study were fairly high relative to those in 
earlier reports26-27, they were consistent with the upward trend toward breastfeeding that has 
been taking place in Western countries since the 1990.28 The analyses were based on internal 
comparison within this selective study population, and the effect estimates are valid for this 
cohort. The selection towards a more healthy and higher educated population might result in a 
limited generalizability of the results.
Over the past decades there has been increased interest in the influence of infant nutri-
tion, especially breastfeeding, on development of cardiovascular morbidity and mortality in 
later life. A possible association between breastfeeding and cardiovascular disease might be 
explained by developmental plasticity.10 The association of breastfeeding with cardiovascular 
diseases and its risk factors in later life may reflect the long term consequences of adaptive 
responses in cardiovascular morphology to nutrition in infancy. Singhal and Lucas proposed 
the more specified growth acceleration hypothesis, suggesting that a high-nutrient diet in 
infancy adversely programs the principal components of the metabolic syndrome by promot-
ing growth acceleration.29 This suggests that relative slower or normal infant growth would be 
protective for later cardiovascular health. Breastfed infants show slower growth than those who 
are formula fed.30 Thus reduced early growth due to a lower nutrient intake is the potential link 
between breastfeeding and reduced cardiovascular disease late in life.29 Our study provided no 
support for the hypothesis that breastfeeding leads to cardiovascular developmental adapta-
tions in early life. No association between partial or exclusive breastfeeding duration with left 
cardiac structures and their growth, fractional shortening or blood pressure was found. It is 
still possible that more detailed functional cardiovascular measurements, such as endothelial 
dysfunction, arterial stiffness or left ventricular diastolic filling patterns might be influenced by 
breastfeeding. 
Various other studies have been conducted to investigate the association of breastfeeding in 
infancy with the development of cardiovascular disease and its risk factors. Systematic reviews 
and meta-analyses showed inconsistent results and publication bias and socioeconomic 
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confounding appeared of important concern.6 Studies focused on cardiovascular risk factors 
in younger subjects, which make recall bias less likely, presented conflicting results as well. Two 
meta-analyses on the association of breastfeeding with blood pressure in later life both found 
that adults who were breastfed had a slightly lower systolic blood pressure.5-6 The evidence for 
publication bias was strong though, with smaller effects of marginal statistical significance in 
the larger studies. A meta-analysis on blood cholesterol levels in infancy, childhood and adult 
life showed that breastfeeding is associated with elevated total cholesterol and LDL-cholesterol 
levels in infancy but lower levels in adult life.3 In a randomized trial, adolescents born preterm 
who received breastfeeding , had a lower ratio of LDL-cholesterol to HDL-cholesterol and also a 
lower serum C-reactive protein compared to those who were formula fed, indicative of a lower 
risk for cardiovascular disease.31 On the contrary, a large cohort study among 2818 adults, 
provided no evidence of a protective influence of breast feeding on the total cholesterol and 
LDL-cholesterol levels.2 Several studies have shown associations between breastfeeding and in 
obesity in children and in adults consistently32-34, although a study from Belarus reported that 
prolonged breastfeeding had no effect on the rate of obesity.35
Thus both the beneficial effects of breastfeeding on cardiovascular diseases outcomes and 
the potential underlying mechanisms are still not clear.
ConCluSion
Our results did not show any cardiovascular adaptations, measured as left cardiac structures 
and function and blood pressure in early childhood, in response to breastfeeding duration. Fur-
ther studies are needed to assess whether and at what age the associations of infant nutrition 
with cardiac morphology and function appear. Also, studies on more detailed dietary patterns 
and cardiovascular function in early childhood are needed.
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Table S2. Association of duration and exclusivity of breastfeeding with systolic and diastolic blood 
pressure at the age of 24 months
Systolic blood pressure 
(mmhg)
Diastolic blood pressure 
(mmhg)
breastfeeding 24 months (N = 555) 24 months (N = 555)
Ever
Never (N = 91) 1.50 (-1.85, 4.85) -0.33 (-3.02, 3.68)
Ever (N = 842) Reference Reference
Duration
Never (N = 91) 2.00 (-1.59, 5.60) -0.17 (-3.79, 3.44)
0 - 2 months (N = 190) 2.65 (-0.09, 5.39) 0.26 (-2.49, 3.01)
2 - 4 months (N = 158) -2.51 (-5.31, 0.30) -2.83 (-5.64, -0.01)*
4 - 6 months (N = 93) -1.18 (-4.50, 2.15) -3.35 (-6.69, -0.01)*
≥6 months (N = 264) Reference Reference
P for trend 0.58 0.21
Exclusive breastfeeding
Never (N = 61) 2.64 (-1.11, 6.39) 0.86 (-2.90, 4.62)
Partial ≥4 months (N = 340) 1.42 (-0.97, 3.80) 0.36 (-2.03, 2.75)
Exclusive ≥4 months (N = 169) Reference Reference
Values are regression coefficients (95% confidence interval) based on multiple linear regression models. 
Models are adjusted for infant sex, gestational age adjusted SD scores for birth weight, Apgar score at 5 
minutes, age, height and weight at measurement, weight gain from birth to moment of measurement, 
and for maternal age, anthropometrics, parity, maternal family history, cardiovascular risk factors, 
delivery or pregnancy complications, socio-economic status, smoking status and alcohol consumption 
during pregnancy. *P <0.05
Table S3. Association of breastfeeding with growth of left cardiac structures between 6 and 24 months
Change in left atrial 
diameter (mm)
Change in aortic root 
diameter (mm)
Change in left 
ventricular mass (g)
breastfeeding (N = 532) (N = 531) (N = 487)
Ever
Never (N = 91) -0.60 (-1.49, 0.30) 0.27 (-0.21, 0.74) 0.66 (-1.43, 2.75)
Ever (N = 842) Reference Reference Reference
Duration
Never (N = 91) -0.59 (-1.56, 0.39) 0.15 (-0.37, 0.68) -0.01 (-2.27, 2.25)
0 - 2 months (N = 190) -0.11 (-0.63, 0.85) -0.19 (-0.59, 0.21) -0.96 (-2.67, 0.75)
2 - 4 months (N = 158) -0.07 (-0.74, 0.87) -0.27 (-0.69, 0.17) -0.67 (-2.52, 1.18)
4 - 6 months (N = 93) 0.03 (-0.91, 0.98) -0.08 (-0.59, 0.42) -0.30 (-2.47, 1.86)
≥6 months (N = 264) Reference Reference Reference
P for trend 0.68 0.21 0.58
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Table S3. Association of breastfeeding with growth of left cardiac structures between 6 and 24 months 
(continued)
Exclusive breastfeeding
Change in left atrial 
diameter (mm)
Change in aortic root 
diameter (mm)
Change in left 
ventricular mass (g)
Never (N = 61) -0.37 (-1.38, 0.65) 0.18 (-0.37, 0.72) -0.14 (-2.50, 2.21)
Partial ≥4 months (N = 340) 0.37 (-0.29, 1.02) -0.14 (-0.50, 0.21) -1.05 (-2.56, 0.46)
Exclusive ≥4 months (N = 169) Reference Reference Reference
Values are regression coefficients (95% confidence interval) based on multiple linear regression models. 
Models are adjusted for infant sex, gestational age adjusted SD scores for birth weight, Apgar score at 5 
minutes, age, height and weight at measurements, weight gain from birth to moment of measurement, 
and for maternal age, anthropometrics, parity, maternal family history, cardiovascular risk factors, delivery 
or pregnancy complications, socio-economic status, smoking status and alcohol consumption during 
pregnancy.
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AbSTRACT
background Aim of this study was to investigate the associations of C-reactive protein levels, 
as marker of low grade inflammation, with blood pressure development during pregnancy and 
the risks gestational hypertensive complications. We also explored the role of maternal body 
mass index in these associations.
methods High sensitivity C-reactive protein levels were measured in early pregnancy (median 
13.2 weeks, 95% range 9.6 to 17.6) in 5,816 mothers participating in a population-based 
prospective cohort study in the Netherlands. Blood pressure measurements were performed 
in each trimester. Information about pregnancy induced hypertension and preeclampsia was 
retrieved from hospital charts of the women.
Results Longitudinal analyses showed that C-reactive protein levels were not associated with 
systolic and diastolic blood pressure patterns throughout pregnancy. Trimester specific multi-
variate linear regression models showed that as compared to low C-reactive protein levels (<5.0 
mg/L), elevated levels (≥20.0 mg/L) were associated with maternal systolic and diastolic blood 
pressure. Elevated C-reactive protein levels in early pregnancy were associated with the risks 
of pregnancy induced hypertension (Odds ratio 2.78, 95% CI 1.66 to 4.66). After adjustment for 
maternal body mass index, all associations attenuated.
Conclusion Our results suggest that first trimester C-reactive protein levels are associated 
with systolic and diastolic blood pressure levels throughout pregnancy and with gestational 
hypertensive complications, but these associations are largely explained by maternal body 
mass index.
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inTRoDuCTion
Pregnancy induced hypertension and preeclampsia are leading causes of maternal and fetal 
morbidity and mortality worldwide.1-2 The clinical features of preeclampsia can partly be 
explained as clinical responses to generalized endothelial dysfunction.3 An exaggerated mater-
nal systemic inflammatory response to pregnancy is considered to have a crucial role in the 
pathophysiologic mechanisms leading to endothelial dysfunction.4-5
C-reactive protein is an acute phase protein6-7, and is used as a diagnostic indicator of 
tissue damage in both acute and chronic inflammation. Circulating C-reactive protein levels 
are elevated in normal pregnancy8, and this elevation is suggested to be more profound in 
preeclamptic women.9-14 However, results from studies focused on C-reactive protein levels in 
pregnant women, and its potential use as a risk factor for preeclampsia have been conflicting.15 
Various studies showed higher C-reactive protein levels in preeclamptic pregnancies9, 11-12, 14, 
and C-reactive protein levels seem to be associated with the severity of preeclampsia.16 Other 
studies suggested that the effect of C-reactive protein levels on the risk of preeclampsia might 
be explained by maternal obesity.10, 13 A more profound activation of inflammatory markers 
and alterations C-reactive protein levels has been shown in overweight and obese pregnant 
women.17-18 Inflammation in early pregnancy might also be associated with blood pressure 
changes within the normal range during pregnancy. These subclinical vascular adaptations 
to inflammation might be involved in the pathways that predispose to maternal gestational 
hypertensive disorders.
Therefore, we investigated in a large population-based prospective cohort study the asso-
ciations of high sensitivity C-reactive protein levels in early pregnancy with blood pressure in 
different periods of pregnancy and the risk of gestational hypertensive disorders. Next, we 
explored how maternal body mass index could be a confounding factor in these associations.
mEThoDS
Study design and population
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from early fetal life onwards in the city of Rotterdam, The Netherlands.19-20 All children 
were born between April 2002 and January 2006. The overall response rate was 61% and was 
based on the number of children born to eligible mothers during the inclusion period of the 
study.20 The study has been approved by the Medical Ethical Committee of the Erasmus MC, 
Rotterdam. Written informed consent was obtained from all participants. Of the total of 8,880 
mothers who were enrolled during pregnancy, 76% (N = 6,748) were enrolled before a gesta-
tional age of 18 weeks. Of these mothers, blood plasma samples were collected in 95% (N = 
6,398) and C-reactive protein was successfully measured in 90% (N = 6,091). To exclude women 
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with high-risk pregnancies and women predisposed for gestational hypertensive disorders, 
we excluded twin pregnancies (N = 69), mothers with extremely high C-reactive protein levels 
(>100 mg/L) (N = 6), pre-existing hypertension (N = 103), pre-existing diabetes (N = 20), high 
cholesterol (N = 28), Systemic Lupus Erythematosus (N = 1) and a chronic heart condition (N 
= 59). The total cohort comprised 5,816 mothers with singleton live births for analysis (65% of 
8,880) (Figure 1). Women excluded from the study because of extremely high C-reactive protein 
levels and an increased risk of developing hypertensive disorders, were of higher age at intake, 
were heavier, were less inclined to drink alcohol during pregnancy, had higher C-reactive pro-
tein levels and had higher systolic and diastolic blood pressures during the three trimesters of 
pregnancy as shown in Supplementary material (Table S1).
high-sensitivity C-reactive protein levels 
Maternal venous blood samples were collected in early pregnancy and transported to the 
regional laboratory (Star-MDC, Rotterdam, The Netherlands) for processing and storage.19 
Processing was aimed to be finished within a maximum of 3 hours after venous puncture. Blood 
samples were immediately stored at -80 ºC after processing. C-reactive protein concentrations 
figure 1. Flowchart of participants included in the analyses (N = 5,816)
Prenatally included mothers 
N = 8,880 
 N = 2,132 Excluded, not included <18 
weeks of gestation 
 
Plasma samples collected <18 weeks  
N = 6,398 
 
C-reactive protein measured <18 weeks of gestation 
N = 6,091 
 
Singleton live births 
N = 6,022 
 
Total population for analysis 
N = 5,816 
 
Maternal blood pressure: 
First trimester N = 5,772 
Second trimester N = 5,546 
Third trimester N = 5,520 
 
Pregnancy complications: 
Pregnancy induced hypertension N = 228 
Preeclampsia N = 106 
N = 307 Excluded, due to missing data on 
C-reactive protein 
 
N = 69 Excluded, due to twin pregnancies 
 
N = 6 Excluded, due to extreme C-reactive 
protein levels (>100 mg/L) 
 
N = 200 Excluded due to diagnosis of: 
Hypertension (N = 103) 
Diabetes Mellitus (N = 20) 
High cholesterol (N = 28) 
Systemic Lupus Erythematosus (N = 1) 
Heart condition (N = 59) 
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were measured in EDTA plasma samples at the Department of Clinical Chemistry of the Erasmus 
MC in 2009. We measured high-sensitivity C-reactive protein since traditional clinically used 
C-reactive protein methods lack the sensitivity in low ranges needed for predicting future risk 
of events in apparently healthy individuals.21 C-reactive protein levels were analyzed using an 
immunoturbidimetric assay on the Architect System (Abbott Diagnostics B.V., Hoofddorp, The 
Netherlands). The within run precision for C-reactive protein was 1.3% at 12.9 mg/L and 1.2% 
at 39.9 mg/L. The lowest level of detection was 0.2 mg/L. Assessments of C-reactive protein 
were blinded to outcome. We created five categories of C-reactive protein levels (<5.0, 5.0 - 9.9, 
10.0 - 15.0, 15.0 - 19.9, and ≥20 mg/L). Levels <5.0 mg/L and ≥20.0 mg/L were considered as low 
(reference) and elevated levels, respectively.22
blood pressure measurements
Systolic and diastolic blood pressure were measured in first, second and third trimester with 
the Omron 907 automated digital oscillometric sphygmanometer (OMRON Healthcare Europe 
B.V. Hoofddorp, The Netherlands), which was validated in non-pregnant adults.23 Participants 
were seated in a chair with back support and blood pressure measurement started after 5 to 10 
minutes of rest. A cuff was placed around the nondominant upper arm, which was supported at 
the level of the heart, with the bladder midline over the brachial artery pulsation. If the circum-
ference of the upper arm exceeded 33 centimeter (cm), a larger cuff (32-42 cm) was used. For 
each participant, the mean value of two blood pressure readings over a 60-second interval was 
documented. In total, N = 5,772, N = 5,546, and N = 5,520 blood pressure measurements were 
available in first, second and third trimester, respectively. 
Pregnancy induced hypertension and preeclampsia
Information on pregnancy complications was obtained from medical records. Women 
suspected of pregnancy complications based on these records were crosschecked with the 
original hospital charts. Details of these procedures have been described elsewhere.24
Doctor-diagnosed pregnancy induced hypertension was defined according to the criteria 
described by the International Society for the Study of Hypertension in Pregnancy (ISSHP) 
as the development of systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure 
≥90 mm Hg without proteinuria after 20 weeks of gestation in previously normotensive 
women.25Doctor-diagnosed preeclampsia was defined as the development of systolic blood 
pressure at least 140 mmHg and/or diastolic blood pressure at least 90 mmHg after 20 weeks of 
gestation in previously normotensive women and proteinuria (defined as two or more dipstick 
readings of 2+ or greater, one catheter sample reading of 1+ or greater, or a 24 hour urine 
collection containing at least 300 mg of protein).
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Covariates
Information about maternal age, educational level, ethnicity and parity was obtained by a 
questionnaire at enrolment in the study. Maternal smoking and alcohol consumption habits 
were assessed by questionnaires in each trimester. Maternal height and weight were measured 
without shoes and heavy clothing at enrolment and body mass index was calculated as weight/
height2 (kg/m2). Information about maternal weight just before pregnancy was obtained by 
questionnaires. In our population for analysis, 63% and 100% of all women were enrolled and 
assessed before a gestational age of 14 and 18 weeks, respectively. As enrolment in our study 
was in pregnancy, we were not able to measure maternal weight before pregnancy. However, 
correlation of pre-pregnancy weight obtained by questionnaire and weight measured at enrol-
ment was 0.95 (P <0.001).
Statistical analysis
First, the associations of C-reactive protein levels with repeatedly measured maternal systolic 
and diastolic blood pressure were analyzed using the unbalanced repeated measurement 
regression analysis. This regression technique takes the correlation of multiple measurements 
within one subject into account and allows for incomplete outcome data.26 The best fitting 
models were constructed using fractional polynomials of gestational age.27 C-reactive protein 
was included in the models as intercept and as interaction term with gestational age. The 
models can be written as:
Systolic Blood Pressure = β0 + β1 x C-reactive protein + β2 x gestational age + β3 x gestational 
age-2 + β4 x C-reactive protein x gestational age
Diastolic Blood Pressure = β0 + β1 x C-reactive protein + β2 x gestational age + β3 x gestational 
age0.5 + β4 x C-reactive protein x gestational age
In these models, “β0 + β1 x C-reactive protein” reflects the intercept, “β2 x gestational age + β3 
x gestational age-2” reflects the slope of change in systolic blood pressure per week, and “β2 x 
gestational age + β3 x gestational age
0.5” reflects the slope of change in diastolic blood pressure 
per week. The term “β4 x C-reactive protein x gestational age” reflects the difference in change 
in blood pressure per week between the different C-reactive protein categories for systolic and 
diastolic blood pressure. Second, the trimester specific associations of first trimester C-reactive 
protein levels with first, second and third trimester maternal blood pressure were assessed 
using multiple linear regression models. To explore the role of maternal obesity, we repeated 
these analyses in strata of body mass index (<20.0 kg/m2, 20.0-24.9 kg/m2, 25.0-29.9 kg/m2 and 
≥30.0 kg/m2, representing respectively lean, normal weight, overweight and obese women). 
Finally we assessed the associations of first trimester C-reactive protein level with the risks of 
pregnancy complications (pregnancy induced hypertension and preeclampsia) with multiple 
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logistic regression models. Tests for trends were performed using logarithmically transformed 
C-reactive protein as continuous variable in the linear and logistic regression analyses. All mod-
els were adjusted for gestational age at venous puncture, gestational age at blood pressure 
measurement, maternal age, education, ethnicity, parity, smoking, alcohol consumption and 
body mass index. The percentages of missing values within the population for analysis were 
lower than 1% for continuous data and lower than 13% for the categorical data. We applied 
multiple imputation for covariates.28 Since there were no major differences in the observed 
results between analyses with imputed missing data or complete cases only, only results 
including imputed missing data are presented. Statistical analyses were performed using the 
Statistical Analysis System version 9.2 (SAS for Windows Version 9.2; SAS Institute, Cary, NC, 
USA), including the PROC MIXED module for unbalanced repeated measurements, as well as 
the Statistical Package of Social Sciences version 17.0 for Windows (SPSS Inc, Chicago, IL, USA).
RESulTS
Subject Characteristics
Subject characteristics and data on maternal and fetal complications are presented in Table 
1. Median maternal age was 30.3 years, with a 95% range of 19.5 to 38.8 years. Of all women 
included in the study, 56.7% was primipara. Median C-reactive protein level was 4.4 mg/L (95% 
range 0.60 to 25.22). In total, 228 (3.9%) and 106 (1.8%) mothers developed pregnancy induced 
hypertension and preeclampsia, respectively.
Table 1. Characteristics of study participants included in the analyses
maternal characteristics at enrolment n = 5,816
Age (years) 30.3 (19.5 – 38.8)
Height (cm) 167.6 ± 7.4
Weight (kg)a 68.5 ± 12.8
Body mass index (kg/m2) 24.4 ± 4.3
Parity
  0 3,298 (56.7)
  ≥1 2,468 (42.8)
  Missing 50 (0.9)
Highest completed educational level
  Primary school 524 (9.0)
  Secondary school 2,438 (41.9)
  Higher education 2,433 (41.8)
  Missing 421 (7.2)
Ethnic background
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C-reactive protein levels and blood pressure in different trimesters 
Figure 2 shows the longitudinally measured maternal systolic and diastolic blood pressure 
patterns in the different C-reactive protein level categories. Systolic blood pressure increased 
continuously with increasing gestational age. For diastolic blood pressure, a mid-pregnancy 
dip in was found in all C-reactive protein categories. As compared to the lowest C-reactive 
protein category of <5.0 mg/L, higher C-reactive protein levels were not consistently associated 
Table 1. Characteristics of study participants included in the analyses (continued)
maternal characteristics at enrolment n = 5,816
  European 3,385 (58.2)
  Non-European 2,094 (36.0)
  Missing 337 (5.8)
Smoking during pregnancy
  No smoking 3,723 (64.0)
  First trimester only 462 (7.9)
  Continued smoking 879 (15.1)
  Missing 752 (12.9)
Alcohol consumption during pregnancy
  No alcohol consumption 2,320 (39.9)
  First trimester only 767 (13.2)
  Continued alcohol consumption 2,004 (34.5)
  Missing 725 (12.5)
Gestational age at enrolment (weeks) 13.2 (9.6-17.6)
Maternal pregnancy complications
  Pregnancy induced hypertension 228 (3.9)
  Preeclampsia 92 (1.6)
  HELLP 11 (0.2)
  Preeclampsia and HELLP 14 (0.2)
  Eclampsia 0 (0.0)
Fetal pregnancy complications
  Small for gestational ageb 287 (4.9)
  Preterm birthc 279 (4.8)
  Stillbirth 0 (0.0)
  Neonatal deathd 11 (<0.1)
C-reactive protein level (mg/L) 4.4 (0.60-25.22)
Abbreviations: HELLP, Hemolysis Elevated Liver enzymes, Low Platelets
Values are means (± SD), medians (95% range), or no.’s (%).
aWeight was measured at enrolment in the study
bDefined as sex specific gestational age adjusted birth weight <5th percentile in study cohort
cDefined as birth <37 weeks of gestation
dDefined as infant death during the first 28 competed days of life
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with the systolic or diastolic blood pressure pattern. The specific effect estimates for gestational 
age independent (intercept) and gestational age dependent differences (interaction C-reactive 
protein and gestational age) are given in Supplementary material (Table S2).
Table 2 shows the associations between C-reactive protein levels in early pregnancy and 
maternal blood pressure in different trimesters of pregnancy. As compared to low C-reactive 
protein levels (<5.0 mg/L), elevated levels (≥20.0 mg/L) were not consistently associated with 
systolic blood pressure, but were positively associated with higher diastolic blood pressure in 
each trimester (differences 1.69 mmHg (95% CI: 0.54 to 2.85) in the first trimester, 1.00 mmHg 
(95% CI: -0.16 to 2.16) in the second trimester and 1.39 mmHg (95% CI: 0.21 to 2.57 ) in the 
third trimester (all P values for trend <0.05). Body mass index was the only covariate which 
attenuated the associations of C-reactive protein with maternal blood pressure. The results for 
the analyses without adjustment for body mass index are given in the Supplementary material 
(Table S3) and showed consistent positive associations between C-reactive protein levels and 
both systolic and diastolic blood pressure.
figure 2.  Systolic and diastolic blood pressure patterns in different C-reactive protein categories.
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The change in blood pressure in mmHg per C-reactive protein category, compared to the reference 
group of women with a C-reactive protein level of <5.0 mg/L, is shown based on repeated measurement 
analysis.
A. Systolic blood pressure 
b. Diastolic blood pressure
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Table 3 shows the results for the analyses focused on the associations of C-reactive protein 
levels with systolic and diastolic blood pressure in different trimesters of pregnancy within 
strata of body mass index. We observed tendencies towards positive associations between 
C-reactive protein and systolic blood pressure. C-reactive protein was positively associated with 
diastolic blood pressure in normal weight, overweight and obese women. For both systolic and 
diastolic blood pressure, the effect estimates seem to be largest in obese mothers.
Table 2. Associations of maternal C-reactive protein levels in early pregnancy with maternal blood 
pressure
Systolic blood pressure
first trimester (N = 5,772) Second trimester (N = 5,546) Third trimester (N = 5,520)
C-reactive 
protein level
No.
Difference
(95% CI)
No.
Difference
(95% CI)
No.
Difference
(95% CI)
<5.0 mg/L
N = 
3,178
Reference N = 3,063 Reference N = 3,056 Reference
5.0 – 9.9 mg/L
N = 
1,578
0.36 (-0.33, 1.05) N = 1,506 0.34 (-0.35, 1.03) N = 1,503 0.39 (-0.31, 1.10)
10.0 – 14.9 mg/L N = 557 0.58 (-0.47, 1.61) N = 539 0.36 (-0.68, 1.39) N = 531 0.74 (-0.32, 1.80)
15.0 – 19.9 mg/L N = 207 0.09 (-1.53, 1.70) N = 197 0.35 (-1.27, 1.97) N = 191 0.30 (-1.37, 1.97)
≥20.0 mg/L N = 252 0.17 (-1.31, 1.65) N = 241 -0.62 (-2.10, 0.86) N = 239 -0.62 (-2.14, 0.90)
Trend test
P for 
trend 
0.051
0.77 (0.00, 1.54)
P for 
trend 
0.196
0.51 (-0.26, 1.29)
P for 
trend 
0.182
0.54 (-0.25, 1.33)
Diastolic blood pressure
first trimester (N = 5,772) Second trimester (N = 5,546) Third trimester (N = 5,520)
C-reactive 
protein level
No.
Difference
(95% CI)
No.
Difference
(95% CI)
No.
Difference
(95% CI)
<5.0 mg/L
N = 
3,178
Reference N = 3,063 Reference N = 3,056 Reference
5.0 – 9.9 mg/L
N = 
1,578
0.55 (0.01, 1.09)* N = 1,506 0.67 (0.13, 1.22)* N = 1,503 0.20 (-0.35, 0.75)
10.0 – 14.9 mg/L N = 557 0.72 (-0.10, 1.53) N = 539 0.20 (-0.62, 1.01) N = 531 0.46 (-0.38, 1.29)
15.0 – 19.9 mg/L N = 207 1.43 (0.17, 2.69)* N = 197 0.69 (-0.58, 1.96) N = 191 0.45 (-0.85, 1.76)
≥20.0 mg/L N = 252 1.69 (0.54, 2.85)** N = 241 1.00 (-0.16, 2.16) N = 239 1.39 (0.21, 2.58)*
Trend test
P for 
trend 
<0.001
1.54 (0.93, 2.15)
P for 
trend 
0.002
0.94 (0.33, 1.55)
P for 
trend 
0.010
0.82 (0.20, 1.44)
Values were based on multivariate linear regression models and reflect the difference (95% CI) in maternal 
systolic and diastolic blood pressure for each C-reactive protein level group compared to the reference 
group (<5.0 mg/L). Models were adjusted for gestational age at blood puncture, gestational age at blood 
pressure measurement, maternal age, education, ethnicity, parity, smoking and alcohol consumption, 
and maternal body mass index. Tests for trend were based on multiple linear regression models with the 
logarithmically transformed C-reactive protein as a continuous variable. *P <0.05 **P <0.01
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C-reactive protein levels and risks of hypertensive disorders
Table 4 presents the associations of C-reactive protein levels with the risks of pregnancy com-
plications, in different adjustment models. The multivariate models unadjusted for maternal 
body mass index show that compared to the reference category (C-reactive protein levels <5.0 
mg/L) mothers with elevated C-reactive protein levels (≥20.0 mg/L) had a higher risk of preg-
nancy induced hypertension (Odds ratio 2.78, 95% CI 1.66 to 4.66). No significant association 
was observed for the risk of preeclampsia in mothers with elevated C-reactive protein levels, 
but the trend test showed an association of higher C-reactive protein levels with an increased 
risk of preeclampsia (P for trend <0.05). However, all effect estimates attenuated towards the 
null after adjustment for maternal body mass index.
Table 3. Associations of maternal C-reactive protein levels in early pregnancy with maternal blood 
pressure, stratified by maternal body mass index
Systolic blood pressure
first trimester (N = 5,772) Second trimester (N = 5,546) Third trimester (N = 5,520)
body mass index No. Difference (95% CI) No. Difference (95% CI) No.
Difference (95% 
CI)
<20.0 kg/m2 N = 577 0.27 (-0.59, 1.12) N = 555 0.15 (-0.69, 0.98) N = 551 0.39 (-0.42, 1.19)
20.0 - 24.9 kg/m2 N = 3,206 0.46 (0.05, 0.87)* N = 3,104 0.39 (-0.02, 0.79) N = 3,078 0.46 (0.04, 0.87)*
25.0 - 29.9 kg/m2 N = 1,394 0.33 (-0.36, 1.03) N = 1,324 0.44 (-0.29, 1.16) N = 1,337 -0.22 (-0.96, 0.51)
≥30.0 kg/m2 N = 595 1.92 (0.63, 3.21)** N = 563 1.02 (-0.24, 2.28) N = 554 0.98 (-0.33, 2.28)
Diastolic blood pressure
first trimester (N = 5,772) Second trimester (N = 5,546) Third trimester (N = 5,520)
body mass index
No.
Difference (95% CI) No. Difference (95% CI) No.
Difference (95% 
CI)
<20.0 kg/m2 N = 577 0.32 (-0.38, 1.03) N = 555 0.46 (-0.24, 1.15) N = 551 0.33 (-0.38, 1.03)
20.0 - 24.9 kg/m2 N = 3,206 0.72 (0.41, 1.04)** N = 3,104 0.36 (0.04, 0.68)* N = 3,078 0.38 (0.06, 0.71)*
25.0 - 29.9 kg/m2 N = 1,394 0.75 (0.21, 1.30)** N = 1,324 0.64 (0.08, 1.21)* N = 1,337 0.24 (-0.32, 0.80)
≥30.0 kg/m2 N = 595 1.93 (0.97, 2.88)** N = 563 1.76 (0.86, 2.66)** N = 554 1.70 (0.77, 2.63)**
Estimates reflect the change (95% CI) in systolic- and diastolic blood pressure per change in SD C-reactive 
protein in four different categories of maternal body mass index. Models were adjusted for gestational 
age at blood puncture, gestational age at blood pressure measurement, maternal age, education, 
ethnicity, parity, smoking and alcohol consumption. *P <0.05 **P <0.01
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DiSCuSSion
In this population-based, prospective cohort study we observed associations between first 
trimester maternal C-reactive protein levels and maternal systolic and diastolic blood pres-
sure measured in the three trimesters of pregnancy. However, these associations were largely 
explained by maternal body mass index. Similarly, we demonstrated that the associations 
between first trimester maternal C-reactive protein levels and the risks of pregnancy induced 
hypertension and preeclampsia were fully explained by body mass index. In addition, we did 
not observe consistent associations of C-reactive protein levels with the systolic or diastolic 
blood pressure pattern during pregnancy.
A strength of this study was the large population-based cohort from early pregnancy 
onwards and information about a large number of potential confounders being available. The 
Table 4. Associations of maternal C-reactive protein levels in early pregnancy with the risks of maternal 
pregnancy complications
Pregnancy induced hypertension model A model b model C
C-reactive 
protein level
No. of 
mothers
No. of 
cases 
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
<5.0 mg/L 3,060 112 Reference Reference Reference
5.0 – 9.9 mg/L 1,520 62 1.12 (0.82, 1.54) 1.28 (0.93, 1.76) 0.91 (0.62, 1.33)
10.0 – 14.9 mg/L 533 21 1.08 (0.67, 1.74) 1.39 (0.86, 2.26) 0.50 (0.25, 0.99)
15.0 – 19.9 mg/L 195 14 2.04 (1.15, 3.62)* 2.56 (1.41, 4.62)** 1.20 (0.58, 2.48)
≥20.0 mg/L 243 19 2.23 (1.35, 3.70)** 2.78 (1.66, 4.66)** 1.23 (0.64, 2.36)
Trend test
1.43 (1.03, 2.00)
P for trend 0.035
1.84 (1.30, 2.59)
P for trend 0.001
0.87 (0.59, 1.27)
P for trend 0.472
Preeclampsia model A model b model C
C-reactive 
protein level
No. of 
mothers
No. of 
cases 
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
<5.0 mg/L 3,001 53 Reference Reference Reference
5.0 – 9.9 mg/L 1,485 27 1.03 (0.65, 1.64) 1.09 (0.68, 1.75) 0.81 (0.46, 1.42)
10.0 – 14.9 mg/L 526 14 1.52 (0.84, 2.76) 1.71 (0.93, 3.13) 1.41 (0.71, 2.80)
15.0 – 19.9 mg/L 188 7 2.15 (0.96, 4.80) 2.41 (1.07, 5.45)* 1.49 (0.54, 4.16)
≥20.0 mg/L 229 5 1.24 (0.49, 3.14) 1.38 (0.54, 3.52) 0.61 (0.17, 2.16)
Trend test
1.66 (1.02, 2.71)
P for trend 0.041
1.87 (1.13, 3.09)
P for trend 0.015
1.29 (0.75, 2.22)
P for trend 0.358
Values were bases on multivariate logistic regression models and reflect the odds ratio (95% CI) for 
pregnancy complications for each C-reactive protein level group compared to the reference group (<5.0 
mg/L). Model A was unadjusted. Model B was adjusted for gestational age at blood puncture, maternal 
age, education, ethnicity, parity, smoking and alcohol consumption. Model C was adjusted for gestational 
age at blood puncture, maternal age, education, ethnicity, parity, smoking, alcohol consumption and 
maternal body mass index. Tests for trend were based on multiple linear regression models with the 
logarithmically transformed C-reactive protein as a continuous variable. *P <0.05 **P <0.01
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design of the study allowed the retrospective assessment of maternal systemic inflammation 
status determined in early pregnancy and the subsequent development of maternal blood 
pressure and hypertensive complications. However, potential limitations of the study warrant 
discussion. The response rate of the study was 61%. Pregnant women who participated in the 
study were higher educated, healthier and more frequently of European origin than those 
who did not participate.20The mothers in this study do therefore not fully represent the source 
population and this selective participation might have led to bias. Although selection bias in 
a prospective follow up studies arises primary from loss to follow up instead of non-response 
at baseline, it is difficult to ascertain whether the association between C-reactive protein and 
blood pressure development would be different in non-responders. Our results should there-
fore be carefully interpreted to the general population of pregnant women. The small number 
of pregnancy induced hypertension cases (N = 228, 3.9%) and preeclampsia cases (N = 106, 
1.8%) might be a reflection of this selection towards a more healthy and homogeneous popu-
lation, and might have led to lower statistical power to detect the associations of C-reactive 
protein levels with gestational hypertensive complications. Second, as in all observational 
studies, residual confounding due to unmeasured covariates might be a potential source of 
bias. Third, C-reactive protein levels were assayed only once in the first trimester of pregnancy. 
Therefore, the change in maternal inflammation status during the course of pregnancy and its 
influence on blood pressure development could not be determined. Finally, the OMRON 907 
device has been validated only in non-pregnant adults.23 Further validation studies are needed 
to make definite statements about the accuracy of this device in pregnant women.
Normal pregnancy evokes a mild systemic inflammatory response, with evidence for an 
acute-phase reaction and activation of multiple components of the inflammatory network.29 
C-reactive protein provides an objective and sensitive index of overall inflammatory activity in 
the body7, and C-reactive protein levels have been shown to be elevated in healthy pregnancy 
as compared to the non-pregnant state.8 C-reactive protein levels are raised already at the 
fourth week of gestation, suggesting that the maternal inflammatory response is established 
during the earliest phases of implantation.30
It has been postulated that the pathogenesis of preeclampsia may involve an excessive gen-
eralized maternal inflammatory response to pregnancy. Redman and colleagues introduced 
the concept that the processes that generate preeclampsia are an intrinsic part of normal preg-
nancy and that the systemic inflammatory response of preeclampsia is not a different condition 
but a more extreme part of the spectrum common to all pregnancies.29 Studies on inflamma-
tion in pregnancies complicated by hypertensive disorders have shown conflicting results. 
C-reactive protein levels have been shown to be elevated in preeclamptic women, and concen-
trations were significantly higher in severe preeclampsia as compared to mild preeclampsia.16 
C-reactive protein levels have been demonstrated to be elevated already in the first trimester of 
pregnancy in women who subsequently developed preeclampsia.9 However, in a prospective 
study by Wolf et al., the association between elevated first-trimester C-reactive protein levels 
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and subsequent development of preeclampsia was mitigated after adjusting for maternal body 
mass index.13 In our study, C-reactive protein levels in early pregnancy were positively associ-
ated with maternal systolic and diastolic blood pressure in all trimesters of pregnancy and with 
the development of gestational hypertensive disorders, providing evidence of involvement of 
systemic inflammation. After the adjustment for maternal body mass index however, the asso-
ciations attenuated substantially. Second, the results of the longitudinal analyses do not show 
a consistent association of C-reactive protein levels with the systolic or diastolic blood pressure 
pattern during pregnancy, indicating that C-reactive protein levels in early pregnancy might 
not influence the longitudinal blood pressure development during pregnancy. However, blood 
pressure, most notably diastolic blood pressure, typically falls early in gestation and increases 
from mid-pregnancy onwards.31 These changes in blood pressure during pregnancy might 
mask the associations between C-reactive protein levels and blood pressure before pregnancy. 
The role of C-reactive protein levels before pregnancy in the pathways leading to gestational 
hypertensive disorders should be studied in further detail.
Body mass index is an important determinant of C-reactive protein in pregnant women17, 
and obesity is a well-established risk factor for gestational hypertensive disorders.32 Inflamma-
tion has therefore been proposed to have a mediating role in the association between body 
mass index and preeclampsia. Previous studies suggested that approximately 31% of the total 
effect of body mass index on the risk of preeclampsia, was mediated through inflammation.33 
To study the effects of C-reactive protein on maternal blood pressure and gestational hyper-
tensive disorders independent of maternal body mass index, we performed stratified analyses. 
In normal weight, overweight and obese women, C-reactive protein concentrations were posi-
tively associated with maternal diastolic blood pressure throughout pregnancy. This suggests 
not only a combined contribution to maternal blood pressure development, but also an effect 
of C-reactive protein on diastolic blood pressure independent of maternal body mass index.
The mechanisms through which C-reactive protein levels are related to maternal blood 
pressure and the development of gestational hypertensive disorders are unclear though. In the 
non-pregnant state, C-reactive protein levels are associated with changes indicative of progres-
sive atherosclerosis and endothelial dysfunction.34-35 Structural and functional changes in the 
endothelium influence blood pressure development and ultimately lead to hypertension.34, 36 
These changes could also be involved in the pathway of inflammation, blood pressure develop-
ment and the pathogenesis of hypertensive disorders in pregnancy.
Conclusion
In conclusion, this study showed that the associations of first trimester high sensitivity C-reactive 
protein levels with maternal blood pressure and the risks of pregnancy induced hypertension 
and preeclampsia were largely explained by maternal body mass index. Whether C-reactive 
protein is an intermediate in the pathway between maternal body mass index and gestational 
hypertensive disorders remains subject to further research.
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Table S1. Characteristics of study participants included and excluded from the analyses
Characteristics of women
Excluded1
n = 206
included
n = 5,816
P value
Age (years) 31.2 (19.2 – 40.1) 30.3 (19.5 – 38.8) <0.01
Height (cm) 167.6 ± 7.2 167.6 ± 7.4 0.999
Weight (kg) 76.8 ± 18.9 68.5 ± 12.8 <0.01
Body mass index (kg/m2) 27.4 ± 6.3 24.4 ± 4.3 <0.01
Parity 0.88
  0 115 (55.8) 3,298 (56.7)
  ≥1 90 (43.7) 2,468 (42.8)
  Missing  1 (0.5) 50 (0.9)
Highest completed educational level 0.05
  Primary school 25 (12.1) 524 (9.0)
  Secondary school 101 (49.0) 2,438 (41.9)
  Higher education 73 (35.4) 2,433 (41.8)
  Missing 7 (3.4) 421 (7.2)
Ethnic background 0.94
  European 123 (59.7) 3,385 (58.2)
  Non-European 77 (37.4) 2,094 (36.0)
  Missing 6 (2.9) 337 (5.8)
Smoking during pregnancy 0.77
  Not 142 (68.9) 3,723 (64.0)
  First trimester only 18 (8.7) 462 (7.9)
  Continued 29 (14.1) 879 (15.1)
  Missing 17 (8.3) 752 (12.9)
Alcohol consumption during pregnancy 0.04
  Not 104 (50.5) 2,320 (39.9)
  First trimester only 25 (12.1) 767 (13.2)
  Continued 61 (29.6) 2,004 (34.5)
  Missing 16 (7.8) 725 (12.5)
Gestational age at enrollment (weeks) 13.6 (9.4-17.3) 13.2 (9.6-17.6) 0.73
C-reactive protein level (mg/L) 6.2 (0.51-113.19) 4.4 (0.60-25.22) <0.01
First trimester systolic blood pressure (mmHg) 125.6 ± 17.1 115.2 ± 12.0 <0.01
First trimester diastolic blood pressure (mmHg) 77.2 ± 13.2 67.9 ± 9.3 <0.01
Second trimester systolic blood pressure (mmHg) 125.5 ± 14.7 116.9 ± 11.8 <0.01
Second trimester diastolic blood pressure (mmHg) 75.3 ± 11.5 67.0 ± 9.2 <0.01
Third trimester systolic blood pressure (mmHg) 125.0 ± 15.0 118.3 ± 11.9 <0.01
Third trimester diastolic blood pressure (mmHg) 76.3 ± 12.1 68.9 ± 9.2 <0.01
Values are means (± SD), medians (95% range), or no.’s (%). Differences between included and excluded 
women were compared using independent samples t-tests or Chi-square tests.
1Mothers with extremely high C-reactive protein levels (>100 mg/L) (N = 6), pre-existing hypertension (N 
= 103), pre-existing diabetes (N = 20), high cholesterol (N = 28), Systemic Lupus Erythematosus (N = 1) 
and a chronic heart condition (N = 59).
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Table S2. Longitudinal associations between C-reactive protein levels and systolic and diastolic blood 
pressure
Difference in systolic blood pressure
C-reactive protein level
intercept
mmHg (95% CI)
P value Slope
mmHg (95% CI)
P value
<5.0 mg/L 110.46 (109.22, 111.71) <0.01 Reference
5.0 – 9.9 mg/L 112.20 (109.88, 114.53) <0.01 -0.02 (-0.06, 0.03) 0.47
10.0 – 14.9 mg/L 112.97 (110.11, 115.84) <0.01 -0.01 (-0.07, 0.06) 0.82
15.0 – 19.9 mg/L 115.33 (111.55, 119.13) <0.01 -0.05 (-0.15, 0.05) 0.33
≥20.0 mg/L 115.30 (111.74, 118.87) <0.01 -0.09 (-0.18, 0.00) 0.06
Difference in diastolic blood pressure
C-reactive protein level
intercept
mmHg (95% CI)
P value Slope
mmHg (95% CI)
P value
<5.0 mg/L 96.03 (91.98, 100.07) <0.01 Reference
5.0 – 9.9 mg/L 98.29 (93.41, 103.17) <0.01 -0.04 (-0.07, -0.01) 0.02
10.0 – 14.9 mg/L 99.01 (93.70, 104.31) <0.01 -0.04 (-0.09, 0.01) 0.12
15.0 – 19.9 mg/L 101.70 (95.68, 107.72) <0.01 -0.09 (-0.17, -0.01) 0.03
≥20.0 mg/L 101.18 (95.33, 107.02) <0.01 -0.05 (-0.12, 0.03) 0.22
Values are based on repeated measurement analysis and reflect the change in blood pressure in mmHg 
per C-reactive protein category, compared to the reference group of women with a C-reactive protein 
level of <5.0 mg/L.
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Table S3. Associations of maternal C-reactive protein levels in early pregnancy with maternal blood 
pressure
Systolic blood pressure
first trimester (N = 5,772) Second trimester (N = 5,546) Third trimester (N = 5,520)
C-reactive protein 
level
No. Difference (95% CI) No. Difference (95% CI) No. Difference (95% CI)
<5.0 mg/L N = 3,178 Reference N = 3,063 Reference N = 3,056 Reference
5.0 – 9.9 mg/L N = 1,578 1.97 (1.26, 2.68)‡ N = 1,506 2.11 (1.40, 2.83)‡ N = 1,503 1.78 (1.06, 2.50)‡
10.0 – 14.9 mg/L N = 557 3.32 (2.26, 4.38)‡ N = 539 3.24 (2.17, 4.30)‡ N = 531 3.22 (2.15, 4.29)‡
15.0 – 19.9 mg/L N = 207 4.69 (3.05, 6.33)‡ N = 197 5.10 (3.45, 6.76)‡ N = 191 4.09 (2.40, 5.77)‡
≥20.0 mg/L N = 252 4.52 (3.02, 6.01)‡ N = 241 3.78 (2.27, 5.29)‡ N = 239 3.24 (1.72, 4.76)‡
Trend test
P for trend 
<0.001
4.08 (3.31, 4.84)
P for trend 
<0.001
3.95 (3.18, 4.71)
P for trend 
<0.001
3.40 (2.63, 4.17)
Diastolic blood pressure
first trimester (N = 5,772) Second trimester (N = 5,546) Third trimester (N = 5,520)
C-reactive protein 
level
No. Difference (95% CI) No. Difference (95% CI) No. Difference (95% CI)
<5.0 mg/L N = 3,178 Reference N = 3,063 Reference N = 3,056 Reference
5.0 – 9.9 mg/L N = 1,578 1.74 (1.19, 2.29)‡ N = 1,506 2.02 (1.46, 2.57)‡ N = 1,503 1.33 (0.77, 1.89)‡
10.0 – 14.9 mg/L N = 557 2.78 (1.95, 3.60)‡ N = 539 2.42 (1.59, 3.26)‡ N = 531 2.44 (1.60, 3.28)‡
15.0 – 19.9 mg/L N = 207 4.78 (3.50, 6.06)‡ N = 197 4.29 (2.99, 5.59)‡ N = 191 3.45 (2.13, 4.77)‡
≥20.0 mg/L N = 252 4.92 (3.76, 6.09)‡ N = 241 4.31 (3.13, 5.49)‡ N = 239 4.47 (3.28, 5.66)‡
Trend test
P for trend 
<0.001 
3.98 (3.39, 4.58)
P for trend 
<0.001
3.56 (2.96, 4.16)
P for trend 
<0.001
3.10 (2.50, 3.71)
Values were based on multivariate linear regression models and reflect the difference (95% CI) in maternal 
systolic and diastolic blood pressure for each C-reactive protein level group compared to the reference 
group (<5.0 mg/L). Models were adjusted for gestational age at blood puncture, gestational age at blood 
pressure measurement, maternal age, education, ethnicity, parity, smoking and alcohol consumption. 
Tests for trend were based on multiple linear regression models with the logarithmically transformed 
C-reactive protein as a continuous variable. ‡P <0.01
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AbSTRACT
objective To examine the associations of maternal C-reactive protein levels with fetal growth 
and the risks of neonatal complications. 
Study design C-reactive protein levels were measured in early pregnancy in 6,016 women. 
Main outcome measures were fetal growth in each trimester and neonatal complications.
Results As compared to the reference group (C-reactive protein levels (<5 mg/L), elevated 
maternal C-reactive protein levels (≥25 mg/L) were associated with lower estimated fetal 
weight in third trimester and lower weight at birth (differences: -29 grams, 95% CI -58, 0 and 
-128 grams, 95% CI -195, -60, respectively). Elevated maternal C-reactive protein levels were also 
associated with an increased risk of a small size for gestational age in the offspring (adjusted 
odds ratios 2.94, 95% CI 1.61, 5.36).
Conclusion Maternal C-reactive protein levels in early pregnancy are associated with fetal 
growth restriction and increased risks of neonatal complications.
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inTRoDuCTion
C-reactive protein is an acute-phase reactant and a frequently used marker of low grade sys-
temic inflammation, which levels increase in response to both infectious and non-infectious 
exposures.1 Elevated C-reactive protein levels are associated with increased risks of common 
diseases such as cardiovascular disease and type 2 diabetes.2-3 However, it is still not clear 
whether these associations reflect causal pathways.4-5 Elevated C-reactive protein levels during 
pregnancy, as a marker of low grade inflammation, have also been suggested to be associated 
with increased risks of fetal growth restriction and neonatal complications, like preterm birth, 
low birth weight and small size for gestational age.6-8 Low grade inflammation is associated 
with endothelial dysfunction, leading to vascular dysfunction and suboptimal placental devel-
opment. Maternal systemic inflammation might also be a response to ischemia of the placenta, 
due to suboptimal placentation.9-10 Subsequently, suboptimal placental development might 
predispose mothers to increased risks for various pregnancy complications.11-12 Although the 
association of elevated C-reactive protein levels with preterm birth has been shown in several 
studies, results from studies relating C-reactive protein levels with fetal growth measures or 
neonatal complications are not consistent 7-8,13,14. Differences in results might be due to dif-
ferences in study designs and populations. It is not known whether and in which trimester 
C-reactive protein levels affect fetal growth measures. 
In a population-based prospective cohort study among 6,016 pregnant women, we exam-
ined the associations of maternal C-reactive protein levels, as marker of low grade inflammation 
in early pregnancy, with fetal growth characteristics in different trimesters of pregnancy and 
the risks of neonatal complications.
mATERiAlS AnD mEThoDS
Design and population
This study was embedded in the Generation R Study, a population-based prospective cohort 
study from early fetal life onwards in the city of Rotterdam, the Netherlands.15 Enrollment was 
aimed in early pregnancy but was allowed until birth of the child. All mothers were enrolled 
between 2001 and 2005. Response rate was 61%.15 The study has been approved by the Medi-
cal Ethical Committee of the Erasmus MC, Rotterdam. Written informed consent was obtained 
from all participants.
Of the total of 8,880 mothers who were enrolled during pregnancy, 76% (N = 6,748) were 
enrolled before a gestational age of 18 weeks.15 Of these mothers, blood plasma samples were 
collected in 95% (N = 6,398) and C-reactive protein was successfully measured in 90% (N = 
6,091). Mothers with extremely high C-reactive protein levels (>100 mg/L) (N = 6), and mothers 
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with twin pregnancies were excluded (N = 69), leaving 6,016 mothers with singleton live births 
for analysis (Figure S1 of Supplementary material shows the study participants flow chart).
high sensitivity C-reactive protein levels 
Maternal venous blood samples were collected in early pregnancy (median 13.2, 95% range 
9.6 to 17.6 weeks) and transported to the regional laboratory (Star-MDC, Rotterdam, The 
Netherlands) for processing and storage.16 Blood samples were stored at -80 ºC. C-reactive 
protein concentrations were measured in EDTA plasma samples at the Department of Clinical 
Chemistry of the Erasmus MC in 2009. We measured high-sensitivity C-reactive protein since 
traditional clinically used C-reactive protein methods lack the sensitivity in low ranges needed 
for predicting future risk of events in apparently healthy individuals.17 C-reactive protein levels 
were analyzed using an immunoturbidimetric assay on the Architect System (Abbott Diagnos-
tics B.V., Hoofddorp, The Netherlands). The within run precision for C-reactive protein was 1.3% 
at 12.9 mg/L and 1.2% at 39.9 mg/L. The lowest level of detection was 0.2 mg/L. We created 6 
categories of C-reactive protein levels (<5.0, 5.0 - 9.9, 10.0 - 14.9, 15.0 - 19.9, 20.0 - 24.9 and ≥25 
mg/L). Levels <5.0 mg/L and ≥25 mg/L were considered as low (reference) and elevated levels, 
respectively. 
fetal growth characteristics 
Fetal ultrasound examinations were performed in one of the two dedicated research centers 
in each trimester of pregnancy. Median gestational age for first, second and third trimester 
visits were 12.4 weeks (95% range 10.7 to 14.5), 20.5 weeks (95% range 18.7 to 23.1), and 30.4 
weeks (95% range 28.6 to 32.8), respectively. In the second and third trimester of pregnancy, we 
measured fetal head circumference, abdominal circumference and femur length to the nearest 
millimeter using standardized ultrasoundprocedures.18 Estimated fetal weight was calculated 
using the formula by Hadlock.19 Longitudinal growth curves and gestational age-adjusted 
standard deviation scores (SDS) were constructed for all fetal growth measurements.20
Information about offspring sex, gestational age, weight, length, and head circumference at 
birth was obtained from medical records and registries. Since head circumference and length 
at birth were not routinely measured at birth, missing birth measures were completed with 
data from the first month visit at the routine child health center. Preterm birth was defined as a 
gestational age of <37 weeks at delivery, low birth weight was defined as birth weight <2,500 
grams, and small size for gestational age at birth was defined as a sex specific gestational age 
adjusted birth weight below the fifth percentile in the study cohort (standard deviation score 
≤1.81 for boys, and ≤1.78 for girls). 
Covariates
Information about maternal educational level, ethnicity and parity was obtained by a ques-
tionnaire at enrollment in the study. Maternal smoking and alcohol consumption habits were 
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assessed by questionnaires in each trimester. Maternal anthropometrics, including height and 
weight, were measured without shoes and heavy clothing and body mass index (BMI) was cal-
culated (weight/height2 (kg/m2)) at enrollment.21 Maternal systolic and diastolic blood pressure 
were measured at intake, using standardized methods. For each participant, the mean value of 
two blood pressure readings over a 60-second interval was documented.22 Folate levels were 
analyzed from venous samples drawn in the first trimester of pregnancy. Maternal age was 
registered at enrolment.
Statistical analysis
We assessed the associations of maternal characteristics with C-reactive protein levels as out-
come levels using multivariate linear regression models. Since C-reactive protein levels were 
not normally distributed, we applied a logarithmic transformation for these analyses. Results 
are presented as geometric means (95% range) per determinant category and an overall 
P for trend based on these regression models. Associations of C-reactive protein levels with 
fetal growth characteristics were assessed using linear regression models. These models were 
adjusted for gestational age at the measurement, fetal sex, and maternal age, BMI, education, 
ethnicity, parity, smoking, alcohol consumption and folate level at intake. BMI is known to be 
highly correlated with levels of C-reactive protein23, and with birth weight21,24, and therefore 
expected to be our main confounder. Further variables were included in these models based 
on their association with both the C-reactive protein levels and pregnancy outcomes, or a 10% 
change in the effect estimate. Next, we assessed the associations of C-reactive protein level 
with the risks of neonatal complications (preterm birth, low birth weight and small size for 
gestational age). These models were adjusted for maternal age, BMI, education, ethnicity, par-
ity, smoking, alcohol consumption and folate level at intake. Tests for trends were performed 
using C-reactive protein as continuous variable in multivariate linear and logistic regression 
analyses. The percentages of missing values within the population for analysis were <1% for 
continuous data and <13% for the categorical data. We applied multiple imputations for covari-
ates.25 Since there were no major differences in the observed results between analyses with 
imputed missing data or complete cases only, only results including imputed missing data are 
presented. All measures of association are presented with their 95% confidence intervals (CI). 
All statistical analyses were performed using the Statistical Package of Social Sciences version 
17.0 for Windows (SPSS Inc., Chicago, IL, USA).
RESulTS
Maternal age ranged from 15.3 years to 46.3 years, with a mean of 29.8 years (Table 1). Median 
C-reactive protein level was 4.5 mg/L (95% range 0.60 - 25.46). Mean offspring birth weight 
was 3,420 grams (standard deviation (SD) 564 grams), and median gestational age at birth 
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Table 1. Characteristics of study participants
maternal characteristics at enrolment (n = 6,016)
Age (years) 29.8 (5.1)
Height (cm) 167.6 (7.4)
Weight (kg) 68.8 (13.1)
Body-mass index, (kg/m2) 24.5 (4.4)
Parity
  0 3,412 (56.7)
  1 1,797 (29.9)
  ≥2 756 (12.6)
  Missing 51 (0.8)
Highest completed educational level
  Primary school 549 (9.1)
  Secondary school 2,534 (42.1)
  Higher education 2,505 (41.6)
  Missing 428 (7.1)
Ethnic background
  European 3,502 (58.2)
  Non-European 2,171 (36.1)
  Missing 343 (5.7)
Smoking during pregnancy
  Not 3,865 (64.2)
  First trimester only 480 (8.0)
  Continued 908 (15.1)
  Missing 763 (12.7)
Alcohol consumption during pregnancy
  Not 2,424 (40.3)
  First trimester only 792 (13.2)
  Continued 2,065 (34.3)
  Missing 735 (12.2)
Gestational age at enrolment 13.2 (9.6-17.6)
C-reactive protein level (mg/L) 4.5 (0.60-25.46)
Folate level (nmol/L) 15.70 (5.50-37.50)
birth characteristics
Birth weight (grams) 3,420 (564)
Gestational age at birth (weeks) 40.1 (35.6-42.3)
Males 3,032 (50.4)
Preterm birth (<37 weeks) 302 (5.0)
Low birth weight (<2,500 grams) 293 (4.9)
Small size for gestational age (≤5th percentile) 299 (5.0)
Values are presented as means (SD), medians (95% range), or number (%).
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was 40.1 weeks (95% range 35.6, 42.3). Maternal education, BMI, parity and gestational age 
were associated with C-reactive protein levels. Mothers with a higher parity had a higher mean 
C-reactive protein level (means for C-reactive protein levels from 3.84 mg/L for a parity of 0 
to 6.15 mg/L with a parity of ≥2) and lower maternal education was associated with higher 
C-reactive protein levels (means for C-reactive protein levels from 5.40 mg/L for mothers with 
primary school only to 3.62 mg/L for mothers with higher education). A strong effect was seen 
for maternal BMI, with monotonous increasing means for C-reactive protein from 2.78 mg/L for 
the group with BMI<20 to 10.87 mg/L for the group with BMI ≥35 (data shown in Table S1 and 
Figure S2 of Supplementary material).
As compared to maternal C-reactive protein levels of <5.0 mg/L, maternal C-reactive protein 
levels of ≥25 mg/L were inversely associated with estimated fetal weight in third trimester and 
with birth weight (difference -29 grams, 95% CI -58, 0 and -128 grams, 95% CI -195, -60 respec-
tively). No consistent associations were observed between maternal C-reactive protein levels 
in early pregnancy and fetal head circumference in second or third trimester or at birth (Table 
2). We used femur length in second and third trimester and body length at birth as fetal length 
measures. Maternal C-reactive protein levels were not consistently associated with fetal length. 
Table 2. C-reactive protein levels and fetal growth
Second trimester Third trimester birth
head circumference 
Head circumference  (N = 
5,774)
Head circumference  (N = 
5,748)
Head circumference (N = 
4,743)
C-reactive 
protein 
level
No. of 
children
Difference 
(mm) (95% CI)
No. of children Difference 
(mm) (95% CI)
No. of 
children
Difference 
(mm) 
(95% CI)
<5.0 mg/L N = 3,162 Reference N = 3,153 Reference N = 2,638 Reference
5.0 – 9.9 
mg/L
N = 1,573 -0.07 (-0.44, 
0.31)
N = 1,566 0.10 (-0.45, 
0.66)
N = 1,300 -0.08 (-1.05, 
0.88)
10.0 – 14.9 
mg/L
N = 570 -0.21 (-0.77, 
0.35)
N = 563 -0.34 (-1.17, 
0.48)
N = 437 -1.85 (-3.33, 
-0.36)
15.0 – 19.9 
mg/L
N = 210 -0.37 (-1.24, 
0.50)
N = 206 0.07 (-1.22, 
1.36)
N = 162 -0.50 (-2.80, 
1.81)
20.0 – 24.9 
mg/L
N = 109 0.44 (-0.73, 
1.61)
N = 107 -1.21 (-2.95, 
0.54)
N = 82 -1.02 (-4.18, 
-2.14)
≥25.0 mg/L N = 150 -0.75 (-1.76, 
0.25)
N = 153 -0.51 (-1.99, 
0.96)
N = 124 -1.49 (-4.08, 
1.10)
P for trend 0.240 0.300 0.109
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Figure 1 shows that, as compared to levels of <5.0 mg/L, the relative effect of C-reactive 
protein levels of ≥25.0 mg/L on fetal head circumference, length, and weight, presented as 
difference in standard deviation score, tended to be greater at birth.
Table 3 presents both the unadjusted and adjusted associations of C-reactive protein levels 
with the risks of neonatal complications. The differences between the unadjusted and adjusted 
Table 2. C-reactive protein levels and fetal growth (continued)
length
Femur length (N = 5,787) Femur length (N = 5,789) Birth length (N = 4,804)
C-reactive 
protein 
level
No. of 
children
Difference 
(mm) (95% CI)
No. of children Difference 
(mm) (95% CI)
No. of 
children
Difference 
(mm) 
(95% CI)
<5.0 mg/L N = 3,174 Reference N = 3,176 Reference N = 2,659 Reference
5.0 – 9.9 
mg/L
N = 1,569 0.10 (-0.01, 
0.21)
N = 1,578 0.03 (-0.10, 
0.17)
N = 1,313 -0.01 (-1.38, 
1.37)
10.0 – 14.9 
mg/L
N = 575 0.08 (-0.08, 
0.24)
N = 565 0.04 (-0.16, 
0.24)
N = 458 -1.00 (-3.08, 
1.08)
15.0 – 19.9 
mg/L
N = 210 0.03 (-0.22, 
0.28)
N = 208 0.06 (-0.25, 
0.37)
N = 168 -0.23 (-3.46, 
3.01)
20.0 – 24.9 
mg/L
N = 109 0.22 (-0.12, 
0.56)
N = 108 0.18 (-0.25, 
0.37)
N = 80 -3.08 (-7.63, 
1.46)
≥25.0 mg/L N = 150 -0.18 (-0.47, 
0.11)
N = 154 -0.27 (-0.63, 
0.09)
N = 126 -2.74 (-6.40, 
0.92)
P for trend 0.972 0.395 0.275
weight 
Estimated fetal weight (N = 
5,763)
Estimated fetal weight (N = 
5,768)
Birth weight (N = 5,979)
C-reactive 
protein 
level
No. of 
children
Difference (g) 
(95% CI)
No. of children Difference (g) 
(95% CI)
No. of 
children
Difference (g) 
(95% CI)
<5.0 mg/L N = 3,161 Reference N = 3,167 Reference N = 3,271 Reference
5.0 – 9.9 
mg/L
N = 1,559 -1 (-3, 2) N = 1,570 7 (-4, 18) N = 1,630 10 (-15, 36)
10.0 – 14.9 
mg/L
N = 575 1 (-3, 4) N = 562 -3 (-20, 13) N = 586 -47 (-85, -9)
15.0 – 19.9 
mg/L
N = 209 0 (-6, 6) N = 207 14 (-12, 46) N = 221 -28 (-87, 30)
20.0 – 24.9 
mg/L
N = 109 3 (-5, 10) N = 108 12 (-23, 46) N = 112 -86 (-165, -6)
≥25.0 mg/L N = 150 -6 (-12, 1) N = 154 -29 (-58, 0) N = 159 -128 (-195, 
-60)
P for trend 0.274 0.115 <0.001
All models were adjusted for maternal age, body mass index, height, systolic and diastolic blood 
pressure at intake, education, ethnicity, parity, smoking, alcohol, folate level at intake, gestational age at 
measurement, gestational age at blood collection and fetal sex. 
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models were mainly explained by including maternal BMI in the models. The adjusted models 
show that as compared to the reference category (C-reactive protein levels <5.0 mg/L) mothers 
with elevated C-reactive protein levels (≥25.0 mg/L) were more likely to deliver children with a 
small size for gestational age at birth (adjusted odds ratio 2.94, 95% CI 1.61, 5.36). 
figure 1. Elevated maternal C-reactive protein levels and fetal growth characteristics
-0,4
-0,3
-0,2
-0,1
0,0
0,1
0,2
0,3
2nd trimester 3rd trimester Birth
D
iff
er
en
ce
 in
 fe
ta
l h
ea
d 
cu
rc
um
fe
re
nc
e 
 
(S
D
S)
 
-0,5
-0,4
-0,3
-0,2
-0,1
0,0
0,1
0,2
0,3
2nd trimester 3rd trimester Birth
D
iff
er
en
ce
 in
 fe
ta
l l
en
gt
h 
 
(S
D
S)
 
-0,6
-0,5
-0,4
-0,3
-0,2
-0,1
0,0
0,1
0,2
0,3
2nd trimester 3rd trimester Birth
D
iff
er
en
ce
 in
 fe
ta
l w
ei
gh
t  
(S
D
S)
 
Values are regression coefficients (95% CI) and represent the difference in growth standard deviation 
score (SDS) between elevated levels of maternal C-reactive protein levels in early pregnancy (≥25 mg/L) 
as compared to the reference group (<5.0 mg/L). All models were adjusted for maternal age, body mass 
index, height, systolic and diastolic blood pressure at intake, education, ethnicity, parity, smoking, alcohol, 
use of folate level at intake, gestational age at blood collection and fetal sex.
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Table 3. C-reactive protein levels and neonatal complications
Preterm birth, <37 weeks of gestation
C-reactive 
protein level
No. of 
children
No. of cases Odds Ratio
(95% CI)
Pvalue Adjusted Odds 
Ratio (95% CI)
P value
<5.0 mg/L 3,284 141 1.00 1.00
5.0 – 9.9 mg/L 1,646 88 1.26 (0.96, 
1.65)
0.10 1.25 (0.94, 
1.66)
0.12
10.0 – 14.9 
mg/L
590 40 1.62 (1.27, 
2.32)
0.01 1.69 (1.15, 
2.47)
0.01
15.0 – 19.9 
mg/L
222 17 1.85 (1.09, 
3.11)
0.02 1.86 (1.07, 
3.23)
0.03
20.0 – 24.9 
mg/L
112 7 1.49 (0.68, 
3.24)
0.32 1.69 (0.64, 
3.23)
0.38
≥25.0 mg/L 159 9 1.34 (0.67, 
2.66)
0.42 1.42 (0.69, 
2.89)
0.34
P for trend 0.075 0.109
low birth weight, <2,500 grams
C-reactive 
protein level
No. of 
children
No. of cases Odds Ratio
(95% CI)
Pvalue Adjusted Odds 
Ratio (95% CI)
P value
<5.0 mg/L 3,271 154 1.00 1.00
5.0 – 9.9 mg/L 1,630 84 1.09 (0.83, 
1.43)
0.54 1.18 (0.89, 
1.57)
0.25
10.0 – 14.9 
mg/L
586 31 1.12 (0.75, 
1.66)
0.59 1.40 (0.92, 
2.12)
0.12
15.0 – 19.9 
mg/L
221 11 1.05 (0.56, 
1.95)
0.89 1.35 (0.70, 
2.59)
0.38
20.0 – 24.9 
mg/L
112 5 0.94 (0.38, 
2.32)
0.89 1.11 (0.43, 
2.86)
0.82
≥25.0 mg/L 159 8 1.05 (0.51, 
2.17)
0.90 1.43 (0.67, 
3.03)
0.36
P for trend 0.990 0.280
Small for gestational age, ≤5%
C-reactive 
protein level
No. of 
children
No. of cases Odds Ratio
(95% CI)
 Pvalue Adjusted Odds 
Ratio (95% CI)
P value
<5.0 mg/L 3,263 168 1.00 1.00
5.0 – 9.9 mg/L 1,629 73 0.86 (0.65, 
1.14)
0.30 0.98 (0.73, 
1.31)
0.88
10.0 – 14.9 
mg/L
585 29 0.96 (0.64, 
1.43)
0.82 1.32 (0.86, 
2.01)
0.21
15.0 – 19.9 
mg/L
221 10 0.87 (0.45, 
1.66)
0.67 1.31 (0.66, 
2.59)
0.44
20.0 – 24.9 
mg/L
112 5 0.86 (0.74, 
2.12)
0.74 1.23 (0.48, 
3.16)
0.66
≥25.0 mg/L 159 14 1.76 (1.00, 
3.11)
0.05 2.94 (1.61, 
5.36)
<0.01
P for trend 0.379 0.003
Adjusted odds ratio’s were adjusted for maternal age, body mass index, height, systolic and diastolic 
blood pressure at intake, education, ethnicity, parity, smoking, alcohol, folate level at intake and 
gestational age at blood collection.
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Mothers with elevated C-reactive protein levels (≥25.0 mg/L) tended to be more likely to 
deliver preterm (adjusted odds ratio 1.42, 95% CI 0.69, 2.89) or a child with a low birth weight 
(adjusted odds ratio 1.43, 95% CI 0.67, 3.03), as compared to the reference category, although 
not significantly.
DiSCuSSion
In this population-based prospective cohort study, we observed associations of maternal 
socio-demographic and anthropometric measures and life style habits with C-reactive protein 
levels in early pregnancy. After adjustment for these variables, elevated maternal C-reactive 
protein levels (≥25.0 mg/L)in early pregnancy were associated with fetal growth restriction, and 
increased risks of preterm birth and small size for gestational age at birth. 
C-reactive protein is known to be slightly elevated during pregnancy, due to the maternal 
inflammatory reaction to the pregnancy.26 Previous studies showed that measures of unhealthy 
life style habits such as cigarette smoking are also associated with elevated C-reactive protein 
levels, whereas moderate alcohol consumption and increased physical activity are associated 
with lower C-reactive protein levels.27-29 Increased BMI and adiposity are strongly associated 
with elevated C-reactive protein levels.30-31 In our population-based cohort among pregnant 
women, maternal BMI, parity and smoking during pregnancy were all positively associated with 
C-reactive protein levels. Higher maternal education, European background, and continued 
maternal alcohol consumption were associated with lower C-reactive protein levels. Our results 
suggest that markers of unhealthy life style habits lead to elevated C-reactive protein levels.
Our results indicate that elevated C-reactive protein levels, as a marker of maternal low 
grade inflammation, are associated with fetal growth restriction. The effect estimates are rela-
tively small. Our findings may be important from an etiological perspective on population level. 
Future studies should explore the role of C-reactive protein levels in clinical practice.
 We did observe an association between elevated maternal C-reactive protein levels in early 
pregnancy and the risk of small size for gestational age, which remained significant after adjust-
ment. The differences between the unadjusted and adjusted models were mainly explained 
by including maternal BMI in the model. Maternal BMI is positively associated with C-reactive 
protein levels32 and fetal growth.21 After adjusting our models for maternal BMI, elevated 
C-reactive protein levels were still associated with fetal growth restriction and increased risks of 
small size for gestational age, suggesting that these associations are independent of maternal 
BMI. Our results are in line with previous smaller studies, which suggested an increased risk of 
preterm delivery among mothers with elevated C-reactive protein in early or mid-pregnancy. 
However, these studies did not demonstrate associations with fetal growth retardation.7,14
The mechanisms underlying these associations should further be explored, but might 
include that maternal low grade systemic inflammation, indicated by elevated C-reactive 
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protein levels, results in suboptimal placental development9-10, and subsequently increase 
the risks of pregnancy complications. However, higher levels of C-reactive protein may also 
be associated with vascular dysfunction that leads in turn to suboptimal placental develop-
ment.9-10 Both fetal growth and pregnancy induced hypertensive disorders might have at least 
part of their origin in suboptimal early placenta development.33 Also, the associations might 
not reflect causality, since elevated C-reactive protein levels can be markers of other risk factors 
or processes leading fetal growth restriction. Previous studies focused on the associations of 
C-reactive protein genotypes and levels with cardiovascular disease, which used a Mendelian 
randomization approach, suggested that C-reactive protein is not causally related to cardio-
vascular disease but rather a marker of other risk factors.4-5, 34 Such studies have not yet been 
performed in pregnancy.
Some methodological issues need to be considered. To our knowledge, this is the largest 
cohort study that has examined the associations of maternal C-reactive protein levels in early 
pregnancy and placenta related complications in mother and child. Of all mothers enrolled 
in pregnancy, 76% was enrolled in early pregnancy. Non-response at baseline would lead 
to selection bias if the associations would differ between those with and without complete 
data. This seems unlikely. Biased estimates in large cohort studies primarily arise from loss to 
follow-up rather than from non-response at baseline.35 Since follow-up information at birth 
was available in 93%, we do not expect biased results due to loss to follow-up. We were able to 
adjust or models for multiple potential confounders, related to maternal socio-demographic 
status, anthropometrics and life style habits. However, as in all observational studies, residual 
confounding due to unmeasured covariates might still be the case.
In conclusion, maternal low grade inflammation in early pregnancy, as measured by 
C-reactive protein levels, was associated with fetal growth restriction and increased risks of 
neonatal complications. Further studies are needed to explore the underlying mechanisms and 
causality for these associations.
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Table S1. Associations of maternal characteristics with C-reactive protein levels in early pregnancy
n = 6,016 C-reactive protein
maternal age 
<20 years N = 204 3.42 (0.51-21.00)
20 - 24.9 years N = 965 4.61 (0.70-27.62)
25 - 29.9 years N = 1,673 4.68 (0.60-27.01)
30 - 34.9 years N = 2,337 4.12 (0.60-25.21)
35 - 39.90 years N = 759 4.18 (0.60-23.50)
≥40 years N = 78 4.73 (1.13-21.48)
P for trend 0.127
Adjusted P for trend 0.475
maternal body mass index at intake
<19.9 kg/m2 N = 542 2.78 (0.35-17.92)
20 – 24.9 kg/m2 N = 3,260 3.54 (0.60-20.75)
25 – 29.9 kg/m2 N = 1,453 5.58 (1.00-25.22)
30 – 34.9 kg/m2 N = 470 8.45 (1.98-29.92)
≥35 kg/m2 N = 229 10.87 (1.50-43.02)
Missing N =62 4.92 (0.51-21.53)
P for trend <0.001
Adjusted P for trend <0.001
Parity
0 N = 3,412 3.84 (0.60-23.07)
1 N = 1,797 4.67 (0.60-28.21)
≥2 N = 756 6.15 (0.99-27.10)
Missing N = 51 5.66 (0.40-36.83)
P for trend <0.001
Adjusted P for trend <0.001
highest completed educational level
Primary School N = 549 5.40 (0.50-30.22)
Secondary School N = 2,534 4.75 (0.70-26.46)
Higher Education N = 2,505 3.62 (0.60-22.34)
Missing N = 428 5.40 (0.67-32.60)
P for trend <0.001
Adjusted P for trend <0.001
Ethnic background
European N = 3,502 3.95 (0.60-24.50)
Non-European N = 2,171 4.85 (0.60-27.07)
Missing N = 343 5.41 (0.70-33.43)
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Table S1. Associations of maternal characteristics with C-reactive protein levels in early pregnancy 
(continued)
n = 6,016 C-reactive protein
P for trend <0.001
Adjusted P for trend 0.103
Smoking
Not N = 3,865 4.23 (0.60-26.04)
First trimester only N = 480 3.95 (0.60-22.09)
Continued N = 908 4.60 (0.60-22.13)
Missing N = 763 4.84 (0.70-28.93)
P for trend 0.048
Adjusted P for trend 0.956
Alcohol consumption
Not N = 2,424 4.79 (0.60-26.18)
First trimester only N = 792 4.04 (0.70-22.25)
Continued N = 2,065 3.80 (0.74-24.10)
Missing N = 735 4.86 (0.70-30.30)
P for trend <0.001
Adjusted P for trend 0.095
Values are presented as geometric means (95% range). Values are based on multivariate linear regression 
models with adjustment for all maternal characteristics from this table.
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figure S1. Flow chart of participants included in the study
 
 
Prenatally included mothers 
N = 8,880 
 N = 2,132 Excluded, due to inclusion >= 
18 weeks of gestation 
 
Plasma samples collected <18 weeks  
N = 6,398 
 
C-reactive protein measured <18 weeks of gestation 
N = 6,091 
 
Singleton live births 
N = 6,022 
 
Total population for analysis 
N = 6,016 
 
Fetal growth characteristics 
First trimester N = 1,599 
Second trimester N = 5,787  
Third trimester N = 5,789 
Birth N = 5,979 
 
Neonatal complications 
Preterm birth N = 302  
Low birth weight N = 293 
Small for gestational age N = 299 
 
N = 307 Excluded, due to missing data on 
C-reactive protein 
 
N = 69 Excluded, due to twin pregnancies 
 
N = 6 Excluded, due to extreme C-reactive 
protein levels (>100 mg/L) 
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figure S2. Correlation of gestational age and maternal body mass index with C-reactive protein levels
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Plots represent the correlation of gestational age at blood collection and body mass index at intake with 
C-reactive protein levels, respectively. C-reactive protein was not normally distributed and therefore log-
transformation was performed.
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inTRoDuCTion
Over the past decades, epidemiological studies have provided evidence that early envi-
ronmental exposures influence the risk of various health outcomes in adulthood. Low birth 
weight, as an indicator of impaired fetal growth, has been associated with the development of 
cardiovascular disease1 and its risk factors.2 Later studies suggested that high growth rates in 
childhood following low birth weight may have important influences on the increased risk of 
cardiovascular disease in later life.3-4 These findings have led to the “Developmental Plasticity” 
hypothesis, which describes the ability of an organism to develop in various ways, depending 
on the particular environment.5 Developmental adaptations in response to environmental 
exposures might contribute to better short-term survival, but may increase the susceptibility of 
cardiovascular disease in adulthood. Many of the published studies examining the associations 
between fetal factors and the risk of cardiovascular disease in later life have been performed 
retrospectively in cohorts of adults. The interpretation of the influence of early growth and its 
determinants is complicated by the possibility of confounding by factors related to cardiovas-
cular disease over the course of adult life. In early life, the effect of these confounding factors 
is expected to be limited. Therefore, research on the early origins of cardiovascular disease has 
been extended from studies in adults on birth weight, into studies on the influence of fetal and 
early postnatal life measures in childhood on cardiovascular risk development.
The exact underlying biological mechanisms linking early growth with cardiovascular dis-
ease in later life are largely unknown. It has been hypothesized that the association between 
early growth and cardiovascular disease in later life might be explained by cardiovascular 
adaptations due to early suboptimal growth and environment. Therefore, this thesis focused on 
the effect of prospectively measured fetal and childhood growth patterns and its determinants 
on cardiovascular and metabolic development in childhood and adulthood. The majority of the 
studies presented in this thesis were embedded in the Generation R Study, a population-based 
prospective cohort study from fetal life until young adulthood in Rotterdam, The Netherlands.6-7 
This study is designed to identify early environmental and genetic determinants of growth, 
development and health in fetal life and childhood. In addition, two studies were performed in 
the Nurses’ Health Study II, an ongoing prospective cohort study of 116,430 female registered 
nurses that started in 1989.8 In this chapter, the most important studies designed to explore the 
associations between early growth and cardiovascular diseases in adulthood are discussed, and 
the results of studies performed as part of the current thesis are considered in the context of 
this previous research. In addition, general methodological issues are described and perspec-
tives for future research are provided.
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CARDiovASCulAR DEvEloPmEnT fRom fETAl lifE To ADulThooD
The heart is the first functional organ of a human embryo, and starts beating approximately 
21 days after conception. The fetal heart grows mainly through proliferation of the small and 
mononucleated cardiomyocytes, referred to as cardiomyocyte hyperplasia.9 The plastic nature 
of the developing fetal heart provides the opportunity to adjust to the increased workload 
imposed to it by the enlarging vascular system.10 At the end of gestation the cardiomyocytes 
tend to differentiate, and their capacity to proliferate decreases. Postnatal cardiac growth is 
mainly established by hypertrophia of cardiomyocytes and non-muscle cell hyperplasia.9 The 
growth and maturation of conduit arteries and peripheral vascular beds are determined during 
intrauterine life and in the early postnatal months11, and are suggested to be influenced by 
blood flow.12 The rates of elastin synthesis in blood vessels increase to a maximum in the peri-
natal period, followed by a rapid fall in the synthesis rates thereafter.13-14 Factors that interfere 
in these early processes might permanently influence cardiovascular development.
Previous studies demonstrated that various measures of the cardiovascular system track 
in childhood and adulthood, describing that individuals within a particular structural or func-
tional range relative to other individuals tend to remain in this range.15-20 A large number of 
studies have been conducted to investigate the development of blood pressure over time.15 
A review and meta-analyses based on cohort studies in diverse pediatric populations showed 
moderate blood pressure tracking between childhood and adulthood.15 On the cardiac 
structural level, moderate tracking of left cardiac structures in pre-school children during the 
first 2 years of life has been demonstrated within the Generation R Study.16 Data from older 
children and young adults indicated more profound tracking of left ventricular mass.17-18 In 
adults, longitudinal observations have shown that left ventricular mass and left atrial diameter 
progressively increase over the course of life, particularly in the presence of risk factors such as 
elevated blood pressure and BMI.19-20
In addition to the tracking of cardiovascular structural and functional measures, studies have 
shown that factors that influence cardiovascular remodeling measured in childhood, remain in 
their rank order into adulthood. Children who have measures of body size in a high percentile 
rank tend to remain in this high rank as they mature, while children who are in a low percentile, 
stay low.21
In adulthood, various cardiovascular structural and functional properties are independently 
associated with cardiovascular health outcomes. High blood pressure is a well-established risk 
factor of the premature development of cardiovascular disease, forming a major health issue in 
all world regions.22 The clinical value of arterial elastic properties in assessing cardiovascular risk 
is now recognized and arterial stiffness is increasingly used for the prediction of cardiovascular 
outcomes.23-24 Structurally, an increase in left atrial diameter is a sign of atrial remodeling and 
has a prognostic significance with regard to the risk of cardiovascular morbidity.25 A reduced 
cross-sectional area of the aorta and large conduit arteries will decrease the volume of blood 
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flow and might lead to tissue ischemia26, while aortic root and ascending aortic dilatation might 
form a thoracic aneurysm.27 Increased left ventricular mass, as detected by echocardiography, 
is a predictor of a higher incidence of cardiovascular disease related clinical events.28
These data suggest that factors that contribute to cardiovascular remodeling in early life 
might have implications for cardiovascular structures and function in later life. Early markers 
of cardiovascular adaptations might therefore provide insight in the mechanisms linking early 
growth and cardiovascular disease in later life.
EARly GRowTh AnD CARDiovASCulAR DEvEloPmEnT
fetal growth and cardiovascular adaptations
Although the underlying mechanisms linking low birth weight with cardiovascular disease in 
later life are largely unknown, recent evidence from diverse animal and human populations 
suggests a potentially crucial role of both fetal and early childhood cardiovascular adaptations 
linked to early growth. Fetal growth restriction due to placental insufficiency is associated with 
fetal circulatory adaptations, contributing to the preferential perfusion of vital fetal organs, such 
as the heart and the brain, at the expense of less critical organs. This “brain sparing” is caused by 
a reduction of the vascular resistance in the fetal brain, and an increase in the peripheral vascu-
lar resistance.29 Growth restricted fetuses showed coronary vasodilatation and it is suggested 
that this occurs in order to maintain myocardial oxygenation in the presence of hypoxemia 
and deteriorating venous flow velocity waveforms.30 Within the Generation R Study, decreased 
fetal growth was associated with cardiac remodeling and cardiac output changes consistent 
with a gradual increase in afterload and previously compromised arterial compliance.31 These 
changes were already noticeable before the onset of clinical apparent fetal growth restriction.
fetal growth and cardiovascular adaptations in childhood and adulthood
To investigate the hypothesis that impaired fetal growth has lasting effects on future cardio-
vascular health, various studies have been performed on the relation of fetal growth charac-
teristics and postnatal cardiovascular adaptations. Martyn and Greenwald suggested that fetal 
growth restriction was associated with impaired elastin synthesis in the walls of the aorta and 
other large arteries, and that this deficiency could initiate permanent loss of arterial elasticity.14 
Indeed, adaptations in arterial properties are detectable in both children32-33 and adults34-35 
born with low birth weight, although results are inconsistent.36-37 In the current study, we 
observed an inverse association of birth weight and birth weight for gestational age with 
systolic and diastolic blood pressure in 6,415 children aged 6 years. We did not find consistent 
evidence of associations of second or third trimester fetal growth with carotid-femoral pulse 
wave velocity. Montgomery et al. also observed no association of birth measures and arterial 
stiffness in adults aged 25 years, and the authors explained the difference with their study 
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and previous studies in adults by a possible increasing influence of atherosclerosis on arterial 
compliance in older individuals.37
Studies on the relation between birth measures and arterial diameter showed positive 
associations in both preterm and term individuals16, 38-39, although the results do not seem 
consistent.40 In a study designed to define echocardiographic normative data, aortic root 
dimensions tended to increase with increasing birth weight in healthy neonates, although 
increments were reduced at higher birth weights.41 In our study, we observed that length and 
weight growth rates from 2nd to 3rd trimester of pregnancy were consistently associated with 
aortic root diameter at the age of 6 years, suggesting the presence of a critical period of devel-
opmental programming of the vascular system. In addition, we observed positive associations 
of birth weight with aortic root diameter at the child age of 6 years, consistent with results from 
previous studies in children aged 24 months16 and 9 years.39
Studies on the influence of early growth on cardiac dimensions show inconsistent results.16, 
39, 42-43 In a study conducted in 200 young children, fetal growth restriction was suggested 
to induce primary changes in cardiac morphology, with a linear increase with the severity of 
growth restriction.44 In a recent study among 418 adolescents, a direct positive association 
between birth weight and left ventricular mass was described, independent of current weight.45 
In contrast, in a study of 9 year old children, no significant associations of birth weight with left 
ventricular mass, left ventricular diameter or atrial diameter were found.39 In adult males, birth 
weight was not related to left ventricular mass either.42 We observed a smaller left ventricular 
mass in 6 year old children with restricted fetal growth from 2nd to 3rd trimester and born with a 
small size for their gestational age. It has been hypothesized that cardiac hypertrophy may have 
a developmental origin in the reduction in cardiomyocyte number through either reduced cel-
lular proliferation or increased apoptosis.46 Our results may be explained by the inability of the 
left ventricle to hypertrophy according to the increased workload that is imposed at birth, due 
to a lower number of cardiomyocytes.
We also hypothesized that fetal haemodynamic adaptations related to fetal growth restric-
tion may have a persistent influence on cardiovascular development. Twin studies showed 
that in uncomplicated monochorionic twins, no differences were seen in fetal haemodynamic 
structures between the bigger fetus and the smaller co-twin. However, in the twin-twin transfu-
sion syndrome, the recipient fetuses had increased aortic and pulmonary velocities compared 
with their donor co-twin.47 In human infants, pulse wave velocity in the brachioradial arterial 
segment was higher in the donor twin of the twin-twin transfusion syndrome, implying that 
cardiovascular adaptations of the donor fetus to haemodynamic disturbances may influence 
arterial properties.48 We found no evidence that third trimester placental or fetal haemodynam-
ics were associated with blood pressure or arterial stiffness, but we observed weak associations 
with cardiac structural outcomes in childhood.
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Growth in childhood and cardiovascular development
For an adequate evaluation of echocardiographically measured cardiovascular structures, an 
evidence-based determination of reference values is essential.49 To correctly differentiate nor-
mal from pathological cardiac development, normalization of cardiac structures to body size 
is necessary. Based on previous studies on cardiovascular allometry, BSA as calculated by the 
Haycock formula50 seems a more important determinant of the size of cardiovascular structures 
than age, height, or weight.51 The longitudinal collected data on child BSA and cardiovascular 
development in the Generation R Study provided the opportunity to establish reference charts 
for left cardiac structures until the age of 24 months. Moreover, to increase the usefulness of 
the reference charts in clinical practice, Z-scores were created to facilitate the assessment of the 
deviation of a particular measurement from the mean for a given BSA.52
In childhood and adolescence, cardiovascular structures and function are closely related to 
physical growth.53-54 In a retrospective review based on clinical data from pediatric primary 
care practices, blood pressure already increased with rising BMI in children aged 2 to 5 years.55 
Studies on cardiac development have shown associations of height, weight, BMI and BSA with 
various cardiac dimensions.18, 56-58 In a subgroup consisting of Dutch mothers and their chil-
dren, we observed positive associations of child anthropometrics and left cardiac structures in 
the first 24 months of life. In addition, infant growth in the first 24 months of life was associated 
with blood pressure and left ventricular mass at the age of 6 years. Our results suggest that 
not only cross-sectionally measured child anthropometrics are closely related to cardiovascular 
structures and function, but that growth in the first months of life influences cardiovascular 
development in later childhood.
obesity and cardiometabolic health in childhood
The worldwide prevalence of obesity, known for the adverse effect on the cardiovascular sys-
tem in later life, is increasing rapidly in the pediatric population.59 Childhood obesity is already 
associated with several metabolic and hemodynamic abnormalities in childhood60, and is a 
major risk factor for the development of cardiovascular disease in later life.61 The recognition of 
obesity as an important determinant of cardio-metabolic health has led to increased interest 
in the influence of overweight measurements and obesity on early cardiovascular structural 
and functional development. The increase in the prevalence of obesity in children results in 
an overall elevation of childhood blood pressure.62 Preclinical alterations in the aortic elastic 
properties of obese children have been found63 and childhood obesity is related to endothelial 
dysfunction64, a marker of the early stage of atherosclerotic disease.65 In children and adoles-
cents, overweight measurements and obesity are associated with cardiac structural changes, 
such as an increase in left atrial diameter and left ventricular dimensions.57-58, 66 We observed 
that obesity, defined by BMI cutoffs, was related to cardiovascular structures and function 
already at the age of 2 years.
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A major disadvantage of the use of BMI as an indicator of obesity is that it does not account 
for the distribution of different body tissues. Studies in both adults and children provided 
evidence that next to BMI, body fat mass and an android fat pattern are major predictors of 
the cardiometabolic profile in children67, and cardiovascular disease in later life.68 The findings 
from Project HeartBeat! indicated that body size, especially when measured as fat free mass, 
was the strongest determinant of left ventricular mass in children and adolescents.56 In a cross-
sectional study by Daniels et al. on body fat distribution determined by DXA and cardiovascular 
risk factors in children and adolescents, the authors observed that an android fat pattern was 
associated with a higher systolic blood pressure and left ventricular mass.69 Studies focused on 
the effect of fat mass and fat distribution may therefore be of great value in understanding the 
association of body size and cardiovascular risk development.
longitudinal approach of fetal and childhood growth
It has been proposed that the pattern of childhood growth mediates the association between 
restricted fetal growth and the risk of cardiovascular disease. Barker and colleagues described 
that reduced birth weight followed by accelerated child growth was related to a higher risk of 
coronary heart disease in later life.3 In 1,258 men participating in the Caerphilly study, the risk 
of coronary heart disease associated with low birth weight was present only in individuals with 
a high BMI in adulthood.70 In the current thesis, we investigated whether infant growth pat-
terns influenced the association of size at birth on childhood cardiovascular development. We 
observed that children born small for gestational age or appropriate for gestational age that 
subsequently experienced catch-up growth in the first 24 months of life, had a higher systolic 
blood pressure than children born appropriate for gestational age followed by normal growth. 
In addition, children born small for gestational age with overweight or obese measurements 
had the highest blood pressure, whereas children born large for gestational age with catch-up 
growth in infancy or recorded as overweight or obese in childhood had the highest left ven-
tricular mass. These results support the hypothesis that variations in both fetal and childhood 
growth lead to adaptations in the cardiovascular system. 
fETAl AnD infAnT ExPoSuRES AnD CARDiovASCulAR DEvEloPmEnT
The hypothesis that early adverse exposures may lead to postnatal cardiovascular disease by 
affecting cardiovascular properties is supported by data from a broad range of epidemiological 
studies. Research has been focused on parental and childhood life style habits, behavior, health 
and disease. 
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Parental smoking in pregnancy
Maternal smoking in pregnancy is one of the most important, potentially modifiable adverse 
exposures in Western countries71-72, and the effect of fetal smoke exposure on cardiovascular 
disease and its risk factors have been studied extensively. Fetal smoke exposure is associated 
with numerous complications, such as fetal growth restriction and preterm birth.73-74 There is 
a growing body of evidence for changes in cardiovascular structures and function in children 
born to mothers who smoked during pregnancy, although results are inconsistent.75-80 It is not 
clear whether the association of maternal smoking with cardiovascular outcomes is explained 
by direct intrauterine mechanisms, or by unmeasured confounders.76 The results of the Genera-
tion R Study suggest that continued maternal smoking during pregnancy is associated with 
higher diastolic blood pressure and fractional shortening, but not with left cardiac structures 
and carotid-femoral pulse wave velocity in children at the age of 6 years. To assess the role of 
confounding, we also investigated whether paternal smoking during pregnancy was associ-
ated with cardiovascular structures and function. Among mothers who did not smoke during 
pregnancy, paternal smoking was associated with aortic root diameter, but not with other 
cardiovascular outcomes. The stronger effect estimates for maternal smoking, compared to 
paternal smoking, might suggest that direct intrauterine mechanisms are involved. However, 
we must be careful to conclude intrauterine effects, since effect estimates were small and 
paternal smoking was associated with childhood aortic root diameter.
Thus far, the majority of studies on the effect of fetal smoke exposure has been conducted 
in childhood populations, and has mainly been focused on the effect of maternal smoking 
only on blood pressure development. To investigate the impact of smoking of both parents 
in pregnancy on the risk of adult hypertension, we assessed the associations of maternal and 
paternal smoking in pregnancy with hypertension in adulthood, in a large cohort of US women 
participating in the Nurses’ Health Study II. We observed weak positive associations between 
both maternal and paternal smoking during pregnancy with the risk of hypertension in their 
adult daughters. However, observed associations were largely eliminated after adjustment 
for body weight throughout life, with BMI closest to the diagnosis of hypertension having 
the greatest impact. Previous studies suggested that intrauterine smoke exposure leads to 
adaptations in weight and predisposition to an increased risk of being overweight and obesity 
in the offspring in childhood, adolescence and adulthood.81-83 Obesity and weight gain are 
major risk factors for developing hypertension.84-85 Thus the association of parental smoking 
during pregnancy with the risk of hypertension in adulthood might be mediated through the 
programming of body weight throughout life. These findings are supported by a large study 
in children, which suggested that childhood BMI and weight trajectory largely mediated the 
associations of maternal smoking during pregnancy with the offspring’s systolic blood pressure 
at the age of seven.86 However, BMI should also be considered as a potential confounder of 
the associations. The influence of birth weight in the pathway appeared to be limited. In line 
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with our findings, in a recent meta-analysis the associations of fetal smoke exposure with child 
overweight were independent of birth weight.82
In the same ongoing longitudinal cohort study, we investigated the associations of mater-
nal and paternal smoking in pregnancy with the risks of type 2 diabetes. The first report of an 
inverse association between low birth weight and impaired glucose tolerance in adulthood 
dated from 1991.87 A recent meta-analysis among 30 studies including more than 150,000 indi-
viduals suggested a decrease in risk of type 2 diabetes with increasing birth weight. Maternal 
smoking leads to restricted blood flow in the vascular beds of the fetus and placenta, leading 
to suboptimal nutrition supply to various organs, such as the fetal pancreas.88 Studies in rats 
demonstrated that high maternal nicotine levels during pregnancy influenced the develop-
ment of pancreas islets, control of fat storage and homeostasis of energy expenditure and 
blood vessel structure and reactivity.88-89 We observed positive associations between maternal 
smoking during pregnancy and the risk of type 2 diabetes in adulthood, independent of birth 
weight and adult risk factors for type 2 diabetes. However, observed associations attenuated 
after adjustment for body weight throughout life, with BMI closest to the diagnosis of type 2 
diabetes having the greatest impact.
Early nutrition in childhood
Early nutritional exposures may chronically affect cardiovascular development and lead to car-
diovascular disease in later life.90 Previous studies suggested a protective effect of breastfeeding 
on cardiovascular disease in later life91-92, although a large meta-analysis did not confirm these 
results.93 In studies focused on cardiovascular risk factors, breastfeeding duration was inversely 
associated with blood pressure94-96, obesity97, cholesterol levels98, and insulin resistance99. In 
addition, the timing of weaning has been inversely related to cholesterol levels and percentage 
of body fat and weight in childhood92, 100, although results were inconsistent.101-102 The effect 
of breastfeeding on the risk of cardiovascular disease in later life might be explained by early 
cardiovascular structural and functional adaptations due to early nutritional exposures.103-104 
School age children exclusively breastfed for 3 to 6 months had a greater carotid intima-media 
thickness compared to exclusively formula-fed children103, and young adults breastfed for 4 
months or more had a lower arterial distensibility.104 We observed that never breastfed children 
tended to have a smaller left atrial diameter during the first 24 months of life compared to 
breastfed children, although results were nonsignificant. At the age of 6 years, children who 
had never been breastfed had a higher carotid-femoral pulse wave velocity, smaller left atrial 
diameter and lower left ventricular mass compared to breastfed children. Children with a 
younger age at introduction of solid foods had a higher blood pressure. Results from this study 
suggest support the hypothesis that early nutrition may influence cardiovascular structural and 
functional development in childhood.
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inflAmmATion in PREGnAnCy, mATERnAl AnD nEonATAl 
ComPliCATionS
Worldwide, pregnancy-induced hypertension and preeclampsia are leading causes of maternal 
and fetal morbidity and mortality.105-106 The clinical features of preeclampsia can partly be 
explained as responses to endothelial dysfunction107, with a potential crucial role for an exag-
gerated maternal systemic inflammatory response to pregnancy.108-109 C-reactive protein is an 
acute-phase protein110-111, and is used as a diagnostic indicator of tissue damage in both acute 
and chronic inflammation. Although circulating C-reactive protein levels show a more profound 
elevation in preeclamptic women than in normal pregnancy112-115, its potential use as a predic-
tive factor for gestational hypertensive disorders is not clear.116 Previous studies showed higher 
C-reactive protein levels in preeclamptic pregnancies, while other studies postulated that this 
might be explained by maternal obesity.113, 117 BMI is an important determinant of C-reactive 
protein levels in pregnancy118-119, and obesity is a well-established risk factor for gestational 
hypertensive disorders.119 In this study, we demonstrated that the associations between first 
trimester maternal C-reactive protein levels and maternal systolic and diastolic blood pres-
sure measured throughout pregnancy, were largely explained by maternal BMI. Similarly, we 
observed that the associations between first-trimester maternal C-reactive protein levels and 
the risks of pregnancy-induced hypertension and preeclampsia disappeared after adjustment 
for maternal BMI. This study provides further ground for the hypothesis of a mediating role of 
BMI in the association between inflammation and preeclampsia.
Elevated C-reactive protein levels during pregnancy have also been suggested to be associ-
ated with increased risks of fetal growth restriction and neonatal complications.114, 120-121 We 
observed associations of elevated first trimester maternal C-reactive protein levels (≥25.0 mg/L) 
with fetal growth restriction, and increased risks of preterm birth and SGA. After adjusting for 
maternal BMI, as this is associated with both C-reactive protein levels and fetal growth, these 
associations remained present. The mechanisms underlying these associations are largely 
unknown. A possible explanation might be that maternal low-grade systemic inflammation 
results in suboptimal placental development.122-123 In addition, C-reactive protein levels might 
be associated with vascular dysfunction, leading to suboptimal placental development.122-123 
However, C-reactive protein levels could also be markers of other risk factors or processes lead-
ing to fetal growth restriction. Further studies are needed to explore whether maternal or fetal 
systemic inflammatory markers also affect cardiovascular development of the fetus and child.
mEThoDoloGiCAl ConSiDERATionS
Most of the studies presented in this thesis have been performed within the Generation R Study, 
a prospective, population-based cohort study from fetal life onwards. Furthermore, two studies 
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have been embedded in the Nurses’ Health Study II, an ongoing prospective cohort study of 
female registered nurses.8 Specific methodological considerations of the presented studies 
have been discussed in the separate chapters of this thesis. In the following paragraphs, some 
general methodological issues regarding three types of bias that may occur in epidemiological 
studies are discussed: Selection bias, information bias and confounding.
Selection bias
Selection bias occurs if the relation between determinant and outcome is different in those who 
participate and those who were eligible, but do not participate. Of all eligible children at birth, 
is estimated that 61% participated in the Generation R Study. This non response at baseline is 
not likely to be random. Participants in the Generation R Study generally had a higher socio-
economic status and were more likely to be native Dutch compared to non-participants. The 
percentages of children born preterm or with low birth weight are smaller than expected on 
population figures in Rotterdam, reflecting a selection toward a relative healthy study popula-
tion. This selection towards a more affluent and healthy population is expected to lead to bias in 
etiological association studies if the selection mechanisms are related to both the determinant 
and the outcome measures, and the associations differ between the study population and the 
total eligible population. The selection towards a more homogeneous population might affect 
the generalizability of the results and the frequency rates of our determinant and outcome 
measures, reducing the statistical power of our studies. In addition, selection bias may also arise 
from selective loss to follow up if the associations of early growth and cardiovascular develop-
ment differ between participants lost to follow up and those that continued participating in the 
study. Of all children included in the Generation R Study, 83.9% (N = 8,305) participated in the 
follow up studies at age 6 years, and 67.0% participated in one of the cardiovascular follow up 
measurements. Selection bias due to selective loss to follow up is of concern if the associations 
of the various determinants with cardiovascular structures and function differ between those 
included and those not included in the analyses. Although this seems unlikely, these associa-
tions cannot be investigated.
information bias
Information bias is an error that arises in a study because of misclassification of the determi-
nants or outcome measurements. Misclassification of either determinant or outcome can be 
non-differential and differential.124 Non-differential misclassification refers to independent 
misclassification, where the determinant status is not related to the outcome status, and vice 
versa. In the case of differential misclassification, determinant and outcome status are related. 
Whereas non-differential misclassification in general will attenuate results, differential misclas-
sification can either exaggerate or underestimate an effect.124 For the current thesis, data on 
exposures and outcomes were mainly obtained by physical examinations, questionnaires and 
biological samples. The main determinants of the studies performed within the Generation 
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R Study were obtained prospectively without reference to the cardiovascular outcome mea-
sures. This makes differential misclassification of the exposure unlikely. A major limitation of 
the Nurses’ Health Study II was the retrospective collection of data on parental smoking and 
associated perinatal covariates. It is assumed that any resulting misclassification is likely to be 
non-differential with respect to hypertension status. This would bias the associations towards 
the null. However, in a subgroup of the Nurses’ Health Study II population, a good agreement 
of the daughters’ reports of maternal smoking during pregnancy as compared to the mothers’ 
accounts was reported.125 Second, part of the data on exposure was obtained through mater-
nal self-report by questionnaires in both the Generation R Study and the Nurses’ Health Study 
II. It has proven to be difficult to acquire reliable and valid measures of life style habits, and 
assessment by questionnaire might lead to differential misclassification. For example, mothers 
might underreport the number of cigarettes they smoked during pregnancy126, causing an 
underestimation of the differences in cardiovascular structures and function between children 
of non-smoking and smoking mothers. A possibility to overcome these limitations is the use of 
biomarkers for the exposure or outcome measures, such as cotinine in maternal urine samples 
as a biomarker for measuring tobacco exposure.127-128 However, the use of cotinine levels was 
not superior to the use of self-reporting by questionnaires in studying the effect of maternal 
smoking in pregnancy on birth weight129, and the use of biomarkers is usually not possible in 
the case of retrospective data collection.
Confounding
A confounder is an extraneous variable that correlates with both the determinant and the 
outcome, and is not an intermediate on the causal pathway of the variables of interest. A 
confounder might lead to biased effect estimates. For example, in the study on the association 
of C-reactive protein with the risk of gestational hypertensive disorders, the associations were 
largely explained by maternal BMI. Inflammation has therefore been proposed as a mediator in 
the association between BMI and preeclampsia. The studies on parental smoking in pregnancy 
and cardiovascular development in later life found comparable effect estimates for maternal 
and paternal smoking. Similar effect sizes suggest that the association of maternal smoking 
is explained by other environmental factors, rather than a biological influence of maternal 
smoking on the intrauterine environment. Although comprehensive information about vari-
ous covariates was collected in both the Generation R Study and the Nurses’ Health Study, the 
possibility of residual confounding due to insufficient measured or unmeasured factors should 
always be considered in observational studies. The problem of residual confounding might be 
addressed by randomization, ensuring that confounders are randomly distributed between 
groups.
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imPliCATionS foR fuTuRE RESEARCh
Cardiovascular disease is a leading cause of death in the adult general population. The observa-
tion that early life events have an important role for the susceptibility to cardiovascular diseases 
in adulthood, has led to increased insight in initial development of the disease and its risk fac-
tors. This thesis provided new evidence for an influence of early growth and its determinants on 
cardiovascular development in childhood. However, the significance of our observations with 
regard to the risk of cardiovascular disease in later life remains unclear. Although cardiovascular 
structures and function seem to track in childhood and adulthood, the implications of the car-
diovascular changes due to early growth and development should be topic of future research. 
Our findings need to be followed over time to learn if the altered cardiovascular structures and 
function persist and are a precursor to cardiovascular disease in later life. To gain more insight in 
the longitudinal associations between early influences and cardiovascular development, regu-
lar cardiovascular assessments during childhood beyond the age of 6 years and adolescence 
should be performed.
In the Generation R Study, blood pressure and carotid-femoral pulse wave velocity mea-
surements have been obtained to investigate cardiovascular function, and echocardiographic 
measurements of left cardiac structures have been performed to gain insight into cardiac devel-
opment. Other markers of cardiovascular adaptations might provide complementary views on 
the underlying mechanism of the association between low birth weight and cardiovascular 
disease in later life. Autopsy studies in children have shown that the atherosclerotic process, 
associated with cardiovascular disease in later life, begins to develop many years before car-
diovascular complications. Endothelial dysfunction and impaired vascular reactivity induced 
by dyslipidemia is an initial step in atherosclerosis130, and carotid intima media thickness is 
considered as a marker of preclinical atherosclerosis in adults.131 Ultrasound techniques make 
it possible to visualize endothelial function and the intima media thickness non-invasively, and 
this might provide adequate markers of preclinical atherosclerosis already in childhood.132 
The retina is the only site of the body where the human vasculature can be directly and non-
invasively visualized.133 Retinal vascular imaging provides a unique opportunity to study the 
influence of environmental factors on the microvasculature in children. Biomarkers such as 
cholesterol and C-reactive protein are well-established determinants of cardiovascular disease 
in adulthood, and future studies should investigate how subtle changes in biomarker levels 
relate to cardiovascular development at younger ages. In addition, imaging techniques such as 
magnetic resonance imaging and three dimensional ultrasounds of the cardiovascular system 
can visualize cardiovascular development in more detail. These imaging techniques do not use 
harmful ionizing radiation to acquire images, which improves their application to the pediatric 
population.
The epigenetics is an emerging field of research and comprises the study of heritable 
changes in gene expression that are not caused by modification of the DNA sequence.134 
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Epigenetic dysregulation causes human disease and it has been proposed that epigenetic 
modifications might be involved in the biological mechanisms underlying the developmental 
origins hypothesis.135 The epigenetic epidemiology of this hypothesis focuses on the concept 
that early environmental influences induce epigenetic variation and thereby permanently 
affect metabolism and the risk of chronic diseases.135 A study testing for the effects of maternal 
smoking in pregnancy demonstrated alterations in methylation of placental CYP1A1, and 
showed that these changes are correlated with CYP1A1 gene expression and fetal growth 
restriction.136 In adults exposed to undernutrition during the Dutch Famine, lower methylation 
of the IGF2 gene, a main factor in human growth and development, was found.137 This suggests 
that epigenetic modifications induced by early exposures, such as maternal smoking and fetal 
nutrition, may have phenotypic consequences throughout life. Therefore, future studies on the 
role of epigenetics may contribute to the understanding of the biological mechanisms linking 
early exposures and disease in adulthood.
Knowledge of the early origins of cardiovascular disease may provide a window of opportu-
nity for new prevention initiatives in pregnancy and childhood. The results of the studies pre-
sented in this thesis suggest that risk control for long-term prevention of cardiovascular disease 
should begin from pregnancy onwards. The development of non-invasive measurements and 
tests could facilitate the detection of high risk children. Lowering risk factors in these children 
may prevent or postpone the processes that ultimately lead to cardiovascular disease in later 
life. Evidence for the pathogenic importance of parental and childhood modifiable behavioral 
and life style factors should be translated into public health policies on the population level.
ConCluSion
To conclude, both fetal and childhood growth and determinants seem to influence cardiovascu-
lar development from early childhood onwards. Although the long-term clinical importance of 
cardiovascular changes is largely unknown, structural and functional adaptations may possibly 
have a lasting influence on cardiovascular risk in later life. Therefore, risk control for prevention 
of future cardiovascular disease should begin from early life onwards.
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SummARy
Worldwide, cardiovascular diseases are leading causes of morbidity and mortality in adulthood. 
Epidemiological studies have provided evidence that early environmental exposures influence 
the susceptibility to disease in later life. Low birth weight has been associated with an increased 
risk for the development of cardiovascular disease and its risk factors, particularly in individuals 
who show postnatal catch-up growth. These findings have led to the “Developmental plastic-
ity” hypothesis, describing the ability of an organism to develop in various ways, depending on 
the particular environment. This developmental plasticity contributes to short-term survival, 
but may increase the susceptibility of cardiovascular disease in adulthood.
The exact underlying biological mechanisms linking early growth with cardiovascular dis-
ease in later life are largely unknown. It has been hypothesized that the association between 
early growth and the susceptibility to cardiovascular disease in later life might partly be 
explained by suboptimal cardiovascular adaptations in response to impaired growth and an 
adverse environment. Therefore, this thesis focused on the effects of prospectively measured 
fetal and childhood growth patterns and their determinants on cardiovascular outcomes in 
childhood and adulthood.
Most studies presented in this thesis were embedded in the Generation R Study, a popula-
tion-based prospective cohort study from the fetal stage until young adulthood in Rotterdam, 
The Netherlands. The Generation R Study is designed to identify early environmental and 
genetic determinants of growth, development and health in fetal life and childhood. In addi-
tion, two studies were performed within the Nurses’ Health Study II, an ongoing prospective 
cohort study of female registered nurses from 15 US states that commenced in 1989.
In Chapter 2 we described the influence of early growth patterns on cardiovascular develop-
ment in childhood. In Chapter 2.1, we established sex-specific longitudinal reference charts 
and corresponding Z-scores for left cardiac structures and function according to BSA in healthy 
children until the age of 24 months. These reference charts may contribute to the quantitative 
assessment of left cardiac structures by ultrasound in early childhood in clinical settings and 
epidemiological studies. In Chapter 2.2, we examined the associations of child anthropomet-
rics with cardiovascular structures and function during the first 24 months of life in a subgroup 
of Dutch children participating in the Generation R Study. We observed positive associations 
of length, weight, BMI and BSA with left cardiac structures until the age of 24 months. Fur-
thermore, this study provided evidence that overweight factors and obesity already exert an 
influence on cardiac size in early childhood. To investigate the hypothesis that impaired growth 
in early life has lasting effects on future cardiovascular health, we studied the associations 
of fetal and infant growth patterns with cardiovascular structures and function in childhood 
(Chapter 2.3). Preterm birth and small size at birth were associated with higher systolic blood 
pressure, and smaller left atrial diameter, aortic root diameter, and left ventricular mass in 
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children aged 6 years. We observed that fetal and infant growth characteristics were associated 
with cardiovascular structural and functional outcomes in childhood, independent of current 
BMI. Children with fetal growth restriction and accelerated growth in the first 24 months of 
life have higher blood pressure, whereas children with both high fetal and infant growth rates 
have larger left ventricular mass. The study described in Chapter 2.4 explored the associa-
tions of third trimester placental and fetal haemodynamics with the cardiovascular system in 
childhood. The results did not provide evidence for an association of placental, fetal cerebral or 
fetal cardiac haemodynamics with blood pressure or carotid-femoral pulse wave velocity, but 
we observed associations of third trimester cardiac structural and functional measures with 
cardiac structural outcomes in childhood.
The aims of the studies described in Chapter 3 were to identify fetal and infant exposures 
that affect cardiovascular development in children. In Chapter 3.1, we examined the associa-
tions of fetal smoke exposure with cardiovascular structures and function in childhood in the 
Generation R Study. Continued maternal smoking during pregnancy was associated with 
higher diastolic blood pressure and fractional shortening at the age of 6 years. We observed 
stronger effect estimates for maternal smoking compared to paternal smoking, suggesting 
that direct intrauterine mechanisms might be involved. However, effect estimates were small 
and paternal smoking was associated with childhood aortic root diameter. This suggests a 
possible influence of unmeasured shared social and environmental factors, rather than direct 
intrauterine effects. To investigate the impact of smoking of both parents in pregnancy on the 
risk of adult hypertension, we assessed the associations of maternal and paternal smoking in 
pregnancy with hypertension in adulthood in the Nurses’ Health Study II (Chapter 3.2). We 
observed positive associations of both maternal and paternal smoking during pregnancy, with 
the risk of hypertension in their adult daughters. However, these associations were largely 
attenuated after adjustment for body weight throughout life, with BMI closest to the diagnosis 
of hypertension having the greatest impact. In the same ongoing longitudinal cohort study, we 
investigated the associations of maternal and paternal smoking in pregnancy with the risks of 
type 2 diabetes in Chapter 3.3. We found positive associations between maternal or paternal 
smoking during pregnancy and the risk of type 2 diabetes in adulthood, independent of birth 
weight and adult risk factors for type 2 diabetes. However, the effect estimates attenuated after 
adjustment for body weight throughout life. Early nutritional exposures may chronically affect 
cardiovascular development and lead to cardiovascular disease in later life. The effect of early 
nutritional exposures on the risk of cardiovascular disease in later life might be explained by 
early cardiovascular structural and functional adaptations due to breastfeeding. Therefore, the 
purpose of Chapter 3.4 was to evaluate the influence infant feeding patterns on cardiovascular 
development in the first 24 months of life. Never breastfed children tended to have a smaller 
left atrial diameter during the first 24 months of life compared to breastfed children, although 
results were nonsignificant. At the age of 6 years, children who had never been breastfed had 
a higher carotid-femoral pulse wave velocity, a smaller left atrial diameter and a lower left 
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ventricular mass compared to breastfed children (Chapter 3.5). In addition, age of introduction 
of solid foods was negatively related to systolic and diastolic blood pressure at the age of 6 
years. We concluded that early nutrition may influence cardiovascular structural and functional 
development in childhood.
In Chapter 4, the associations of inflammation in pregnancy with maternal and neonatal 
complications were evaluated. Chapter 4.1 describes the associations between first trimester 
C-reactive protein levels in pregnancy, maternal blood pressure development and gestational 
hypertensive disorders. We observed that the associations between first trimester maternal 
C-reactive protein levels and maternal systolic and diastolic blood pressure measured through-
out pregnancy, attenuated after adjustment for maternal BMI. Similarly, the associations 
between first-trimester maternal C-reactive protein levels and the risks of pregnancy-induced 
hypertension and preeclampsia were largely explained by maternal BMI. This study provides 
further ground for the hypothesis of a mediating role of inflammation in the association 
between BMI and preeclampsia. In Chapter 4.2 we investigated whether elevated C-reactive 
protein levels during pregnancy were associated with increased risks of fetal growth restriction 
and neonatal complications. We observed associations of elevated first trimester maternal 
C-reactive protein levels (≥25.0 mg/L) with fetal growth restriction and increased risks of pre-
term birth and SGA, independent of maternal BMI.
Finally, Chapter 5 provides a general discussion on the studies described in this thesis and 
considers the results in the context of the current literature. In addition, general methodologi-
cal issues are described and perspectives for future research are suggested.
In conclusion, the studies described in this thesis suggest that fetal, infant and childhood 
growth and its determinants influence cardiovascular development from early life onwards. 
Structural and functional adaptations may possibly have a lasting influence on cardiovascular 
risk in later life. However, the long-term clinical importance of the cardiovascular changes is 
largely unknown and further follow-up investigations of this and other cohorts are urgently 
needed.
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SAmEnvATTinG
Cardiovasculaire aandoeningen zijn wereldwijd een belangrijke oorzaak van zowel morbiditeit 
als mortaliteit bij volwassenen. Verschillende epidemiologische studies hebben verbanden 
aangetoond tussen de vroege leefomgeving en het risico op ziekte op latere leeftijd. Deze 
studies hebben geleid tot de “Developmental plasticity” hypothese, welke beschrijft dat een 
organisme zich op verschillende manieren kan ontwikkelen, afhankelijk van de specifieke 
omgevingsinvloeden. Deze plasticiteit kan bijdragen aan de overleving op korte termijn, maar 
kan negatieve consequenties hebben voor de gezondheid op lange termijn.
De onderliggende biologische mechanismen die het verband tussen de vroege groei, 
omgeving en cardiovasculaire ziekten verklaren, zijn grotendeels onbekend. Een mogelijke 
oorzaak zou een suboptimale cardiovasculaire ontwikkeling als gevolg van groeivertraging 
en een ongunstige vroege omgeving kunnen zijn. Daarom zijn de studies in dit proefschrift 
gericht op het effect van prospectief gemeten groeipatronen en omgevingsinvloeden op de 
cardiovasculaire ontwikkeling van zowel kinderen als volwassenen.
De meeste studies beschreven in dit proefschrift zijn uitgevoerd binnen de Generation R 
Studie, een populatie-gebaseerd prospectief cohort onderzoek onder bijna 10.000 kinderen 
vanaf de vroege foetale fase tot in de jongvolwassenheid. De Generation R Studie is opge-
zet om de factoren van invloed op de groei, ontwikkeling en gezondheid van kinderen te 
onderzoeken. Daarnaast is voor twee studies gebruik gemaakt van gegevens verzameld in de 
Nurses’ Health Study II, een prospectief cohort onderzoek onder vrouwelijke geregistreerde 
verpleegsters, gestart in 1989.
In hoofdstuk 2 is de invloed van vroege groeipatronen op de cardiovasculaire ontwikkeling 
in de kindertijd onderzocht. In hoofdstuk 2.1 hebben we referentiecurven gecreëerd voor 
de groei van verschillende cardiovasculaire structuren tot de leeftijd van 24 maanden in een 
Nederlandse subgroep van het Generation R cohort. Daarnaast hebben we Z-scores geformu-
leerd, wat de klinische toepasbaarheid van de curven verhoogd. In hoofdstuk 2.2 zijn de asso-
ciaties van antropometrie en cardiovasculaire structuren en functie bij Nederlandse kinderen 
in de eerste 24 maanden van het leven beschreven. We hebben een positief verband gevonden 
tussen lengte, gewicht, body mass index en body surface area en linker cardiovasculaire 
structuren. Daarnaast hebben we geconstateerd dat overgewicht en obesitas mogelijk invloed 
hebben op de cardiovasculaire ontwikkeling bij kinderen op de leeftijd van 24 maanden. In 
hoofdstuk 2.3 is de hypothese dat suboptimale groei in de eerste levensfasen een effect heeft 
op de cardiovasculaire ontwikkeling in de kindertijd onderzocht. Vroeggeboorte en een te laag 
gewicht voor de zwangerschapsduur waren geassocieerd met een hogere systolische en dias-
tolische bloeddruk, en met een kleinere linker atrium diameter, diameter van de aortabasis, en 
linker ventrikel massa op de leeftijd van 6 jaar. De toename van foetale beenlengte en geschat 
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foetaal gewicht tussen het tweede en derde trimester van de zwangerschap, alsmede tussen 
het derde trimester en geboorte, lieten eveneens een verband zien met de diameter van de 
aortabasis en linker ventrikel massa. In de studie beschreven in hoofdstuk 2.4 is nagegaan of 
aan groeivertraging gerelateerde veranderingen in de bloedstroom profielen van de placenta 
of foetus geassocieerd waren met het cardiovasculaire systeem in de kindertijd. We hebben 
geen relatie gevonden tussen placenta of foetale haemodynamiek in het derde trimester van de 
zwangerschap en bloeddruk of arteriële vaatwandstijfheid op de leeftijd van 6 jaar. Wel werden 
associaties aangetoond tussen bloedstroom profielen van de placenta of foetus en structurele 
en functionele hartmetingen in het derde trimester, zoals de diameter van de foetale aorta 
ascendens, en linker hartstructuren in de kindertijd. Dit verband bleek onafhankelijk te zijn van 
geschat foetaal gewicht.
In hoofdstuk 3 is onderzoek gedaan naar de verschillende omgevingsfactoren die van 
invloed kunnen zijn op de cardiovasculaire ontwikkeling van kinderen. hoofdstuk 3.1 behan-
delt het verband tussen roken van de ouders tijdens de zwangerschap en cardiovasculaire 
structuren en functie op de leeftijd van 6 jaar in de Generation R Studie. We hebben aange-
toond dat doorroken van de moeder tijdens de zwangerschap leidt tot een hogere diastolische 
bloeddruk en fractional shortening. Daarnaast hebben we geconstateerd dat roken van de 
vader tijdens de zwangerschap geassocieerd is met een grotere diameter van de aortabasis. 
Dit duidt op een mogelijke invloed van onbekende gedeelde sociale- en omgevingsfactoren, 
in plaats van een direct intra-uterien effect van roken. Gebruik makend van de data van de 
Nurses’ Health Study II, is de relatie van roken van beide ouders tijdens de zwangerschap met 
het risico op hypertensie op volwassen leeftijd onderzocht in hoofdstuk 3.2. In deze studie 
is een klein effect gevonden van roken van zowel moeder als vader, en daarnaast zijn aanwij-
zingen gevonden dat deze associaties werden gemedieerd door de huidige body mass index 
van de dochters. In dezelfde cohort studie is aangetoond dat dochters van ouders die gerookt 
hebben tijdens de zwangerschap, een licht verhoogd risico hebben op het ontwikkelen van 
diabetes mellitus type 2 (hoofdstuk 3.3). Echter, ook dit verhoogde risico wordt waarschijnlijk 
gemedieerd door de huidige body mass index. Voeding in de eerste levensfasen is geassocieerd 
met een veranderd cardiovasculair risicoprofiel op de latere leeftijd. Daarom onderzochten 
we in een Nederlands subcohort van de Generation R Studie (hoofdstuk 3.4) de hypothese 
dat borstvoeding in het eerste levensjaar de cardiovasculaire ontwikkeling van kinderen kan 
beïnvloeden. Linker atrium diameter, aortabasis diameter, linker ventrikel massa en fractional 
shortening waren in de eerste twee levensjaren niet verschillend tussen kinderen die wel of 
geen borstvoeding hadden gehad. Ook zijn er geen associaties gevonden tussen de duur of 
exclusiviteit van borstvoeding en linker hartstructuren of functie. In aanvulling op de resultaten 
beschreven in hoofdstuk 3.4, is in hoofdstuk 3.5 het effect van borstvoeding en de introduc-
tie van bijvoeding op de cardiovasculaire ontwikkeling op de leeftijd van 6 jaar onderzocht. 
Deze studie liet zien dat het geven van borstvoeding in het eerste levensjaar geassocieerd is 
met een lagere arteriële vaatwandstijfheid, en een grotere linker atrium diameter en linker 
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ventrikelmassa. Daarnaast was de leeftijd van introductie van bijvoeding negatief geassocieerd 
met zowel systolische als diastolische bloeddruk. We concludeerden hieruit dat voeding in de 
kindertijd mogelijk langdurige gevolgen heeft voor de cardiovasculaire ontwikkeling.
In hoofdstuk 4 is de invloed van ontsteking tijdens de zwangerschap op maternale en 
neonatale complicaties beschreven, aan de hand van de ontstekingsparameter C-reactive 
protein. hoofdstuk 4.1 rapporteert over de positieve associatie tussen C-reactive protein con-
centraties in het eerste trimester van de zwangerschap, en maternale bloeddruk en het risico 
op zwangerschapshypertensie of preeclampsie. Echter, de associaties verminderden wanneer 
rekening gehouden werd met maternale body mass index. Deze studie versterkt de hypothese 
dat ontsteking een mediërende rol speelt in de eerder vastgestelde associatie tussen maternale 
body mass index en preeclampsie. In hoofdstuk 4.2 onderzochten we of maternale C-reactive 
protein concentraties in het eerste trimester van de zwangerschap geassocieerd waren met 
foetale groeipatronen en het risico op neonatale complicaties. We toonden een verband aan 
tussen een C-reactive protein concentratie van minstens 25 mg/L en een verlaagd geschat 
foetaal gewicht en geboortegewicht. Tevens vonden we dat het risico op een laag geboor-
tegewicht voor de zwangerschapsduur hoger was bij kinderen van moeders met verhoogde 
C-reactive protein concentraties.
Tot slot zijn in hoofdstuk 5 de belangrijkste resultaten beschreven in dit proefschrift in de 
context van recent gepubliceerde studies beschouwd. Daarnaast worden methodologische 
beperkingen en de interpretatie van de bevindingen behandeld.
Concluderend, de studies beschreven in dit proefschrift suggereren dat vroege groei en 
verschillende omgevingsfactoren verband kunnen houden met de cardiovasculaire ontwikke-
ling in de kindertijd. Structurele en functionele aanpassingen hebben mogelijk permanente 
gevolgen voor het cardiovasculaire risicoprofiel op latere leeftijd. Echter, het klinisch belang 
van de huidige bevindingen op lange termijn is tot op heden onbekend, wat de waarde van 
vervolgonderzoek onderschrijft.
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